Application of polysaccharide derivative
By introducing benzaldehyde groups into the polysaccharide derivatives to form the Schiff base structure, and using cross-linking reaction, the problems of insufficient stability and low water solubility in water are solved, and stable bonding in organisms is achieved and improved drug sustained release effects, improving its performance in drug delivery systems.
Patent Information
- Application Number
- CN202280091514.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2022-02-16
- Publication Date
- 2024-11-08
AI Technical Summary
The existing polysaccharide derivatives are insufficient in water, resulting in fast drug delayed release and problems such as water solubility and low industrial production efficiency in applications in drug delivery systems.
By introducing benzaldehyde groups into polysaccharide derivatives, a stable Schiff base structure is formed, and its adhesion and modification rate in organisms are improved by cross-linking, combined with divalent metal ions for cross-linking, it is prepared A polysaccharide derivative crosslinked structure with improved adhesion and stability.
The stable adhesion of polysaccharide derivatives in organisms and improved drug sustained release effects are achieved, improving their performance in tissue repair and drug delivery, and avoiding the use of toxic catalysts and complex reaction steps.
Smart Images

Figure CN118922215A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to uses of polysaccharide derivatives, such as tissue adhesive materials. Background Art
[0002] Polysaccharides such as hyaluronic acid or alginic acid generally show excellent solubility in water, water retention, moderate viscosity, adhesiveness, and biocompatibility, and are therefore widely used as additives and thickeners for medical materials, food additives, cosmetics, or daily necessities. For example, hyaluronic acid (HA) is a natural polymer with abundant biodegradability and biocompatibility in the body and is widely used as a material for health care products such as medicines, medical devices, cosmetics, and contact lenses in the fields of plastic surgery or ophthalmology. In addition, alginic acid (AL) is a natural polysaccharide contained in brown algae, etc., and has properties such as high biocompatibility and cross-linking by polyvalent metal ions such as Ca. Therefore, it is used in medicines, medical devices, and pharmaceutical additives such as hemostatic agents or wound dressing materials, or in foods, supplements, and food additives.
[0003] In recent years, research has been underway to effectively utilize these polysaccharides as drug carrier materials in drug delivery systems (DDS). HA specifically binds to the CD44 receptor and is overexpressed on the surfaces of various tumor cells. Its hydroxyl and carboxyl groups can be easily derivatized, making it a popular drug carrier material. For example, several HA-drug conjugates utilizing Schiff bases have been reported (Non-Patent Document 1: Materials Science and Engineering: C, 2014, 36: 287-293; Non-Patent Document 2: Carbohydrate Polymers 134 (2015) 293-299; Non-Patent Document 3: Carbohydrate Polymers 189 (2018) 273-279; Non-Patent Document 4: Carbohydrate Polymers 216 (2019) 63-71). Schiff bases are imino-containing compounds formed by the condensation reaction of primary amines with reactive carbonyl compounds. Schiff bases exhibit reversible pH-responsive dissociation and are therefore expected to selectively release drugs. However, Schiff bases formed between common aldehydes or ketones and amines undergo a rapid reverse reaction in water, resulting in insufficient stability. Consequently, drug conjugates utilizing Schiff bases exhibit rapid sustained-release rates, often failing to achieve adequate performance. On the other hand, by using hydrazide groups instead of amino groups to slow the hydrolysis rate, they can be used as biocompatible in situ cross-linked hydrogels based on hyaluronic acid or alginic acid backbones.
[0004] It is reported that benzaldehyde, due to its aromatic structure, can form a stable Schiff base with the amine groups (amino groups) contained in various drugs (Non-Patent Document 5: Materials Chemistry Frontiers, 2018, 2(10): 1765-1778). Non-Patent Document 6 (J. Biomed. Nanotechnol. 2017, 13, 1647-1659) discloses a conjugate of carboxymethyl chitosan and daunorubicin that forms a Schiff base between the aldehyde group of triazole benzaldehyde and the amino group of daunorubicin. The formation of the conjugate in Non-Patent Document 6 requires not only the complicated multiple reaction steps of reacting the drug with azidobenzaldehyde, which then reacts with alkyne-modified carboxymethyl chitosan to form a triazole ring, thereby binding the drug to chitosan, but also the need to react the drug with azidobenzaldehyde in advance to form the conjugate. In addition, this reaction is accompanied by the use of a copper catalyst, which poses problems in terms of production and safety.
[0005] In addition, non-patent document 7 (Polymer Bulletin 31 (1993) 145-149) discloses: dextran derivatives in which benzaldehyde is introduced into the hydroxyl position of dextran via an ester bond. These polysaccharide derivatives use neutral polysaccharides, i.e. dextran, as the polysaccharide, so it is difficult to introduce hydrophobic benzaldehyde at a high modification rate. Moreover, the obtained polysaccharide derivatives also lack water solubility, which poses problems in terms of application. The document also discloses: derivatives in which benzaldehyde is introduced into derivatized dextran by reacting epihydrochlorin or epoxy groups. In these derivatives, it is expected that hydrophilicity will be improved by introducing hydroxyl groups from epihydrochlorin or epoxy groups into the side chains, but the synthesis of these derivatives requires multiple reaction steps, and there is room for improvement in industrial production or in terms of the modification rate of benzaldehyde.
[0006] There are also numerous reports on conjugates of Schiff base-free hyaluronic acid with drugs. Examples include HA protein conjugates (Non-Patent Document 8: Carbohydrate Polymers 92 (2013) 2163-2170), HA-IFNα2a conjugates (Non-Patent Document 9: Journal of Controlled Release 236 (2016) 79-89), and HA-pemetrexed conjugates (Non-Patent Document 10: European Journal of Pharmaceutical Sciences 138 (2019) 105008).
[0007] Prior art literature
[0008] Non-patent literature
[0009] Non-patent literature 1: Materials Science and Engineering: C, 2014, 36: 287-293;
[0010] Non-patent document 2: Carbohydrate Polymers 134 (2015) 293-299;
[0011] Non-patent literature 3: Carbohydrate Polymers 189 (2018) 273-279;
[0012] Non-patent literature 4: Carbohydrate Polymers 216 (2019) 63-71;
[0013] Non-patent literature 5: Materials Chemistry Frontiers 2 (2018) 1765-1778;
[0014] Non-patent literature 6: J. Biomed. Nanotechnol. 13 (2017) 1647-1659;
[0015] Non-patent document 7: Polymer Bulletin 31 (1993) 145-149;
[0016] Non-patent document 8: Carbohydrate Polymers 92 (2013) 2163-2170;
[0017] Non-patent literature 9: Journal of Controlled Release 236 (2016) 79-89;
[0018] Non-patent literature 10: European Journal of Pharmaceutical Sciences 138(2019)105008. Summary of the Invention
[0019] The present inventors have provided novel polysaccharide derivatives in PCT / JP2021 / 029573 (filing date: August 10, 2021) having a modified group, such as benzaldehyde, capable of forming a Schiff base with an amino group. The present invention relates to further improvements of these polysaccharide derivatives, particularly to further uses of these polysaccharide derivatives, such as tissue adhesives, and their use in improved cross-linked structures.
[0020] A first aspect of the present invention provides a tissue adhesive material having adhesive properties not only to soft tissues in a living body but also to relatively hard and thick tissues and / or connective tissues such as the dura mater, perichondrium, and synovium.
[0021] A second aspect of the present invention provides a cross-linked structure of a polysaccharide derivative and an amino group-containing material containing a polyhydroxyphenyl group, and a tissue adhesive material comprising the same.
[0022] A third aspect of the present invention provides a tissue adhesive material comprising an amino group-containing polysaccharide derivative.
[0023] In several forms, tissue adhesive materials are used to patch / repair biological tissue.
[0024] The present invention is as follows, for example.
[0025] [1] Tissue adhesive materials for use on hard and thick tissues and / or connective tissues,
[0026] The tissue adhesive material comprises a polysaccharide derivative obtained by introducing a group represented by the following formula (A) into an acidic, basic, or amphoteric polysaccharide.
[0027] [Chemistry 1]
[0028]
[0029] (Where R 1 Represents a hydrogen atom or C 1-4 alkyl;
[0030] Ring P is a benzene ring or a pyridine ring, and the aforementioned benzene ring or pyridine ring is optionally substituted by one or more substituents independently selected from halogen atoms, -CF3, -NO2, carboxyl groups and -SO3H;
[0031] Y represents a member selected from -NH-, -C(=O)-, -S-, -O-, C 1-6 Alkylene, -(CH2CH2O) n - and any combination thereof, wherein n is an integer from 1 to 9;
[0032] *Indicates the linker to the polysaccharide.)
[0033] [2] The tissue adhesive material according to [1], wherein the polysaccharide is selected from alginic acid, its derivatives or their salts, hyaluronic acid, its derivatives or their salts, carboxymethylcellulose, its derivatives or their salts, carboxymethyldextran, its derivatives or their salts, carboxymethyl starch, its derivatives or their salts, heparin, its derivatives or their salts, heparan sulfate, its derivatives or their salts, chondroitin sulfate, its derivatives or their salts, dermatan sulfate, its derivatives or their salts, chitosan, its derivatives or their salts, regenerated oxidized cellulose, its derivatives or their salts, and pectic acid, its derivatives or their salts.
[0034] [3] The tissue adhesive material according to [1] or [2], wherein the polysaccharide is a polysaccharide containing a carboxyl group, the group represented by the formula (A) is a group represented by the following formula (A-1), and the group represented by the formula (A-1) is introduced into the polysaccharide by replacing the -OH group of the carboxyl group of the polysaccharide to form an amide bond; or
[0035] The polysaccharide is an amino group-containing polysaccharide, and the group represented by the formula (A) is a group represented by the following formula (A-2). The group represented by the formula (A-2) is introduced into the polysaccharide by replacing the hydrogen atom of the amino group of the polysaccharide to form an amide bond.
[0036] [Chemistry 2]
[0037]
[0038] (In formulas (A-1) and (A-2),
[0039] R 1 Represents a hydrogen atom or C 1-4 alkyl;
[0040] Ring P is a benzene ring or a pyridine ring, and the aforementioned benzene ring or pyridine ring is optionally substituted by one or more substituents independently selected from halogen atoms, -CF3, -NO2, carboxyl groups and -SO3H;
[0041] L 1 is a single bond, or represents a member selected from -C(=O)-, -S-, -O-, C 1-6 Alkylene, -(CH2CH2O) n - and divalent groups in any combination thereof;
[0042] L 2 is a single bond, or represents a member selected from -NH-, -S-, -O-, C 1-6 Alkylene, -(CH2CH2O) n - and divalent groups in any combination thereof;
[0043] n is an integer from 1 to 9;
[0044] *Indicates the linker to the polysaccharide.)
[0045] [4] The tissue adhesive material according to any one of [1] to [3], wherein the polysaccharide is alginic acid, a derivative thereof, or a salt thereof.
[0046] The polysaccharide derivative includes a structural unit represented by the following formula (c11) and / or (c12).
[0047] [Chemistry 3]
[0048]
[0049] (Where R 11 、R 12 、R 13 and R 14 are independently selected from hydrogen atoms, C 1-6 Alkyl and -C(=O)-C 1-6 alkyl;
[0050] R 1 Represents a hydrogen atom or C 1-4 alkyl;
[0051] Ring P is a benzene ring or a pyridine ring, and the aforementioned benzene ring or pyridine ring is optionally substituted by one or more substituents independently selected from halogen atoms, -CF3, -NO2, carboxyl groups and -SO3H;
[0052] Y stands for -L 1 -NH-, at this time, L 1 Bonded to ring P;
[0053] L 1 Selected from single bond, C 1-6 Alkylene and -(CH2CH2O) n -;
[0054] n is an integer from 1 to 9.)
[0055] [5] The tissue adhesive material according to any one of [1] to [4], wherein the group represented by the formula (A) is selected from the following groups:
[0056] [Chemistry 4]
[0057]
[0058] (Wherein, * represents the linking portion to the polysaccharide.)
[0059] [5-1] The tissue adhesive material according to any one of [1] to [4], wherein the hard and thick tissue and / or connective tissue is selected from dura mater tissue, perichondrium tissue, synovial tissue, and periodontal ligament (periodontal membrane) tissue.
[0060] [5-2] The tissue adhesive material according to any one of [1] to [4], wherein the hard and thick tissue and / or connective tissue is dura mater tissue.
[0061] [5-3] The tissue adhesive material according to any one of [1] to [4], wherein the hard and thick tissue and / or connective tissue is a hard and thick tissue.
[0062] [5-4] The tissue adhesive material according to any one of [1] to [4], wherein the hard and thick tissue and / or connective tissue is connective tissue.
[0063] [6] Tissue adhesive materials for use on hard and thick tissues and / or connective tissues,
[0064] The tissue adhesive material comprises a cross-linked structure in which at least a portion of a polysaccharide derivative obtained by introducing a group represented by the following formula (A) into an acidic, basic, or amphoteric polysaccharide is cross-linked.
[0065] [Chemistry 5]
[0066]
[0067] (Where R 1 Represents a hydrogen atom or C 1-4 alkyl;
[0068] Ring P is a benzene ring or a pyridine ring, and the aforementioned benzene ring or pyridine ring is optionally substituted by one or more substituents independently selected from halogen atoms, -CF3, -NO2, carboxyl groups and -SO3H;
[0069] Y represents a member selected from -NH-, -C(=O)-, -S-, -O-, C 1-6 Alkylene, -(CH2CH2O) n - and any combination thereof, wherein n is an integer from 1 to 9;
[0070] *Indicates the linker to the polysaccharide.)
[0071] [6-1] The tissue adhesive material according to [6], wherein the cross-linked structure has a structure obtained by cross-linking a polysaccharide derivative using a cross-linking agent selected from divalent metal ions; amino-containing polymers and amino-containing low molecular weight compounds containing two or more primary amino groups, hydrazide groups or aminooxy groups; and compounds having two or more aldehyde groups such as glutaraldehyde.
[0072] [6-2] The tissue adhesive material according to [6] or [6-1], wherein the polysaccharide is selected from alginic acid, its derivatives or their salts, hyaluronic acid, its derivatives or their salts, carboxymethylcellulose, its derivatives or their salts, carboxymethyldextran, its derivatives or their salts, carboxymethyl starch, its derivatives or their salts, heparin, its derivatives or their salts, heparan sulfate, its derivatives or their salts, chondroitin sulfate, its derivatives or their salts, dermatan sulfate, its derivatives or their salts, chitosan, its derivatives or their salts, regenerated oxidized cellulose, its derivatives or their salts, and pectinic acid, its derivatives or their salts.
[0073] [6-3] The tissue adhesive material according to [6], [6-1] or [6-2], wherein the polysaccharide is a polysaccharide containing a carboxyl group, the group represented by the formula (A) is a group represented by the following formula (A-1), and the group represented by the formula (A-1) is introduced into the polysaccharide by replacing the -OH group of the carboxyl group of the polysaccharide to form an amide bond; or
[0074] The polysaccharide is an amino group-containing polysaccharide, and the group represented by the formula (A) is a group represented by the following formula (A-2). The group represented by the formula (A-2) is introduced into the polysaccharide by replacing the hydrogen atom of the amino group of the polysaccharide to form an amide bond.
[0075] [Chemistry 6]
[0076]
[0077] (In formulas (A-1) and (A-2),
[0078] R 1 Represents a hydrogen atom or C 1-4 alkyl;
[0079] Ring P is a benzene ring or a pyridine ring, and the aforementioned benzene ring or pyridine ring is optionally substituted by one or more substituents independently selected from halogen atoms, -CF3, -NO2, carboxyl groups and -SO3H;
[0080] L 1 is a single bond, or represents a member selected from -C(=O)-, -S-, -O-, C 1-6 Alkylene, -(CH2CH2O) n - and divalent groups in any combination thereof;
[0081] L 2 is a single bond, or represents a member selected from -NH-, -S-, -O-, C 1-6 Alkylene, -(CH2CH2O) n- and divalent groups in any combination thereof;
[0082] n is an integer from 1 to 9;
[0083] *Indicates the linker to the polysaccharide.)
[0084] [6-4] The tissue adhesive material according to any one of [6], [6-1] to [6-3], wherein the polysaccharide is alginic acid, a derivative thereof, or a salt thereof.
[0085] The polysaccharide derivative includes a structural unit represented by the following formula (c11) and / or (c12).
[0086] [Chemistry 7]
[0087]
[0088] (Where R 11 、R 12 、R 13 and R 14 are independently selected from hydrogen atoms, C 1-6 Alkyl and -C(=O)-C 1-6 alkyl;
[0089] R 1 Represents a hydrogen atom or C 1-4 alkyl;
[0090] Ring P is a benzene ring or a pyridine ring, and the aforementioned benzene ring or pyridine ring is optionally substituted by one or more substituents independently selected from halogen atoms, -CF3, -NO2, carboxyl groups and -SO3H;
[0091] Y stands for -L 1 -NH-, at this time, L 1 Bonded to ring P;
[0092] L 1 Selected from single bond, C 1-6 Alkylene and -(CH2CH2O) n -;
[0093] n is an integer from 1 to 9.)
[0094] [6-5] The tissue adhesive material according to any one of [6], [6-1] to [6-4], wherein the group represented by the formula (A) is selected from the following groups:
[0095] [Chemistry 8]
[0096]
[0097] (Wherein, * represents the linking portion to the polysaccharide.)
[0098] [7] The tissue adhesive material according to any one of [1] to [6], which is in the form of a gel, sponge, sheet or film.
[0099] [8] The tissue adhesive material according to any one of [1] to [7], further comprising a nonwoven fabric, sheet or film.
[0100] [9] A cross-linked structure comprising:
[0101] (a) a polysaccharide derivative obtained by introducing a group represented by the following formula (A) into an acidic, basic or amphoteric polysaccharide; and
[0102] (b) at least one of an amino group-containing polymer and an amino group-containing low molecular weight compound containing two or more primary amino groups, hydrazide groups or aminooxy groups and containing a group represented by the following formula (x1),
[0103] The primary amino group, hydrazide group or aminooxy group contained in the amino group-containing polymer and the amino group-containing low molecular weight compound and the group represented by formula (A) contained in the polysaccharide derivative are covalently bonded via a Schiff base to form a crosslink.
[0104] [Chemistry 9]
[0105]
[0106] (In formula (A), R 1 Represents a hydrogen atom or C 1-4 alkyl;
[0107] Ring P is a benzene ring or a pyridine ring, and the aforementioned benzene ring or pyridine ring is optionally substituted by one or more substituents independently selected from halogen atoms, -CF3, -NO2, carboxyl groups and -SO3H;
[0108] Y represents a member selected from -NH-, -C(=O)-, -S-, -O-, C 1-6 Alkylene, -(CH2CH2O) n - and any combination thereof, wherein n is an integer from 1 to 9;
[0109] *Indicates the linker to the polysaccharide.)
[0110] [Chemistry 10]
[0111]
[0112] (In formula (x1), k is an integer from 2 to 5;
[0113] L 5 is a single bond, or represents a member selected from -C(=O)-, -S-, -O-, alkylene, -(CH2CH2O) n- and divalent groups in any combination thereof;
[0114] n is an integer from 1 to 9;
[0115] *Indicates the linking portion to the amino group-containing polymer or amino group-containing low molecular weight compound.)
[0116]
[10] The cross-linked structure according to [9], wherein the amino-containing polymer is at least one selected from the group consisting of linear, branched or dendritic polyamines; polyalkylene glycols substituted with amino groups, hydrazide groups or aminooxy groups; polyallylamine; polyvinylamine; polyacrylamine; amino-containing polysaccharides; amino-containing proteins; and polyamino acids.
[0117]
[11] The cross-linked structure according to [9] or
[10] , wherein the polysaccharide is alginic acid, a derivative thereof, or a salt thereof.
[0118] The polysaccharide derivative includes a structural unit represented by the following formula (c11) and / or (c12).
[0119] [Chemistry 11]
[0120]
[0121] (Where R 11 、R 12 、R 13 and R 14 are independently selected from hydrogen atoms, C 1-6 Alkyl and -C(=O)-C 1-6 alkyl;
[0122] R 1 Represents a hydrogen atom or C 1-4 alkyl;
[0123] Ring P is a benzene ring or a pyridine ring, and the aforementioned benzene ring or pyridine ring is optionally substituted by one or more substituents independently selected from halogen atoms, -CF3, -NO2, carboxyl groups and -SO3H;
[0124] Y stands for -L 1 -NH-, at this time, L 1 Bonded to ring P;
[0125] L 1 Selected from single bond, C 1-6 Alkylene and -(CH2CH2O) n -;
[0126] n is an integer from 1 to 9.)
[0127]
[12] A tissue adhesive material comprising the cross-linked structure according to any one of [9] to
[11] .
[0128]
[13] A tissue adhesive material comprising a polysaccharide derivative obtained by introducing a group represented by the following formula (A-2) into an amino group-containing polysaccharide,
[0129] The group represented by the above formula (A-2) is introduced into the polysaccharide by substituting the hydrogen atom of the amino group of the above polysaccharide to form an amide bond.
[0130] The tissue adhesive material is in the form of a gel.
[0131] [Chemistry 12]
[0132]
[0133] (In formula (A-2),
[0134] R 1 Represents a hydrogen atom or C 1-4 alkyl;
[0135] Ring P is a benzene ring or a pyridine ring, and the aforementioned benzene ring or pyridine ring is optionally substituted by one or more substituents independently selected from halogen atoms, -CF3, -NO2, carboxyl groups and -SO3H;
[0136] L 2 is a single bond, or represents a member selected from -NH-, -S-, -O-, C 1-6 Alkylene, -(CH2CH2O) n - and divalent groups in any combination thereof;
[0137] n is an integer from 1 to 9;
[0138] *Indicates the linker to the polysaccharide.)
[0139]
[14] The composition according to
[13] , wherein the shear rate measured at 25°C is 0.001s -1 The viscosity (η 0.001 ) and shear rate of 1000s -1 The viscosity (η 1000 ) ratio (η 0.001 / η 1000 ) is 10~10 9 .
[0140]
[15] The tissue adhesive material according to
[13] or
[14] , wherein the polysaccharide derivative is cross-linked by forming a covalent bond between the amino group contained in the polysaccharide derivative and the group represented by the formula (A-2) via a Schiff base to form a cross-linked structure.
[0141]
[16] The tissue adhesive material according to any one of
[13] to
[15] , wherein the polysaccharide is chitosan, a derivative thereof, or a salt thereof,
[0142] The polysaccharide derivative includes a structural unit represented by the following formula (c16).
[0143] [Chemistry 13]
[0144]
[0145] (Where,
[0146] R 81 and R 82 are independently selected from hydrogen atoms, C 1-6 Alkyl and -C(=O)-C 1-6 alkyl;
[0147] R 1 Represents a hydrogen atom or C 1-4 alkyl;
[0148] Ring P is a benzene ring or a pyridine ring, and the aforementioned benzene ring or pyridine ring is optionally substituted by one or more substituents independently selected from halogen atoms, -CF3, -NO2, carboxyl groups and -SO3H;
[0149] Y stands for -L 2 -C(=O)-, at this time, L 2 Bonded to ring P;
[0150] L 2 Selected from single bond, C 1-6 Alkylene, -(CH2CH2O) n -、-(CH2) m1 -(CH2CH2O) n -(CH2) m2 - and -(CH2) m1 -O-(CH2CH2O) n -(CH2) m2 -;
[0151] n is an integer from 1 to 9;
[0152] m1 and m2 are each independently an integer of 1 to 9.
[0153] According to a first aspect of the present invention, a tissue adhesive material for patching / repairing biological tissue is provided. The material has adhesive properties not only to soft tissues in the body but also to relatively hard and thick tissues and / or connective tissues, such as the dura mater, perichondrium, and synovium. The tissue adhesive material comprises a polysaccharide derivative. The tissue adhesive material has good adhesion to the tissue by forming a Schiff base between the amino groups of the tissue and the aldehyde of the polysaccharide derivative. According to several aspects, the adhesion to the tissue can be improved by forming hydrophobic interactions and hydrogen bonds between the tissue proteins constituting the tissue and the polysaccharide derivative. The material that adheres to the tissue helps to protect and repair the tissue, for example, in the case of the dura mater, it can prevent leakage of cerebrospinal fluid.
[0154] According to a second aspect of the present invention, a cross-linked structure of a polysaccharide derivative and an amino group-containing material containing polyhydroxyphenyl groups is provided. This cross-linked structure has excellent tissue adhesion and can be used as a tissue adhesive material.
[0155] According to a third aspect of the present invention, there is provided a gel-type tissue adhesive material comprising a polysaccharide derivative containing an amino group. The tissue adhesive material is obtained by modifying the aldehyde group or ketone group (-C(=O)R 1 ) forms a Schiff base between the amino groups of biological tissue and the aldehyde of the polysaccharide derivative, thereby exhibiting excellent tissue adhesion. Furthermore, in some embodiments, the amino groups of the polysaccharide derivative interact with the carboxyl groups of biological tissue, thereby enhancing tissue adhesion. In some embodiments, the amino group-containing polysaccharide derivative exhibits pH-responsive self-crosslinking properties. BRIEF DESCRIPTION OF THE DRAWINGS
[0156] [ Figure 1 ] Figure 1 A shows the benzaldehyde modified alginate (AL-ABA) and alginate (AL) synthesized in Example I-1. 1 HNMR spectroscopy, Figure 1 B shows Figure 1 The peaks b to d shown in A correspond to the regions.
[0157] [ Figure 2 ] Figure 2 The UV-visible absorption spectra (UV-vis) of benzaldehyde-modified alginate (AL-ABA), alginate (AL), and 4-aminobenzaldehyde (ABA) synthesized in Example I-1 are shown.
[0158] [ Figure 3 ] Figure 3 FT-IR spectra of benzaldehyde-modified alginate (AL-ABA) and alginate (AL) synthesized in Example I-1 are shown.
[0159] [ Figure 4 ] Figure 4 The results of cytotoxicity tests (WST assay results) of benzaldehyde-modified alginate (AL-ABA) and alginate (AL) synthesized in Example I-1 with different concentrations (0.01 mg / mL, 0.1 mg / mL and 1 mg / mL) on MeT-5A (human mesothelial cell line), NIH / 3T3 (mouse fetal fibroblasts), HUVEC (human umbilical vein endothelial cells) and RAW264.7 cells (mouse macrophage-like cell line) are shown.
[0160] [ Figure 5 ] Figure 5 The AAP modified alginic acid (AL-AAP) synthesized in Example I-3 is shown 1 H NMR spectrum.
[0161] [ Figure 6 ] Figure 6 The FT-IR spectrum of AAP-modified alginate (AL-AAP) synthesized in Example I-3 is shown.
[0162] [ Figure 7 ] Figure 7 The ADFBA modified alginic acid (AL-ADFBA) synthesized in Example I-4 is shown 1 H NMR spectrum.
[0163] [ Figure 8 ] Figure 8 The FT-IR spectrum of ADFBA-modified alginic acid (AL-ADFBA) synthesized in Example I-4 is shown.
[0164] [ Figure 9 ] Figure 9 The AAP modified alginate (AL-APCA) synthesized in Example I-5 is shown 1 H NMR spectrum.
[0165] [ Figure 10 ] Figure 10 The FT-IR spectrum of AAP-modified alginate (AL-APCA) synthesized in Example I-5 is shown.
[0166] [ Figure 11 ] Figure 11 The ANA modified alginic acid (AL-ANA) synthesized in Example I-6 is shown 1 H NMR spectrum.
[0167] [ Figure 12 ] Figure 12 The FT-IR spectrum of ANA-modified alginic acid (AL-ANA) synthesized in Example I-6 is shown.
[0168] [ Figure 13 ] Figure 13 The benzaldehyde-modified alginate-vancomycin conjugate (AL-ABA-Van) synthesized in Example I-7, the benzaldehyde-modified alginate (AL-ABA) synthesized in Example I-1, vancomycin (Van) and alginate (AL) are shown. 1 H NMR spectrum.
[0169] [ Figure 14 ] Figure 14 The ultraviolet-visible absorption spectra (UV-vis) of the benzaldehyde-modified alginate-vancomycin conjugate (AL-ABA-Van) synthesized in Example I-7, the benzaldehyde-modified alginate (AL-ABA) synthesized in Example I-1, and vancomycin (Van) are shown.
[0170] [ Figure 15 ] Figure 15 FT-IR spectra of the benzaldehyde-modified alginate-vancomycin conjugate (AL-ABA-Van) synthesized in Example I-7, the benzaldehyde-modified alginate (AL-ABA) synthesized in Example I-1, vancomycin (Van), and alginic acid (AL) are shown.
[0171] [ Figure 16A ] Figure 16A The release behavior of vancomycin (Van) from solutions of the benzaldehyde-modified alginate-vancomycin conjugate (AL-ABA-Van) synthesized in Example I-7 at different pH values (pH = 5.0, 6.0, and 7.4) is shown. The Van release rate (cumulative release %) shown on the vertical axis is the cumulative Van release rate (%), calculated from absorbance measured by UV-vis spectroscopy.
[0172] [ Figure 16B ] Figure 16B The release behavior of Van from a mixed solution of sodium alginate and vancomycin (AL+Van) at different pH values (pH = 5.0, 6.0, and 7.4) is shown (control experiment). The Van release rate (cumulative release %) shown on the vertical axis is the cumulative Van release rate (%), calculated from absorbance measured by UV-vis spectroscopy.
[0173] [ Figure 16C ] Figure 16C The release behavior of Van from vancomycin solutions (Van alone) at different pH values (pH = 5.0, 6.0, and 7.4) is shown (control experiment). The Van release rate (cumulative release %) shown on the vertical axis is the cumulative Van release rate (%), calculated from the absorbance measured by UV-vis spectroscopy.
[0174] [ Figure 17 ] Figure 17 Confocal microscopy images of FTSC-loaded AL-ABA capsules and FTSC-loaded AL capsules prepared in Example 1-8 are shown. The top panel shows a confocal microscopy image of the AL-capsules (Alg microcapsules) in saline containing FTSCs, the middle panel shows a confocal microscopy image of the AL-ABA capsules (Alg-ABA microcapsules) in saline containing FTSCs, and the bottom panel shows a confocal microscopy image of the AL-ABA capsules (Alg-ABA microcapsules) in DMEM containing FTSCs. In each panel, the left side shows the transmitted image (Transmitted), the center shows the fluorescent image (amine-fluorescein), and the right side shows a merged image of the two.
[0175] [ Figure 18 ] Figure 18 The release behavior of vancomycin (Van) from the Van-loaded AL-ABA microcapsules (AL-ABA-Van capsules) prepared in Example I-9 and the Van-loaded AL microcapsules (AL-Van capsules) as a control are shown. Figure 18 A is a graph in which the vertical axis shows the cumulative release rate (%) of Van, Figure 18 B is a graph in which the vertical axis shows the release rate of Van (% vancomycin released) at each time point. The release rate of Van (% vancomycin released) was calculated from the absorbance measured by UV-vis spectroscopy.
[0176] [ Figure 19 ] Figure 19 These photographs show the growth of Staphylococcus aureus around filter paper soaked with a sustained-release solution from vancomycin-loaded capsules. (a) shows the results using a sustained-release solution from vancomycin-loaded AL capsules (AL-Van), and (b) shows the results using a sustained-release solution from vancomycin-loaded AL-ABA capsules (AL-ABA-Van). The top panel shows the results immediately after adding the sustained-release solution, while the bottom panel shows the results 24 hours after addition.
[0177] [ Figure 20 ] Figure 20 The figure shows the comparison of the inhibition areas of vancomycin-loaded AL capsule (AL-Van) and vancomycin-loaded AL-ABA capsule (AL-ABA-Van) on the proliferation of Staphylococcus aureus at different sustained-release times (n=3).
[0178] [ Figure 21 ] Figure 21The ultraviolet-visible absorption spectra (UV-vis) of the benzaldehyde-modified alginate-bacitracin conjugate (AL-ABA-Bac) synthesized in Example 1-10, the benzaldehyde-modified alginate (AL-ABA) synthesized in Example 1, and bacitracin (Bac) are shown.
[0179] [ Figure 22 ] Figure 22 FT-IR spectra of the benzaldehyde-modified alginate-bacitracin conjugate (AL-ABA-Bac) synthesized in Example 1-10, bacitracin (Bac), the benzaldehyde-modified alginate (AL-ABA) synthesized in Example 1, and alginic acid (AL) are shown.
[0180] [ Figure 23 ] Figure 23 The benzaldehyde-modified alginate-dopamine conjugate (AL-ABA-DOPA) synthesized in Example I-11 is shown. 1 H NMR spectrum.
[0181] [ Figure 24 ] Figure 24 The FT-IR spectrum of the benzaldehyde-modified alginate-dopamine conjugate (AL-ABA-DOPA) synthesized in Example I-11 is shown.
[0182] [ Figure 25 ] Figure 25 The benzaldehyde-modified alginate-serotonin conjugate (AL-ABA-serotonin) synthesized in Example I-13 is shown. 1 H NMR spectrum.
[0183] [ Figure 26 ] Figure 26 The FT-IR spectrum of the benzaldehyde-modified alginate-serotonin conjugate (AL-ABA-serotonin) synthesized in Example I-13 is shown.
[0184] [ Figure 27 ] Figure 27 The benzaldehyde-modified alginate-celecoxib conjugate (AL-ABA-celecoxib) synthesized in Example I-14 is shown. 1 H NMR spectrum.
[0185] [ Figure 28 ] Figure 28 The preparation method of AL-ABA-Apt and the experimental procedures of the sustained-release experiment of AL-ABA-Apt in Example I-15 are shown.
[0186] [ Figure 29 ] Figure 29The release behavior of the HGF aptamer (Apt) from the AL-ABA-HGF aptamer (AL-ABA-Apt) synthesized in Example 1-15, a mixture of alginic acid and the HGF aptamer (ALG-Apt), and the HGF aptamer monomer (Apt) under physiological pH conditions (pH 7.4) is shown. The vertical axis represents the HGF aptamer release rate (cumulative release rate %), calculated from the absorbance measured by UV-vis spectroscopy.
[0187] [ Figure 30 ] Figure 30 Optical photographs of benzaldehyde-modified alginic acid sponges prepared in Example I-16 are shown. Control represents an AL sponge prepared as a comparison, while A, B, and C represent AL / AL-ABA mixed sponges with AL to AL-ABA blending ratios (by weight) of 75:25, 50:50, and 25:75, respectively.
[0188] [ Figure 31 ] Figure 31 SEM images of the benzaldehyde-modified alginate sponge prepared in Example I-16 are shown. Control represents an AL sponge prepared as a comparison, while A, B, and C represent AL / AL-ABA hybrid sponges with AL to AL-ABA blending ratios (by weight) of 75:25, 50:50, and 25:75, respectively.
[0189] [ Figure 32 ] Figure 32 Swelling / decomposition curves (weight change of the hydrogel) of the Ca-crosslinked AL-ABA hydrogel are shown.
[0190] [ Figure 33 ] Figure 33 This is a SEM photograph of a sponge obtained by freeze-drying a Ca-crosslinked AL-ABA hydrogel (magnification ×500; 24 hours after the start of swelling). The porous structure of the dried hydrogel was confirmed.
[0191] [ Figure 34 ] Figure 34 A schematic diagram showing a cross-linked structure of AL-ABA and an amino group-containing polymer (DPI; dendritic polyethyleneimine) prepared in Example I-18.
[0192] [ Figure 35 ] Figure 35 A photograph showing a hydrogel composed of a cross-linked structure of AL-ABA and DPI.
[0193] [ Figure 36A ] Figure 36A The PEG-COOH prepared in Example I-19 is shown 1HNMR spectrum.
[0194] [ Figure 36B ] Figure 36B The PEGDH prepared in Example I-19 is shown 1 H NMR spectrum.
[0195] [ Figure 36C ] Figure 36C A photograph showing the hydrogel composed of a cross-linked structure of AL-ABA and PEGDH prepared in Example I-19.
[0196] [ Figure 37 ] Figure 37 The results of dynamic viscoelasticity measurement of the hydrogel composed of a cross-linked structure of AL-ABA and an amino group-containing polymer (PEGDH) prepared in Example I-19 are shown.
[0197] [ Figure 38 ] Figure 38 A photograph showing the hydrogel of AL-ABA and polyallylamine prepared in Example I-21.
[0198] [ Figure 39 ] Figure 39 In Example I-22, gels obtained by calcium-crosslinking benzaldehyde-modified alginic acid (AL-ABA) and alginic acid (AL) (AL-ABA gel, AL gel) were administered to the pig esophagus and immersed in physiological saline, and their appearance changed over time. Figure 39 In the figures, ALG (IL-6G) represents AL gel, and ALG-ABA represents AL-ABA gel.
[0199] [ Figure 40 ] Figure 40 The present invention shows the temporal changes in the weight (adhesion rate, %) of the gels obtained by calcium cross-linking benzaldehyde-modified alginate (AL-ABA) and alginic acid (AL) in Example I-22, respectively, when administered to the pig esophagus and immersed in physiological saline. Figure 40 In the figures, ALG (IL-6G) represents AL gel, and ALG-ABA represents AL-ABA gel.
[0200] [ Figure 41 ] Figure 41 Schematic diagram showing the binding of AL-ABA and AL to the esophageal mucosa and submucosa.
[0201] [ Figure 42 ] Figure 42The diagram shows the procedure for evaluating the adhesiveness of AL-ABA and AL to the esophageal mucosal layer and submucosa in Example I-23.
[0202] [ Figure 43 ] Figure 43 In Example 1-23, benzaldehyde-modified alginate (AL-ABA) and alginate (AL) were added to the solution at 50 mM or 100 mM CaCl2. 2+ Calcium-crosslinked gels (AL-ABA, AL) were applied to the mucosa (Control) and submucosa (ESD) of the porcine esophagus and immersed in saline. Circles (dashed lines) in the figure indicate areas where material remains.
[0203] [ Figure 44 ] Figure 44 In Example 1-23, benzaldehyde-modified alginate (AL-ABA) and alginate (AL) were added to the solution at 50 mM or 100 mM CaCl2. 2+ The calcium-crosslinked gels (AL-ABA, AL) were applied to the mucosa (Con) and submucosa (ESD) of the porcine esophagus and immersed in physiological saline to show the temporal changes in the gel weight (adhesion rate, %).
[0204] [ Figure 45 ] Figure 45 is a schematic diagram showing the method of the tensile test in Example I-23.
[0205] [ Figure 46 ] Figure 46 The tensile test results of the AL-ABA and AL Ca cross-linked hydrogels adhered to the mucosa (Control) and submucosa (ESD) in Example I-23 are shown.
[0206] [ Figure 47 ] Figure 47 (A) and (B) are schematic diagrams showing the experimental steps of the overlapping shearing method in Example I-24.
[0207] [ Figure 48 ] Figure 48 The results show the adhesion strength (Pa) of the AL-ABA and AL Ca cross-linked hydrogels adhered to the submucosa tissue (submucosa) and skin tissue (skin) in Example I-24 and conventional tissue adhesives measured by the overlapping shear method.
[0208] [ Figure 49 ] Figure 49 (A) is a schematic diagram showing an apparatus used in the fracture test in Example I-25. Figure 49 (B) is a schematic diagram showing the method of the fracture test.
[0209] [ Figure 50 ] Figure 50 The results of the burst pressure (burst pressure, mmHg) measured by the burst test in Example 1-25 for AL-ABA and AL Ca cross-linked hydrogels adhered to submucosal tissue (submucosa) and skin tissue (skin), as well as existing tissue adhesives, are shown.
[0210] [ Figure 51 ] Figure 51 The benzaldehyde-modified hyaluronic acid (HA-ABA) synthesized in Example II-1 is shown 1 H NMR spectrum.
[0211] [ Figure 52 ] Figure 52 Shown are the ultraviolet-visible absorption spectra (UV-vis) of benzaldehyde-modified hyaluronic acid (HA-ABA), hyaluronic acid (HA), and 4-aminobenzaldehyde (ABA) synthesized in Example II-1.
[0212] [ Figure 53 ] Figure 53 FT-IR spectra of benzaldehyde-modified hyaluronic acid (HA-ABA), hyaluronic acid (HA), and 4-aminobenzaldehyde (ABA) synthesized in Example II-1 are shown.
[0213] [ Figure 54 ] Figure 54 The results of cytotoxicity tests (WST assay results) of benzaldehyde-modified hyaluronic acid (HA-ABA) and hyaluronic acid (HA) synthesized in Example II-1 with different concentrations (0.01 mg / mL, 0.1 mg / mL and 1 mg / mL) on MeT-5A (human mesothelial cell line), HUVEC (human umbilical vein endothelial cells), RAW264.7 cells (mouse macrophage-like cell line), NIH / 3T3 (mouse fetal fibroblasts) and AB22 cells (mouse mesothelioma cells) are shown.
[0214] [ Figure 55 ] Figure 55 The benzaldehyde-modified hyaluronic acid-pemetrexed conjugate (HA-ABA-PMX), benzaldehyde-modified hyaluronic acid (HA-ABA) and hyaluronic acid (HA) and pemetrexed (PMX) synthesized in Example II-2 are shown. 1 H NMR spectrum.
[0215] [ Figure 56 ] Figure 56Shown are the ultraviolet-visible absorption spectra (UV-vis) of the benzaldehyde-modified hyaluronic acid-pemetrexed conjugate (HA-ABA-PMX) and benzaldehyde-modified hyaluronic acid (HA-ABA) synthesized in Example II-2.
[0216] [ Figure 57 ] Figure 57 The release behavior of pemetrexed (PMX) from a benzaldehyde-modified hyaluronic acid-pemetrexed conjugate solution (HA-ABA-PMX) at different pH values (pH = 5.0, 6.0, and 7.4), from a PMX solution (free PMX), and from a mixed solution of HA and PMX (free PMX mixed with HA) is shown. The vertical axis represents the cumulative drug release rate (%) of PMX, calculated from absorbance measured by UV-vis spectroscopy.
[0217] [ Figure 58 ] Figure 58 A and Figure 58 B shows the results of different PMX concentrations (10 -4 μg / mL, 10 -3 μg / mL, 10 -2 μg / mL, 10 -1 The inhibitory effects of the benzaldehyde-modified hyaluronic acid-pemetrexed conjugate (HA-ABA-PMX) synthesized in Example II-2 (1 μg / mL, 1 μg / mL, and 10 μg / mL), free pemetrexed (PMX), and HA-ADH-PMX, in which PMX is irreversibly bound to HA via an amide bond, on AB22 cells (mouse mesothelioma cells) and MeT-5A (human mesothelial cell line). The vertical axis represents cell viability (%).
[0218] [ Figure 59 ] Figure 59 The ultraviolet-visible absorption spectra (UV-vis) of the benzaldehyde-modified hyaluronic acid-doxorubicin (Doxorubicin) conjugate (HA-ABA-DOX) synthesized in Example II-3, the benzaldehyde-modified hyaluronic acid (HA-ABA) synthesized in Example II-1, and doxorubicin (DOX) are shown.
[0219] [ Figure 60 ] Figure 60This figure shows the release behavior of doxorubicin (DOX) from a benzaldehyde-modified hyaluronic acid-doxorubicin conjugate solution (HA-ABA-DOX) at different pH values (pH = 5.0, 6.0, and 7.4). The vertical axis represents the cumulative drug release rate (%) of DOX, calculated from absorbance measured by UV-vis spectroscopy.
[0220] [ Figure 61 ] Figure 61 It was shown that with different DOX concentrations (10 -3 μg / mL, 10 -2 μg / mL, 10 -1 The inhibitory effects of the benzaldehyde-modified hyaluronic acid-doxorubicin conjugate (HA-ABA-DOX) synthesized in Example II-3 (at 400 μg / mL, 1 μg / mL, 10 μg / mL, and 100 μg / mL) and free doxorubicin (DOX) on AB22 cells (mouse mesothelioma cells) are shown. The vertical axis represents cell viability (%).
[0221] [ Figure 62 ] Figure 62 Shown are the ultraviolet-visible absorption spectra (UV-vis) of the benzaldehyde-modified hyaluronic acid-gemcitabine conjugate (HA-ABA-GEM) synthesized in Example II-4, the benzaldehyde-modified hyaluronic acid (HA-ABA) synthesized in Example II-1, and gemcitabine (GEM).
[0222] [ Figure 63 ] Figure 63 The benzaldehyde-modified hyaluronic acid-adenine conjugate (HA-ABA-adenine) synthesized in Example II-5 is shown. 1 H NMR spectrum.
[0223] [ Figure 64 ] Figure 64 The benzaldehyde-modified hyaluronic acid-cytosine conjugate (HA-ABA-cytosine) synthesized in Example II-5 is shown. 1 H NMR spectrum.
[0224] [ Figure 65 ] Figure 65 The benzaldehyde-modified hyaluronic acid-guanine conjugate (HA-ABA-guanine) synthesized in Example II-5 is shown. 1 H NMR spectrum.
[0225] [ Figure 66 ] Figure 66FT-IR spectra of the benzaldehyde-modified hyaluronic acid-DNA nucleotide conjugates (HA-ABA-adenine, HA-ABA-cytosine, and HA-ABA-guanine) synthesized in Example II-5 and the benzaldehyde-modified hyaluronic acid (HA-ABA) synthesized in Example II-1 are shown.
[0226] [ Figure 67 ] Figure 67 The benzaldehyde-modified carboxymethyl cellulose (CMC-ABA) synthesized in Example III-1 is shown 1 HNMR spectrum.
[0227] [ Figure 68 ] Figure 68 FT-IR spectra of benzaldehyde-modified carboxymethyl cellulose (CMC-ABA) and carboxymethyl cellulose (CMC) synthesized in Example III-1 are shown.
[0228] [ Figure 69 ] Figure 69 The benzaldehyde-modified carboxymethyl dextran (CMDX-ABA) synthesized in Example IV-1 is shown. 1 HNMR spectrum.
[0229] [ Figure 70 ] Figure 70 FT-IR spectra of benzaldehyde-modified carboxymethyl dextran (CMD-ABA) and carboxymethyl dextran (CMD) synthesized in Example IV-1 are shown.
[0230] [ Figure 71 ] Figure 71 FT-IR spectra of the benzaldehyde-modified carboxymethyl dextran-DNA nucleotide conjugates (CMD-ABA-adenine, CMD-ABA-cytosine, and CMD-ABA-guanine) synthesized in Example IV-2, the benzaldehyde-modified carboxymethyl dextran (CMD-ABA) synthesized in Example IV-1, and carboxymethyl dextran (CMD) are shown.
[0231] [ Figure 72 ] Figure 72 The benzaldehyde modified chitosan (chitosan-CBA) synthesized in Example V-1 is shown 1 H NMR spectrum.
[0232] [ Figure 73 ] Figure 73 The FT-IR spectrum of the benzaldehyde-modified chitosan (chitosan-CBA) synthesized in Example V-1 is shown.
[0233] [ Figure 74 ] Figure 74(A) is a schematic diagram showing the experimental procedure for evaluating the adhesiveness of dura mater tissue by the overlapping shear method in Example I-26. Figure 74 (B) shows the results of measuring the adhesion strength (Pa) of various alginic acid derivatives (AL-ABA, AL-AFA, AL-AAP, AL-APA, AL-ANA) and existing tissue adhesives to dura mater tissue by the overlapping shear method.
[0234] [ Figure 75A FIG75(A) is a schematic diagram showing the method of the burst test in Example 1-27. FIG75(B) shows the results of the burst pressure (mmHg) measured by the burst test for various alginic acid derivatives (AL-ABA, AL-AFA, AL-AAP, AL-APA, AL-ANA) and existing tissue adhesives adhered to dura mater tissue in Example 1-27. Samples ending with "Neovil" use Neovil (registered trademark) as the nonwoven fabric, and samples ending with "Double Vicryl mesh" and "Single Vicryl mesh" use two and one sheets of "Ethicon Vicryl Mesh" as the nonwoven fabric, respectively.
[0235] [ Figure 75B Figure 75(C) shows the results of a burst test in Example 1-27 measuring the burst pressure (mmHg) of various alginic acid derivatives (AL-ABA, AL-AFA, AL-AAP, AL-APA, AL-ANA) and conventional tissue adhesives adhered to dura mater tissue. Samples ending with "Neovil" used Neovil (registered trademark) as the nonwoven fabric, while samples ending with "Double Vicryl Mesh" and "Single Vicryl Mesh" used two and one sheets of "Ethicon Vicryl Mesh" as the nonwoven fabric, respectively.
[0236] [ Figure 76 ] Figure 76 The results of the viscoelasticity analysis (flow curve) in Example I-28 are shown.
[0237] [ Figure 77 ] Figure 77 The results of the frequency sweep test in Example I-28 are shown.
[0238] [ Figure 78 ] Figure 78 The results of the hemolysis test in Example I-29 are shown.
[0239] [ Figure 79 ] Figure 79 The dendritic poly (ethyleneimine) (DPIGA) synthesized in Example 1-30 and conjugated with gallic acid is shown. 1 H NMR spectra. Spectra of gallic acid (GA) and dendritic poly(ethyleneimine) (DPI) are also shown.
[0240] [ Figure 80 ] Figure 80 The FT-IR spectrum of DPIGA synthesized in Example I-30 is shown. The spectra of GA and DPI are also shown.
[0241] [ Figure 81 ] Figure 81 The ultraviolet-visible absorption spectrum (UV-vis) of DPIGA synthesized in Example I-30 is shown. The spectra of GA and DPI are also shown.
[0242] [ Figure 82 ] Figure 82 (A) shows the results of the overlapping shear method for measuring the adhesion strength (Pa) of the conjugate (crosslinked structure) of AL-ABA and a GA-modified amino-containing polymer prepared in Example I-30 (AL-ABA / DPI-GA) to skin tissue or submucosal tissue. AL-ABA and DPI-GA were used as controls. Figure 82 (B) is a schematic diagram showing the binding morphology of the conjugate of AL-ABA and GA-modified amino-containing polymer (cross-linked structure) to tissues.
[0243] [ Figure 83 ] Figure 83 (A) shows the benzaldehyde-modified chitosan (CH-CBA) synthesized in Example V-2. 1 H NMR spectrum. Figure 83 (B) shows the FT-IR spectrum of CH-CBA prepared in Example V-2. Figure 83 (C) shows the ultraviolet-visible absorption spectrum (UV-vis) of CH-CBA prepared in Example V-2.
[0244] [ Figure 84 ] Figure 84 The results of a gelation test at different pH values measured by the vial inversion method are shown for the CH-CBA prepared in Example V-2.
[0245] [ Figure 85 ] Figure 85 The results of viscoelasticity analysis of CH-CBA prepared in Example V-2 at different pH values are shown. Figure 85 (A) is a graph showing the storage modulus (G') and loss modulus (G") of CH-CBA hydrogels at different pH values. Figure 85 (B) is a graph plotting the loss coefficient (tanδ) of CH-CBA hydrogels at different pH values. Figure 85 (C) is a graph plotting the viscosity (η) of CH-CBA hydrogels at different pH values when the shear rate is changed.
[0246] [ Figure 86 ] Figure 86 The pH of CH-CBA prepared in Example V-2 and the shear rate 10 -3 s -1 The viscosity (η 0.001 ) relative to the shear rate of 10 3 s -1 The viscosity (η 1000 ) viscosity ratio (η 0.001 / η 1000 ) diagram of the relationship.
[0247] [ Figure 87 ] Figure 87 SEM images of the CH-CBA hydrogel prepared in Example V-2 and gelled at different pH values are shown.
[0248] [ Figure 88 ] Figure 88 (A) Schematic diagram showing the pH-responsive self-crosslinking property of CH-CBA hydrogel. Figure 88 (B) is a schematic diagram showing the adhesion of CH-CBA hydrogel to tissue.
[0249] [ Figure 89 ] Figure 89 (A) shows the results of a cytotoxicity test of CH-CBA prepared in Example V-2 (WST-8 assay results). Figure 89 (B) shows the results of the Live / Dead cell viability measurement of the CH-CBA prepared in Example V-2. The results of fibrin glue and albumin / glutaraldehyde (albumin / GTA) as control groups are also shown.
[0250] [ Figure 90 ] Figure 90 is a schematic diagram showing the method of overlapping shear test using CH-CBA hydrogel.
[0251] [ Figure 91AFigures 91(A) and (B) show the results of adhesion tests on CH-CBA hydrogels prepared at different pH values in Example V-2. Figure 91(C) shows the results of overlapping shear tests on mucosa of CH-CBA hydrogels prepared at different pH values in Example V-2.
[0252] [ Figure 91B ] Figures 91 (D) to (E) respectively show the results of overlapping shear tests on submucosal tissue and skin of CH-CBA hydrogels of different pH prepared in Example V-2. DETAILED DESCRIPTION
[0253] In this specification, a "halogen atom" means a fluorine atom (F), a chlorine atom (Cl), a bromine atom (Br), or an iodine atom (I).
[0254] In this manual, "C 1-k The term "alkyl" refers to a linear or branched alkyl group having 1 to k carbon atoms.
[0255] In this manual, "C 1-k The term "alkylene group" refers to a linear or branched alkylene group having 1 to k carbon atoms.
[0256] As used herein, "polysaccharide" refers to a compound composed of two or more monosaccharides linked together by glycosidic bonds, derivatives thereof (e.g., polysaccharides modified by esterification, maleimide modification, thiol modification, acrylate modification, aldehyde modification, disulfide modification (e.g., pyridyl disulfide), alkyne modification including cyclic alkynes, tetrazine modification, furan ring modification, etc.), salts thereof, and cross-linked products thereof. Polysaccharides composed of 2 to 10 linked monosaccharides are sometimes referred to as oligosaccharides, but as used herein, "polysaccharide" includes "oligosaccharides" in addition to the narrowly defined "polysaccharide" composed of 10 or more linked monosaccharides.
[0257] In the present specification, the "polysaccharide derivative-drug conjugate" refers to a complex formed by linking a drug and a polysaccharide derivative via a bond.
[0258] I. First Form
[0259] A first aspect of the present invention relates to a tissue adhesive material for tissues that exhibits adhesive properties not only to soft tissues within a living body but also to relatively hard and thick tissues such as the dura mater and / or connective tissue. This aspect of the tissue adhesive material is a tissue adhesive material for hard and thick tissues and / or connective tissues, and comprises a polysaccharide derivative (hereinafter referred to as a "polysaccharide derivative") obtained by introducing a group represented by the following formula (A) into an acidic, basic, or amphoteric polysaccharide. In some embodiments, the tissue adhesive material is used for repairing / repairing living tissues.
[0260] [Chemistry 14]
[0261]
[0262] (Where R 1 Represents a hydrogen atom or C 1-4 alkyl;
[0263] Ring P is a benzene ring or a pyridine ring, and the aforementioned benzene ring or pyridine ring is optionally substituted by one or more substituents independently selected from halogen atoms, -CF3, -NO2, carboxyl groups and -SO3H;
[0264] Y represents a member selected from -NH-, -C(=O)-, -S-, -O-, C 1-6 Alkylene, -(CH2CH2O) n - and any combination thereof, wherein n is an integer from 1 to 9;
[0265] *Indicates the linker to the polysaccharide.)
[0266] As used herein, "hard and thick tissue" refers to: solid biological components containing calcium and phosphate, such as bones and teeth; and collagen-containing membranes, tubular structures, and flat plates, such as the dura mater, perichondrium, periodontal ligament, and cartilage; or tissues present at the ends of bones. The thickness of such "hard and thick tissue" ranges from 0.1 to 10 mm, for example.
[0267] "Connective tissue" refers to tissue derived from mesenchymal tissue (mesenchyme), which connects various organs and tissues, fills gaps and provides support. Connective tissue is composed of fibers such as collagen fibers and elastic fibers and connective tissue cells such as fibroblasts, lymphocytes, plasma cells, and white blood cells. Depending on the type of fibers or cells that make up the tissue, it is divided into gelatinous tissue, reticular tissue, fibrous connective tissue, elastic tissue, adipose tissue, pigmented tissue, etc. The shape and composition of connective tissue vary. Connective tissue includes, for example, fascia, tendons, ligaments, synovial capsule, cartilage, periosteum, dura mater, sclera, dermis, etc.
[0268] It should be noted that there are some overlapping tissues between "hard and thick tissue" and "connective tissue", and as long as the tissue is included in either of them, the tissue adhesive material can be preferably applied in the first embodiment.
[0269] The target hard and thick tissue, connective tissue, exists throughout the body.
[0270] In a specific embodiment, the hard and thick tissue and / or connective tissue is selected from the group consisting of dura mater, perichondrium, synovium, periodontal ligament, elastic cartilage.
[0271] In some embodiments, the hard and thick tissue and / or connective tissue is selected from the group consisting of dura mater, perichondrium, synovium, and periodontal ligament.
[0272] One of the representative hard and thick tissues and / or connective tissues is the dura mater. The dura mater refers to the dura mater that wraps the brain / spinal cord, and is divided into the dura mater that wraps the brain and the spinal dura mater that wraps the spinal cord. The structures below the dura mater include the arachnoid mater, the pia mater, and the brain / spinal cord substance. The dura mater / arachnoid mater / pia mater are collectively referred to as the meninges, and the dura mater plays a role in protecting the brain and spinal cord from trauma or infection. The dura mater is composed of two layers: the inner layer (also referred to as the inner lobe / inner plate) and the outer layer (also referred to as the outer lobe / outer plate). In the spinal cord, there is a gap between the outer layer and the inner layer called the epidural space (supradural space). In the brain, most of the parts except the dural venous sinuses are tightly closed. There is a gap called the subdural space between the inner arachnoid mater. In this manual, the dura mater can be either the dura mater or the spinal dura mater. The perichondrium is a membrane that covers the cartilage of the knees, elbows, hip joints, fingers, etc., and the synovium is a membrane that covers the joints of the knees, elbows, fingers, etc. Both membranes contain the synovial fluid in the joint cavity.
[0273] The dura mater tissue has primary amino groups on its surface. Specifically, the main component of the dura mater is collagen, and the cross-linking sites of the collagen contain multiple lysine residues (Lys) containing amino groups. According to the tissue adhesive material of this form, the amino group of the lysine residue (Lys) of the amino acid contained in large quantities in collagen is combined with the modification group (A) (aldehyde group or ketone group (-C(=O)R) of the polysaccharide derivative. 1 )) form Schiff bases between them, thus exerting good adhesion to the dura mater tissue.
[0274] In a preferred embodiment, the tissue adhesive material is applied to the dura mater tissue.
[0275] Collagen is the main component of the so-called membranous structure in the body. The fact that this tissue adhesive material exhibits adhesion to the dura mater indicates that this tissue adhesive material also exhibits adhesion to other membrane components besides the dura mater. In the examples described below, the dura mater is used to demonstrate adhesion to hard and thick tissues and / or connective tissues. The reason for focusing on the dura mater is that it is a relatively strong and thick material among the soft tissues or membranous components of the body, and a stronger adhesion that can withstand the leakage pressure of the cerebrospinal fluid beneath the dura mater is sought. In addition to good adhesion, this tissue adhesive material also has appropriate flexibility, resulting in excellent resistance to the leakage pressure of the cerebrospinal fluid.
[0276] In addition, polysaccharide derivatives such as alginic acid derivatives, hyaluronic acid derivatives, and carboxymethyl dextran derivatives form hydrophobic interactions and hydrogen bonds with tissue proteins (for example, hydrogen bonds between the hydroxyl group of the hydroxyproline residue in collagen and the hydroxyl group or carboxyl group of the polysaccharide derivative), which can improve adhesion to tissues.
[0277] Other representative examples of hard and thick tissues and / or connective tissues include perichondrium and periodontal ligament.
[0278] The perichondrium is the connective tissue that covers the surface of cartilage. For example, when transplanting cartilage to fill a cartilage defect, this tissue adhesive material can be used as a replacement for the perichondrium or to cover the perichondrium defect. By mixing not only the donor cartilage but also in vitro cultured cartilage grafts, stem cells, and the like with the tissue adhesive, the defect can be simultaneously filled and bonded, offering the advantage of eliminating the need for a covering material in addition to the filler.
[0279] The periodontal ligament is a membrane containing a large amount of collagen that connects the alveolar bone to the tooth root and has a thickness of about 0.3 mm. This type of tissue adhesive material can also be used in dentistry to bond the alveolar bone to the periodontal ligament or to bond the gum to the periodontal ligament.
[0280] In the first form, tissue adhesive materials are materials used to repair / repair biological tissues. They have adhesive properties not only to soft tissues within the body, but also to relatively hard and thick tissues such as the dura mater and / or connective tissues. They are used to repair / reinforce tissues and damaged areas, and have the function of preventing tissue fractures / enlargement of damaged areas and increasing the physical strength of the reinforced areas.
[0281] The use of tissue adhesive materials is not particularly limited. For example, in neurosurgery, it can be used to repair the outermost dura mater in the meninges, i.e., to repair / repair the dura mater during incision, or to fill a defect with an artificial dura mater (dura mater repair / protection). In plastic surgery, it can be used to repair / protect the dura mater, especially the spinal cord meninges, during spinal / spinal cord surgery. In addition, in otolaryngology, it can be used to bond elastic cartilage such as auricular cartilage, nasal cartilage, and epiglottic cartilage during transplantation / repair.
[0282] There is no particular limitation on the specific location of the biological tissue, and any location where tissue adhesive materials have been used in the past may be suitably used. Examples of such application locations include injured areas, postoperative suture sites, and adhesion sites for bleeding sites.
[0283] In several embodiments, tissue adhesive materials are used for the purpose of repair / regeneration of dural lesions and prevention of cerebrospinal fluid fistulas.
[0284] In some embodiments, the tissue adhesive material is used to repair or prevent regeneration of perichondrial membrane damage or to fill cartilage defects during cartilage transplantation. Furthermore, in some embodiments, the tissue adhesive material is applied to damaged synovial membranes for the purpose of repairing or protecting joints such as the knee, elbow, or finger.
[0285] In some embodiments, the tissue adhesive material is used for the purpose of repairing or preventing regeneration of periodontal ligament damage, for bonding alveolar bone to periodontal ligament in dentistry, or for bonding gum to periodontal ligament.
[0286] Existing tissue adhesive materials include 1) cyanoacrylate adhesives (Dermabond, Dermabond, LIQUIBAND), 2) gelatin-aldehyde adhesives (Bioglue, Bioglue), 3) fibrin adhesives (Beriplast, Bolheal), and 4) other materials (Hydrofit (Matsudaito)).
[0287] 1) Cyanoacrylate adhesives utilize the polymerization reaction of cyanoacrylate monomers, resulting in high bond strength. They also offer the advantage of a short bonding time. However, after fixation, the polymer undergoes hydrolysis in vivo, generating formaldehyde, which is highly toxic to the organism and can sometimes hinder healing at the fixed site. Therefore, their use in areas of the body that come into direct contact with central nervous systems or blood vessels must be avoided.
[0288] 2) Gelatin-aldehyde adhesives utilize the crosslinking reaction between biopolymer gelatin and formaldehyde or glutaraldehyde. While these adhesives offer high adhesion and polymer strength after fixation, they exhibit biotoxicity due to the use of toxic formaldehyde compounds as crosslinkers.
[0289] 3) Fibrin adhesives are adhesives that utilize biological components such as blood coagulation reactions. They are formed using fibrin in the blood and are non-toxic to biological tissues. They are the most commonly used tissue adhesives for use in vivo. Since they are derived from biological components, they have a high affinity with biological tissues and will not hinder tissue regeneration at the site of use. However, as an adhesive, they are soft and have weak adhesive strength. In addition, they need to be mixed immediately before use, and the two solutions need to be adjusted when used and assembled into a dedicated filling device, etc., which leads to the problem of long preparation and modulation time in advance. In addition, since the temporarily dissolved adhesive has a short usage time, there is also the problem of not being able to place it in advance. In addition, the raw material of fibrin, which is the raw material, is also human blood. Therefore, it is difficult to ensure the blood used as the raw material and avoid the risk of contamination by viruses that become pathogens.
[0290] 4) Other raw materials include urethane adhesives. Urethane is a non-absorbent material used primarily for local hemostasis. It is a viscous liquid composed of a polyether-based fluorinated urethane prepolymer. At the vascular anastomosis, it reacts with water in blood and tissue to form a polymer, forming a gel-like polymer that adheres tightly to the anastomosis and stops bleeding.
[0291] On the other hand, the tissue adhesive material of this form uses polysaccharide components such as alginic acid. For 1) and 2), toxic formaldehyde can be omitted; for 3), the risk of infection from the blood can be avoided; for 4), there is an advantage in that it can be avoided due to its non-absorbability and remain in the organism. In addition, in contrast to 1) cyanoacrylate-based adhesive materials that firmly and quickly adhere and fix, the tissue adhesive material of this form also has appropriate flexibility (stickiness) after adhesion. Thus, the tissue adhesive material of this form also has the advantage of preventing liquid from being exposed from the bonding site (gap) and also excellent in tolerance to leakage pressure.
[0292] Like this, consider that the tissue adhesive material of this form is used in vivo, aspect biocompatibility, safety, is excellent.In addition, according to the difference of use position, must bond very moistening or be rich in the tissue of blood / body fluid, but can think: even if the tissue adhesive material of this form also can be brought into play function by directly bonding with the protein that constitutes tissue under this moistening condition.In addition, existing tissue adhesive is used for the purpose that makes the soft tissue in organism and soft tissue (for example, make bioabsorbable raw material occur close fitting etc. in the repair of the tissue of excising at vascular anastomosis portion, by operation), discovery also can be bonded in the hard tissue such as being positioned at the outermost dura mater among the meninges and means the improvement as novel tissue adhesive material, can widen the scope of use at medical site.
[0293] The good tissue adhesiveness of the present embodiment of the tissue adhesive material to the dura mater tissue is shown in, for example, Examples I-26 and I-27 described later. In particular, as shown in Example I-26 ( Figure 74 As shown in Figure (B), many existing tissue adhesives (DuraSeal (registered trademark) (a gel of PEG with activated ester ends obtained using NHS and Trilysin) and fibrin paste) lack dura mater adhesion. This type of tissue adhesive material, which exhibits excellent adhesion to dura mater tissue, is highly useful. It is speculated that this type of tissue adhesive material exhibits these excellent properties, including adhesiveness, due to the moderate hydrophobicity of the benzaldehyde groups of the polysaccharide derivative and the abundant hydroxyl groups in the polysaccharide, which contribute to its hydrophilicity.
[0294] 1. Polysaccharide derivatives
[0295] In the present invention, the polysaccharide derivative is an acidic, basic, or amphoteric polysaccharide in which a group represented by the following formula (A) (hereinafter also referred to simply as "modifying group (A)") is introduced.
[0296] [Chemistry 15]
[0297]
[0298] Polysaccharide derivatives can react with primary amino groups under neutral to alkaline pH conditions to form Schiff bases. The Schiff bases formed between polysaccharide derivatives and primary amino groups are stable under neutral to alkaline pH conditions, but dissociate at low pH. Leveraging this property, these compounds can be used as drug delivery vehicles, bioabsorbable materials, medical devices, and separation materials.
[0299] The polysaccharide derivative of this embodiment has at least one of the following advantages.
[0300] (1) Polysaccharide derivatives can form stable conjugates with various drugs having primary amino groups under neutral to alkaline pH conditions, while also releasing the drugs having primary amino groups. In particular, the aforementioned modifying group (A), due to its aromatic structure, can form stable Schiff bases with amine groups (amino groups) contained in various drugs, even in water.
[0301] (2) Since the polysaccharide derivatives are based on acidic, basic, or amphoteric polysaccharides, even if the modification group (A) is hydrophobic and has a benzene ring or pyridine ring, the modification group (A) can be introduced at a good modification rate. Moreover, even when the modification group (A) is introduced at a high modification rate, the resulting polysaccharide derivatives have excellent water solubility due to the presence of unmodified acidic or basic functional groups (anionic groups or cationic functional groups). In particular, polysaccharides having anionic functional groups (such as carboxyl groups) can produce polysaccharide derivatives with particularly excellent water solubility even when the modification rate of the modification group (A) is high.
[0302] (3) Polysaccharides having acidic, basic, or both (amphoteric) functional groups (i.e., charged functional groups) can react with highly hydrophobic benzaldehyde or pyridinecarboxaldehyde compounds under mild and highly safe conditions in a single step, thereby easily introducing modification groups (A) into the polysaccharide.
[0303] (4) In some embodiments, polysaccharide derivatives can be used to conveniently produce stable polysaccharide derivative-drug conjugates in a single pot using mild and highly safe reaction conditions in a single step. Since no modification of the drug is required prior to conjugate formation, nor does it require complex experimental equipment or catalysts for conjugate formation, polysaccharide derivative-drug conjugates can be prepared in situ from the polysaccharide derivative and the drug.
[0304] (5) In some embodiments, polysaccharide derivatives and conjugates of polysaccharide derivatives and drugs can form cross-linked structures of various shapes (e.g., tubular structures, fibrous structures, fibers, beads, gels, approximately spherical gels, capsules, sponges, and sheets) by cross-linking using a cross-linking agent. Furthermore, in some embodiments, polysaccharide derivatives and conjugates of polysaccharide derivatives and drugs can form cross-linked structures of the various forms described above with amino-containing polymers.
[0305] (Modifying group (A): a group represented by formula (A))
[0306] In the above formula (A), R 1 Represents a hydrogen atom or C 1-4 Alkyl. R 1 Preferably, it is a hydrogen atom, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, a tert-butyl group, a sec-butyl group, an isobutyl group, or an n-butyl group, and more preferably a hydrogen atom or a methyl group. 1 A hydrogen atom.
[0307] In the above formula (A), * represents a linking portion to a polysaccharide.
[0308] In the above formula (A), ring P is a benzene ring or a pyridine ring. The above benzene ring or pyridine ring may be substituted by one or more substituents independently selected from halogen atoms (F, Cl, Br and / or I), -CF3 (trifluoromethyl), -NO2, carboxyl and -SO3H.
[0309] In one embodiment, ring P is a benzene ring, which may be substituted with 1 to 4 substituents independently selected from halogen atoms (F, Cl, Br and / or I), -CF3, -NO2, carboxyl and -SO3H. In one embodiment, ring P is an unsubstituted benzene ring.
[0310] In one embodiment, ring P is a pyridine ring, which may be substituted with 1 to 3 substituents independently selected from halogen atoms (F, Cl, Br and / or I), -CF3, -NO2, carboxyl and -SO3H. In one embodiment, ring P is an unsubstituted pyridine ring.
[0311] In the above formula (A), Y represents a group selected from -NH-, -C(=O)-, -S-, -O-, an alkylene group, -(CH2CH2O) n - and any combination thereof, wherein n is an integer of 1 to 9 (preferably 1 to 4, more preferably 1 to 2). From the viewpoint of hydrophilicity, the alkylene group in Y has 1 to 6 carbon atoms, preferably 1 to 4, more preferably 1 to 2, and even more preferably 1.
[0312] In some embodiments, Y is selected from -L 1 -NH- or -L 2 -C(=O)-, at this time L 1 and L 2 It is bonded to the ring P. That is, the modifying group (A) is selected from the following formula (A-1) or (A-2).
[0313] [Chemistry 16]
[0314]
[0315] In the above formulas (A-1) and (A-2), * represents the linking portion to the polysaccharide. 1 The definitions and preferred embodiments of the ring P are the same as those of R in the above formula (A). 1 The definitions and preferred embodiments are the same as those of ring P.
[0316] In formula (A-1), L 1 is a single bond, or represents a member selected from -C(=O)-, -S-, -O-, alkylene, -(CH2CH2O) n - and any combination thereof, wherein n is an integer of 1 to 9 (preferably 1 to 4, more preferably 1 to 2). From the viewpoint of hydrophilicity, L1 The number of carbon atoms of the alkylene group in the group is 1 to 6, preferably 1 to 4, more preferably 1 to 2, and even more preferably 1.
[0317] Among them, L 1 Selected from single bond, C 1-6 Alkylene, -(CH2CH2O) n -、-(CH2) m1 -(CH2CH2O) n -(CH2) m2 - and -(CH2) m1 -O-(CH2CH2O) n -(CH2) m2 -. n is an integer from 1 to 9 (preferably 1 to 4, more preferably 1 to 2). m1 and m2 are each independently an integer from 1 to 9 (preferably 1 to 4, more preferably 1 to 2). From the viewpoint of hydrophilicity, L 1 C in 1-6 The alkylene group is preferably C 1-4 Alkylene, more preferably C 1-2 The alkylene group is more preferably a methylene group.
[0318] In one embodiment, L 1 is a single bond or C 1-2 In one embodiment, L 1 For a single bond.
[0319] In formula (A-2), L 2 is a single bond, or represents a member selected from -NH-, -S-, -O-, alkylene, -(CH2CH2O) n - and any combination thereof, wherein n is an integer of 1 to 9 (preferably 1 to 4, more preferably 1 to 2). From the viewpoint of hydrophilicity, L 2 The number of carbon atoms of the alkylene group in the group is 1 to 6, preferably 1 to 4, more preferably 1 to 2, and even more preferably 1.
[0320] Among them, L 2 Selected from single bond, C 1-6 Alkylene, -(CH2CH2O) n -、-(CH2) m1 -(CH2CH2O) n -(CH2) m2 - and -(CH2) m1 -O-(CH2CH2O) n -(CH2) m2 -. n is an integer from 1 to 9 (preferably 1 to 4, more preferably 1 to 2). m1 and m2 are each independently an integer from 1 to 9 (preferably 1 to 4, more preferably 1 to 2). From the viewpoint of hydrophilicity, L2 C in 1-6 The alkylene group is preferably C 1-4 Alkylene, more preferably C 1-2 The alkylene group is more preferably a methylene group.
[0321] In one embodiment, L 2 is a single bond or C 1-2 In one embodiment, L 2 For a single bond.
[0322] In some embodiments, the modifying group (A) is a group represented by the above formula (A-1), and the ring P is a benzene ring, which can be substituted by 1 to 4 substituents independently selected from halogen atoms (F, Cl, Br and / or I), -CF3, -NO2, carboxyl and -SO3H.
[0323] For example, the modifying group (A) is selected from the following formulae (1), (2), and (3) (hereinafter sometimes referred to as "formulae (1) to (3)").
[0324] [Chemistry 17]
[0325]
[0326] In the above formulas (1) to (3), * represents the linking portion to the polysaccharide. 1 The definitions and preferred embodiments are the same as those of R in the above formula (A) 1 The definition is the same as the preferred embodiment, L 1 The definition and preferred embodiment are the same as those of L in the above formula (A-1) 1 The definition and preferred embodiment are the same.
[0327] In the above formulas (1) to (3), R 51 、R 52 、R 53 and R 54 are independently selected from hydrogen atoms, halogen atoms (F, Cl, Br, I), -CF3, -NO2, carboxyl groups and -SO3H. 51 、R 52 、R 53 and R 54 In one embodiment, R 51 、R 52 、R 53 and R 54 They are independently selected from hydrogen atoms and halogen atoms (F, Cl, Br, I; preferably F).
[0328] In a specific embodiment, in the above formulas (1) to (3), R 1is a hydrogen atom, L 1 is a single bond, R 51 、R 52 、R 53 and R 54 are independently selected from hydrogen atoms, halogen atoms (F, Cl, Br, I), -CF3, -NO2, carboxyl groups and -SO3H. In one embodiment, in the above formulas (1) to (3), R 1 is a hydrogen atom, L 1 is a single bond, R 51 、R 52 、R 53 and R 54 In one embodiment, in the above formulas (1) to (3), R 1 is a hydrogen atom, L 1 is a single bond, R 51 、R 52 、R 53 and R 54 are each independently a hydrogen atom or a halogen atom (F, Cl, Br, I; preferably F).
[0329] In a specific embodiment, in the above formulas (1) to (3), R 1 Methyl, L 1 is a single bond, R 51 、R 52 、R 53 and R 54 are independently selected from hydrogen atoms, halogen atoms (F, Cl, Br, I), -CF3, -NO2, carboxyl groups and -SO3H. In one embodiment, in the above formulas (1) to (3), R 1 Methyl, L 1 is a single bond, R 51 、R 52 、R 53 and R 54 In one embodiment, in the above formulas (1) to (3), R 1 Methyl, L 1 is a single bond, R 51 、R 52 、R 53 and R 54 are each independently a hydrogen atom or a halogen atom (F, Cl, Br, I; preferably F).
[0330] In a specific embodiment, in the above formulas (1) to (3), R 1 is a hydrogen atom, L 1 is methylene (-CH2-) or ethylene (-C2H4-), R 51 、R 52 、R 53 and R54 are independently selected from hydrogen atoms, halogen atoms (F, Cl, Br, I), -CF3, -NO2, carboxyl groups and -SO3H. In one embodiment, in the above formulas (1) to (3), R 1 is a hydrogen atom, L 1 is methylene (-CH2-) or ethylene (-C2H4-), R 51 、R 52 、R 53 and R 54 In one embodiment, in the above formulas (1) to (3), R 1 is a hydrogen atom, L 1 is methylene (-CH2-) or ethylene (-C2H4-), R 51 、R 52 、R 53 and R 54 are each independently a hydrogen atom or a halogen atom (F, Cl, Br, I; preferably F).
[0331] In a specific embodiment, in the above formulas (1) to (3), R 1 Methyl, L 1 is methylene (-CH2-) or ethylene (-C2H4-), R 51 、R 52 、R 53 and R 54 are independently selected from hydrogen atoms, halogen atoms (F, Cl, Br, I), -CF3, -NO2, carboxyl groups and -SO3H. In one embodiment, in the above formulas (1) to (3), R 1 Methyl, L 1 is methylene (-CH2-) or ethylene (-C2H4-), R 51 、R 52 、R 53 and R 54 In one embodiment, in the above formulas (1) to (3), R 1 Methyl, L 1 is methylene (-CH2-) or ethylene (-C2H4-), R 51 、R 52 、R 53 and R 54 are each independently a hydrogen atom or a halogen atom (F, Cl, Br, I; preferably F).
[0332] In one embodiment, the modifying group (A) is selected from the groups represented by the following formulae.
[0333] [Chemistry 18]
[0334]
[0335] (Wherein, * represents the linking portion to the polysaccharide.)
[0336] In one embodiment, the modifying group (A) is a group represented by the following formula.
[0337] [Chemistry 19]
[0338]
[0339] (Wherein, * represents the linking portion to the polysaccharide.)
[0340] In some embodiments, the modifying group (A) is a group represented by the above formula (A-1), and the ring P is a pyridine ring, which can be substituted by 1 to 3 substituents independently selected from halogen atoms (F, Cl, Br, I), -CF3, -NO2, carboxyl and -SO3H.
[0341] For example, the modifying group (A) is selected from the following formulae (4), (5), (6), (7), (8), (9), (10), (11), (12), and (13) (hereinafter also referred to as "formulae (4) to (13)").
[0342] [Chemistry 20]
[0343]
[0344] In the above formulas (4) to (13), * represents the linking portion to the polysaccharide. 1 The definitions and preferred embodiments are the same as those of R in the above formula (A) 1 The definition is the same as the preferred embodiment, L 1 The definition and preferred embodiment are the same as those of L in the above formula (A-1) 1 The definition and preferred embodiment are the same.
[0345] In the above formulas (4) to (13), R 61 、R 62 and R 63 are independently selected from hydrogen atoms, halogen atoms (F, Cl, Br, I), -CF3, -NO2, carboxyl groups and -SO3H. 61 、R 62 and R 63 In one embodiment, R 61 、R 62 and R 63 are independently selected from hydrogen atoms and halogen atoms (F, Cl, Br, I).
[0346] In a specific embodiment, in the above formulas (4) to (13), R1 is a hydrogen atom, L 1 is a single bond, R 61 、R 62 and R 63 are independently selected from hydrogen atoms, halogen atoms (F, Cl, Br, I), -CF3, -NO2, carboxyl groups and -SO3H. In one embodiment, in the above formulas (4) to (13), R 1 is a hydrogen atom, L 1 is a single bond, R 61 、R 62 and R 63 In one embodiment, in the above formulas (4) to (13), R 1 is a hydrogen atom, L 1 is a single bond, R 61 、R 62 and R 63 are each independently a hydrogen atom or a halogen atom (F, Cl, Br, I; preferably F).
[0347] In a specific embodiment, in the above formulas (4) to (13), R 1 Methyl, L 1 is a single bond, R 61 、R 62 and R 63 are independently selected from hydrogen atoms, halogen atoms (F, Cl, Br, I), -CF3, -NO2, carboxyl groups and -SO3H. In one embodiment, in the above formulas (4) to (13), R 1 Methyl, L 1 is a single bond, R 61 、R 62 and R 63 In one embodiment, in the above formulas (4) to (13), R 1 Methyl, L 1 is a single bond, R 61 、R 62 and R 63 are each independently a hydrogen atom or a halogen atom (F, Cl, Br, I; preferably F).
[0348] In a specific embodiment, in the above formulas (4) to (13), R 1 is a hydrogen atom, L 1 is methylene (-CH2-) or ethylene (-C2H4-), R 61 、R 62 and R 63 are independently selected from hydrogen atoms, halogen atoms (F, Cl, Br, I), -CF3, -NO2, carboxyl groups and -SO3H. In one embodiment, in the above formulas (4) to (13), R1 is a hydrogen atom, L 1 is methylene (-CH2-) or ethylene (-C2H4-), R 61 、R 62 and R 63 In one embodiment, in the above formulas (4) to (13), R 1 is a hydrogen atom, L 1 is methylene (-CH2-) or ethylene (-C2H4-), R 61 、R 62 and R 63 are each independently a hydrogen atom or a halogen atom (F, Cl, Br, I; preferably F).
[0349] In a specific embodiment, in the above formulas (4) to (13), R 1 Methyl, L 1 is methylene (-CH2-) or ethylene (-C2H4-), R 61 、R 62 and R 63 are independently selected from hydrogen atoms, halogen atoms (F, Cl, Br, I), -CF3, -NO2, carboxyl groups and -SO3H. In one embodiment, in the above formulas (1) to (3), R 1 Methyl, L 1 is methylene (-CH2-) or ethylene (-C2H4-), R 61 、R 62 and R 63 In one embodiment, in the above formulas (1) to (3), R 1 Methyl, L 1 is methylene (-CH2-) or ethylene (-C2H4-), R 61 、R 62 and R 63 are each independently a hydrogen atom or a halogen atom (F, Cl, Br, I; preferably F).
[0350] In one embodiment, the modifying group (A) is selected from the groups represented by the following formulae.
[0351] [Chemistry 21]
[0352]
[0353] (Wherein, * represents the linking portion to the polysaccharide.)
[0354] In one embodiment, the modifying group (A) is selected from the groups represented by the following formulae.
[0355] [Chemistry 22]
[0356]
[0357] (Wherein, * represents the linking portion to the polysaccharide.)
[0358] In one embodiment, the modifying group (A) is a group represented by the following formula.
[0359] [Chemistry 23]
[0360]
[0361] According to this aspect, the adhesive strength of the tissue adhesive material can be improved.
[0362] In some embodiments, the modifying group (A) is a group represented by the above formula (A-2), and the ring P is a benzene ring, which can be substituted by 1 to 4 substituents independently selected from halogen atoms (F, Cl, Br and / or I), -CF3, -NO2, carboxyl and -SO3H.
[0363] For example, the modifying group (A) is selected from the following formulae (14), (15), and (16) (hereinafter sometimes referred to as "formulae (14) to (16)").
[0364] [Chemistry 24]
[0365]
[0366] In the above formulas (14) to (16), * represents the linking portion to the polysaccharide. 1 The definitions and preferred embodiments are the same as those of R in the above formula (A) 1 The definition is the same as the preferred embodiment, L 2 The definition and preferred embodiment are the same as those of L in the above formula (A-2) 2 The definition and preferred embodiment are the same.
[0367] In the above formulas (1) to (3), R 71 、R 72 、R 73 and R 74 are independently selected from hydrogen atoms, halogen atoms (F, Cl, Br, I), -CF3, -NO2, carboxyl groups and -SO3H. 71 、R 72 、R 73 and R 74 In one embodiment, R 71 、R 72 、R 73 and R 74 They are independently selected from hydrogen atoms and halogen atoms (F, Cl, Br, I; preferably F).
[0368] In a specific embodiment, in the above formulas (14) to (16), R 1 is a hydrogen atom, L 2 is a single bond, R 71 、R 72 、R 73 and R 74 are independently selected from hydrogen atoms, halogen atoms (F, Cl, Br, I), -CF3, -NO2, carboxyl groups and -SO3H. In one embodiment, in the above formulas (14) to (16), R 1 is a hydrogen atom, L 2 is a single bond, R 71 、R 72 、R 73 and R 744 In one embodiment, in the above formulas (14) to (16), R 1 is a hydrogen atom, L 2 is a single bond, R 71 、R 72 、R 73 and R 74 are each independently a hydrogen atom or a halogen atom (F, Cl, Br, I; preferably F).
[0369] In a specific embodiment, in the above formulas (14) to (16), R 1 Methyl, L 2 is a single bond, R 71 、R 72 、R 73 and R 74 are independently selected from hydrogen atoms, halogen atoms (F, Cl, Br, I), -CF3, -NO2, carboxyl groups and -SO3H. In one embodiment, in the above formulas (14) to (16), R 1 Methyl, L 2 is a single bond, R 71 、R 72 、R 73 and R 74 In one embodiment, in the above formulas (14) to (16), R 1 Methyl, L 2 is a single bond, R 71 、R 72 、R 73 and R 74 are each independently a hydrogen atom or a halogen atom (F, Cl, Br, I; preferably F).
[0370] In a specific embodiment, in the above formulas (14) to (16), R 1 is a hydrogen atom, L 2is methylene (-CH2-) or ethylene (-C2H4-), R 71 、R 72 、R 73 and R 74 are independently selected from hydrogen atoms, halogen atoms (F, Cl, Br, I), -CF3, -NO2, carboxyl groups and -SO3H. In one embodiment, in the above formulas (14) to (16), R 1 is a hydrogen atom, L 2 is methylene (-CH2-) or ethylene (-C2H4-), R 71 、R 72 、R 73 and R 74 In one embodiment, in the above formulas (14) to (16), R 1 is a hydrogen atom, L 2 is methylene (-CH2-) or ethylene (-C2H4-), R 71 、R 72 、R 73 and R 74 are each independently a hydrogen atom or a halogen atom (F, Cl, Br, I; preferably F).
[0371] In a specific embodiment, in the above formulas (14) to (16), R 1 Methyl, L 2 is methylene (-CH2-) or ethylene (-C2H4-), R 71 、R 72 、R 73 and R 74 are independently selected from hydrogen atoms, halogen atoms (F, Cl, Br, I), -CF3, -NO2, carboxyl groups and -SO3H. In one embodiment, in the above formulas (14) to (16), R 1 Methyl, L 2 is methylene (-CH2-) or ethylene (-C2H4-), R 71 、R 72 、R 73 and R 74 In one embodiment, in the above formulas (14) to (16), R 1 Methyl, L 2 is methylene (-CH2-) or ethylene (-C2H4-), R 71 、R 72 、R 73 and R 74 are each independently a hydrogen atom or a halogen atom (F, Cl, Br, I; preferably F).
[0372] In one embodiment, the modifying group (A) is selected from the groups represented by the following formulae.
[0373] [Chemistry 25]
[0374]
[0375] (Wherein, * represents the linking portion to the polysaccharide.)
[0376] In some embodiments, Y is selected from -L 3 -S- or -L 4 -, at this time, L 3 and L 4 It is bonded to the ring P. That is, the modifying group (A) is selected from the following formula (A-3) or (A-4).
[0377] [Chemistry 26]
[0378]
[0379] In the above formulas (A-3) and (A-4), * represents the linking portion to the polysaccharide. 1 The definitions and preferred embodiments of the ring P are the same as those of R in the above formula (A). 1 The definitions and preferred embodiments are the same as those of ring P.
[0380] In formula (A-3), L 3 is a single bond, or represents a group selected from -NH-, -C(=O)-, -O-, alkylene, -(CH2CH2O) n - and any combination thereof, wherein n is an integer of 1 to 9 (preferably 1 to 4, more preferably 1 to 2). From the viewpoint of hydrophilicity, L 3 The number of carbon atoms of the alkylene group in the group is 1 to 6, preferably 1 to 4, more preferably 1 to 2, and even more preferably 1.
[0381] Among them, L 3 Selected from single bond, C 1-6 Alkylene, -(CH2CH2O) n -、-(CH2) m1 -(CH2CH2O) n -(CH2) m2 - and -(CH2) m1 -O-(CH2CH2O) n -(CH2) m2 -. n is an integer from 1 to 9 (preferably 1 to 4, more preferably 1 to 2). m1 and m2 are each independently an integer from 1 to 9 (preferably 1 to 4, more preferably 1 to 2). From the viewpoint of hydrophilicity, L 3 C in 1-6The alkylene group is preferably C 1-4 Alkylene, more preferably C 1-2 The alkylene group is more preferably a methylene group.
[0382] In one embodiment, L 3 is a single bond or C 1-2 In one embodiment, L 3 For a single bond.
[0383] In formula (A-4), L 4 is a single bond, or represents a member selected from -NH-, -C(=O)-, -S-, -O-, alkylene, -(CH2CH2O) n - and any combination thereof, wherein n is an integer of 1 to 9 (preferably 1 to 4, more preferably 1 to 2). From the viewpoint of hydrophilicity, L 4 The number of carbon atoms of the alkylene group in the group is 1 to 6, preferably 1 to 4, more preferably 1 to 2, and even more preferably 1.
[0384] Among them, L 4 Selected from single bond, C 1-6 Alkylene, -(CH2CH2O) n -、-(CH2) m1 -(CH2CH2O) n -(CH2) m2 - and -(CH2) m1 -O-(CH2CH2O) n -(CH2) m2 -. n is an integer from 1 to 9 (preferably 1 to 4, more preferably 1 to 2). m1 and m2 are each independently an integer from 1 to 9 (preferably 1 to 4, more preferably 1 to 2). From the viewpoint of hydrophilicity, L 4 C in 1-6 The alkylene group is preferably C 1-4 Alkylene, more preferably C 1-2 The alkylene group is more preferably a methylene group.
[0385] In one embodiment, L 4 C 1-2 Alkylene.
[0386] The modifying group (A) has -C(=O)R 1 (aldehyde or ketone), the -C(=O)R 1 It can react with primary amino groups to form Schiff bases. 1 It can form a hyperconjugated structure with adjacent benzene rings or pyridine rings, and the resulting Schiff base is stabilized, which can improve the binding stability with amino groups.
[0387] (polysaccharide)
[0388] The polysaccharide is an acidic, alkaline or amphoteric polysaccharide, and is not particularly limited as long as it is a polysaccharide into which the above-mentioned modification group (A) can be introduced. It can be a polysaccharide extracted / isolated from a natural plant or animal, a polysaccharide produced by a genetically modified microorganism, or a chemically synthesized polysaccharide.
[0389] Acidic polysaccharides refer to polysaccharides having anionic functional groups (e.g., carboxyl, sulfate, phosphate, etc.) in their structure. Examples of acidic polysaccharides include polysaccharides having uronic acid (e.g., guluronic acid, mannuronic acid, glucuronic acid, iduronic acid, galacturonic acid, etc.), polysaccharides having sulfate or phosphate in a portion of their structure, or polysaccharides having these two structures. Acidic polysaccharides include, in addition to polysaccharides originally having anionic functional groups in their structure, polysaccharides in which anionic functional groups are introduced by replacing the hydrogen atoms of a portion or all of their hydroxyl groups with anionic functional groups such as carboxyl alkyl groups in a polysaccharide (e.g., neutral polysaccharide) that originally does not have anionic functional groups.
[0390] Specific examples of the acidic polysaccharide include alginic acid, hyaluronic acid, carboxymethylcellulose, carboxymethyldextran, carboxymethyl starch, heparin, heparan sulfate, chondroitin sulfate, dermatan sulfate, regenerated oxidized cellulose, pectic acid, gellan gum, gum arabic, xanthan gum, agar, agar gum, carrageenan, and derivatives or salts thereof.
[0391] Basic polysaccharides are polysaccharides that have cationic functional groups (e.g., amino groups) within their structures. Basic polysaccharides include polysaccharides that inherently have cationic functional groups within their structures, as well as polysaccharides that do not inherently have cationic functional groups (e.g., neutral polysaccharides) into which cationic functional groups have been introduced.
[0392] Specific examples of the basic polysaccharide include chitosan, derivatives thereof, and salts thereof.
[0393] Amphoteric polysaccharides are polysaccharides that have both anionic functional groups (e.g., carboxyl groups, sulfate groups, phosphate groups, etc.) and cationic functional groups (e.g., amino groups, etc.) within their structures. Specific examples of amphoteric polysaccharides include anionic modified basic polysaccharides such as succinic acid-modified chitosan; deacetylated polysaccharides such as deacetylated hyaluronic acid; amine-modified acidic polysaccharides such as cationically modified alginic acid and cationically modified hyaluronic acid; phosphocholine-modified polysaccharides such as phosphocholine-modified hyaluronic acid; carboxybetaine-modified polysaccharides; and sulfobetaine-modified polysaccharides.
[0394] By using acidic, basic, or amphoteric polysaccharides, even hydrophobic modifying groups (A) having benzene rings or pyridine rings can be introduced with a good modification rate. Furthermore, even when hydrophobic modifying groups (A) are introduced at a high modification rate, the presence of unmodified acidic or basic functional groups (anionic or cationic functional groups) allows the production of polysaccharide derivatives with excellent water solubility.
[0395] In some embodiments, the polysaccharide is selected from alginic acid, its derivatives or their salts, hyaluronic acid, its derivatives or their salts, carboxymethyl cellulose, its derivatives or their salts, carboxymethyl dextran, its derivatives or their salts, carboxymethyl starch, its derivatives or their salts, heparin, its derivatives or their salts, heparan sulfate, its derivatives or their salts, chondroitin sulfate, its derivatives or their salts, dermatan sulfate, its derivatives or their salts, chitosan, its derivatives or their salts, regenerated oxidized cellulose, its derivatives or their salts, and pectic acid, its derivatives or their salts.
[0396] In the present invention, the derivative of a polysaccharide may be a product in which any modification has been applied to the polysaccharide. For example, polysaccharides modified by esterification, maleimide modification, thiol modification, acrylate modification, aldehyde modification, disulfide modification (e.g., pyridyl disulfide), alkyne modification including cyclic alkynes, tetrazine modification, furan ring modification, etc. can be listed. These modification methods are known to those skilled in the art, and polysaccharides can be modified by conventional methods such as carbodiimide reaction. For example, the method of maleimide modification is described in International Publication No. WO2019 / 189330. As a method of alkyne modification including cyclic alkynes, for example, Akira Takahashi et al., Biomacromolecules, 2013, 14(10), 3581-3588 can be used. As a method for tetrazine modification, for example, the method described in Vianney Delplace et al., Nonswelling, Ultralow Content Inverse Electron-Demand Diels-Alder Hyaluronan Hydrogels with Tunable Gelation Time: Synthesis and In Vitro Evaluation, Advanced Functional Materials, 2020, 30(14) can be used. As a method for furan ring modification, for example, the method described in Nimmo, Chelsea M. et al., BIOMACROMOLECULES, 2011, 12(3)824-830; RSC Adv., 2018, 8, 11036-11042 can be used. By combining these modifications with copper-free click reactions (e.g., reactions between cyclic alkynes and azides), reverse electron-demand Diels–Alder reactions (e.g., reactions between tetrazines and cyclic olefins), and Diels–Alder reactions (e.g., reactions between furans and maleimides), it is possible to introduce a second drug (an additional drug of a different type) into the polysaccharide derivative, or to perform cross-linking.
[0397] In some embodiments, the polysaccharide is an acidic polysaccharide. Polysaccharides having anionic functional groups can provide polysaccharide derivatives having particularly excellent water solubility even when the modification rate of the modification group (A) is high.
[0398] In some embodiments, the polysaccharide is a polysaccharide containing carboxyl groups. The above-mentioned modification group (A) can be introduced into the polysaccharide by reacting the carboxyl groups with the amino groups to form an amide bond.
[0399] In a specific embodiment, the polysaccharide is a polysaccharide containing a carboxyl group, and the group represented by formula (A) is a group represented by formula (A-1). The group represented by formula (A-1) is introduced into the polysaccharide by replacing the -OH group of the carboxyl group of the polysaccharide, thereby forming an amide bond. The formation of an amide bond can provide a polysaccharide derivative with improved stability.
[0400] The polysaccharide having a carboxyl group may be any polysaccharide as long as it has at least one unmodified carboxyl group.
[0401] The polysaccharide having a carboxyl group refers to a polysaccharide having a carboxyl group in its structure or a derivative thereof or a salt thereof (for example, alginic acid, its derivatives or salts thereof, hyaluronic acid, its derivatives or salts thereof, carboxymethylcellulose, its derivatives or salts thereof, carboxymethyldextran, its derivatives or salts thereof, carboxymethyl starch, its derivatives or salts thereof, heparin, its derivatives or salts thereof, heparan sulfate, its derivatives or salts thereof, chondroitin sulfate, its derivatives or salts thereof, dermatan sulfate, its derivatives or salts thereof, pectic acid, its derivatives or salts thereof, regenerated oxidized cellulose, its derivatives or salts thereof, gellan gum, its derivatives or salts thereof, gum arabic, its derivatives or salts thereof, xanthan gum, its derivatives or salts thereof, agarose, its derivatives or salts thereof, agar gum, its derivatives or salts thereof, etc.; preferably alginic acid, its derivatives or salts thereof, hyaluronic acid, its derivatives or salts thereof, carboxymethylcellulose The polysaccharide includes polysaccharides such as chitosan, its derivatives or their salts, curdlan, its derivatives or their salts, agar, its derivatives or their salts, carrageenan, its derivatives or their salts, guar gum, its derivatives or their salts, locust bean gum, its derivatives or their salts, tamarind gum, its derivatives or their salts; preferably chitosan, its derivatives or their salts, etc., in which carboxyl groups are introduced by replacing some or all of the hydrogen atoms of the hydroxyl groups with carboxylalkyl groups.
[0402] In a specific embodiment, the polysaccharide having a carboxyl group is selected from: alginic acid or a salt thereof, hyaluronic acid or a salt thereof, carboxymethyl cellulose or a salt thereof, carboxymethyl dextran or a salt thereof, carboxymethyl starch or a salt thereof, heparin or a salt thereof, heparan sulfate or a salt thereof, chondroitin sulfate or a salt thereof, dermatan sulfate or a salt thereof, pectin acid or a salt thereof, regenerated oxidized cellulose or a salt thereof.
[0403] In a specific embodiment, the polysaccharide is selected from alginic acid, its derivatives or their salts, hyaluronic acid, its derivatives or their salts, carboxymethylcellulose, its derivatives or their salts, and carboxymethyldextran, its derivatives or their salts.
[0404] In a specific embodiment, the polysaccharide is selected from alginic acid or its salts, hyaluronic acid or its salts, carboxymethylcellulose or its salts, and carboxymethyldextran or its salts.
[0405] In a specific embodiment, the polysaccharide is alginic acid, a derivative thereof or a salt thereof, or hyaluronic acid, a derivative thereof or a salt thereof.
[0406] In a specific embodiment, the polysaccharide is alginic acid or a salt thereof, or hyaluronic acid or a salt thereof.
[0407] (Alginic acid)
[0408] In one embodiment, the polysaccharide is alginic acid, its derivatives, or salts thereof (hereinafter also referred to as "alginates").
[0409] Alginic acid is a biodegradable and biocompatible polymer. It is a polymer in which two uronic acids, D-mannuronic acid (M) and L-guluronic acid (G), are polymerized into a linear chain. More specifically, it is a block copolymer formed by arbitrarily combining a homopolymer component (MM component) of D-mannuronic acid, a homopolymer component (GG component) of L-guluronic acid, and a component (MG component) in which D-mannuronic acid and L-guluronic acid are randomly arranged. The constituent ratio (M / G ratio) of D-mannuronic acid and L-guluronic acid of alginic acid mainly varies depending on the type of organisms such as seaweed that are the source. In addition, it is affected by the growth place or season of the organism and covers a wide range of high G types with an M / G ratio of about 0.2 to high M types with an M / G ratio of about 5.
[0410] The derivative of alginic acid is not particularly limited, and it is the product or its salt after alginic acid has been subjected to any modification. The arbitrary modification subjected to alginic acid, for example, includes esterification, sulfation, maleimide modification, thiol modification, acrylate modification, aldehyde modification and disulfide modification (for example, pyridyl disulfide), cation modification (for example, heparin-bound alginic acid). In one embodiment, the derivative of alginic acid is sulfated alginic acid, maleimide modification alginic acid, thiol modification alginic acid, acrylate modification alginic acid, cation modification alginic acid (for example, the heparin-bound alginic acid described in Japanese Patent Application Laid-Open No. 2001-233786). These modifications of alginic acid can be carried out by known method or method based thereon.
[0411] Examples of salts of alginic acid or its derivatives include metal salts of alginic acid or its derivatives. Examples include salts of alginic acid or its derivatives obtained by reacting the hydrogen atom (hydrogen ion) of the 6-position carboxylic acid of alginic acid or its derivatives with a monovalent metal ion (e.g., Na + or K + A water-soluble salt is a salt prepared by ion exchange with an alkali metal ion such as Mg(III). Specifically, sodium alginate, potassium alginate, sodium salt of an alginate derivative, or potassium salt of an alginate derivative, etc. can be listed. In a specific embodiment, the salt of alginic acid or its derivative is sodium alginate or a sodium salt of an alginate derivative. A solution of a univalent metal salt of alginic acid or its derivative forms a gel when mixed with a cross-linking agent. Alternatively, a metal salt of alginic acid or its derivative can be prepared by combining the hydrogen atom (hydrogen ion) of the 6-position carboxylic acid of alginic acid or its derivative with a divalent metal ion (e.g., Mg(III)). 2+ , Ca 2+ A salt (cross-linked body) produced by ion exchange with alkaline earth metal ions such as ions.
[0412] Alginic acid initially has a large molecular weight and high viscosity when extracted from brown algae. However, during heat-based drying, freeze-drying, and purification, its molecular weight decreases and its viscosity decreases. Therefore, by properly managing the temperature during each manufacturing step, alginics with varying molecular weights can be produced. By managing the temperature during each manufacturing step to lower it, alginics with larger molecular weights are obtained, while higher temperatures result in alginics with smaller molecular weights. Furthermore, alginics with varying molecular weights can be produced by appropriately selecting the raw material brown algae or by performing molecular weight fractionation during the manufacturing process. Furthermore, by measuring the molecular weight or viscosity of alginics produced by various methods and then mixing it with another batch of alginics with a different molecular weight or viscosity, alginics with a target molecular weight can be produced.
[0413] The viscosity of the alginic acid used is not particularly limited, but when measured as a 1 w / w% aqueous solution of alginic acid, it is preferably 10 mPa·s to 1000 mPa·s, more preferably 50 mPa·s to 800 mPa·s.
[0414] The viscosity determination of alginic acid aqueous solution can be measured according to a conventional method. For example, a coaxial double-cylinder rotational viscometer, a single cylindrical rotational viscometer (Brookfield type viscometer), a cone-plate rotational viscometer (lamellar viscometer) etc. can be used for measurement. Preferably, the viscosity determination method according to the Japanese Pharmacopoeia (16th edition) is used. More preferably, a lamellar viscometer is used.
[0415] The position of the modifying group (A) introduced into alginic acid is not particularly limited, but is preferably introduced into the 6-carboxyl group of D-mannuronic acid (M) and L-guluronic acid (G) (uronic acid) constituting alginic acid.
[0416] In a specific embodiment, the group represented by the above formula (A-1) is introduced into the polysaccharide by substituting the -OH group of the carboxyl group of alginic acid.
[0417] In one embodiment, the polysaccharide derivative includes a structural unit represented by the following formula (c11) and / or (c12).
[0418] [Chemistry 27]
[0419]
[0420] In formulas (c11) and (c12), R 1 The definitions and preferred embodiments of the ring P are the same as those of R in the above formula (A). 1 The definitions and preferred embodiments are the same as those of ring P.
[0421] In formulas (c11) and (c12), Y represents -L 1 -NH-, at this time L 1 Combined with ring P. L 1 The definition and preferred embodiment are the same as those of L in formula (A-1) 1 The definition and preferred embodiment are the same.
[0422] In formulas (c11) and (c12), R 11 、R 12 、R 13 and R 14 are independently selected from hydrogen atoms, C 1-6 Alkyl and -C(=O)-C 1-6 In one embodiment, R 11 、R 12 、R 13 and R 14 All are hydrogen atoms.
[0423] (Hyaluronic acid)
[0424] In one embodiment, the polysaccharide is hyaluronic acid, a derivative thereof, or a salt thereof (hereinafter also referred to as "hyaluronic acids").
[0425] Hyaluronic acid is a biodegradable and biocompatible polymer, and is a polymer having a linear repeating structure of two sugars, D-glucuronic acid and N-acetyl-D-glucosamine.
[0426] The derivative of hyaluronic acid is not particularly limited, and is a product or its salt to which hyaluronic acid has been subjected to any modification. Any modification to hyaluronic acid, for example, includes esterification, sulfation, maleimide modification, thiol modification, acrylate modification, aldehyde modification, and disulfide modification (for example, pyridyl disulfide). In one embodiment, the derivative of hyaluronic acid is sulfated hyaluronic acid, maleimide modification hyaluronic acid, thiol modification hyaluronic acid, or acrylate modification hyaluronic acid, which are sulfated by hyaluronic acid esters, propylene glycol hyaluronate, or hydroxyl groups. These modifications to hyaluronic acid can be carried out by known methods or based on the method therefor.
[0427] Examples of salts of hyaluronic acid or its derivatives include metal salts of hyaluronic acid or its derivatives. Examples include salts of hyaluronic acid or its derivatives obtained by reacting a hydrogen atom (hydrogen ion) of the 6-position carboxylic acid of hyaluronic acid or its derivatives with a monovalent metal ion (e.g., Na + or K + The water-soluble salts are water-soluble salts made by ion exchange with alkali metal ions such as hyaluronic acid and hyaluronic acid derivatives. Specifically, sodium hyaluronate, potassium hyaluronate, sodium salts of hyaluronic acid derivatives, or potassium salts of hyaluronic acid derivatives can be listed. In a specific embodiment, the salt of hyaluronic acid or its derivatives is sodium hyaluronate or sodium salts of hyaluronic acid derivatives. The monovalent metal salt solution of hyaluronic acid or its derivatives forms a gel when mixed with a cross-linking agent. Alternatively, the metal salt of hyaluronic acid or its derivatives can be a mixture of a hydrogen atom (hydrogen ion) of the 6-position carboxylic acid of hyaluronic acid or its derivatives and a divalent metal ion (for example, Mg 2+ , Ca 2+ A salt (cross-linked body) produced by ion exchange with alkaline earth metal ions such as ions.
[0428] In hyaluronic acid, the position of the modified group (A) to be introduced is not particularly limited, but it is preferably introduced into the position of the carboxyl group of D-glucuronic acid constituting hyaluronic acid.
[0429] In a specific embodiment, the group represented by the above formula (A-1) is introduced into the polysaccharide by substituting the -OH group of the carboxyl group of hyaluronic acid.
[0430] In one embodiment, the polysaccharide derivative includes a structural unit represented by the following formula (c13).
[0431] [Chemistry 28]
[0432]
[0433] In formula (c13), R 1 The definitions and preferred embodiments of the ring P are the same as those of R in the above formula (A). 1 The definitions and preferred embodiments are the same as those of ring P.
[0434] In formula (c13), Y represents -L 1 -NH-, at this time L 1 Combined with ring P. L 1 The definition and preferred embodiment are the same as those of L in formula (A-1) 1 The definition and preferred embodiment are the same.
[0435] In formula (c13), R 21 、R 22 、R 23 and R 24 are independently selected from hydrogen atoms, C 1-6 Alkyl and -C(=O)-C 1-6 In one embodiment, R 21 、R 22 、R 23 and R 24 All are hydrogen atoms.
[0436] (Carboxymethyl cellulose)
[0437] In one embodiment, the polysaccharide is carboxymethylcellulose, a derivative thereof, or a salt thereof (hereinafter also referred to as "carboxymethylcellulose").
[0438] Carboxymethyl cellulose is a cellulose derivative solubilized by introducing carboxymethyl groups into cellulose. It has excellent thickening, water absorption and water retention properties.
[0439] Derivatives of carboxymethyl cellulose are not particularly limited and are products obtained by subjecting carboxymethyl cellulose to any modification, or salts thereof. Examples of modifications to carboxymethyl cellulose include esterification, sulfation, maleimide modification, thiol modification, acrylate modification, aldehyde modification, and disulfide modification (e.g., pyridyl disulfide). These modifications to carboxymethyl cellulose can be performed by known methods or methods based thereon.
[0440] Examples of salts of carboxymethyl cellulose or its derivatives include metal salts of carboxymethyl cellulose or its derivatives. Examples include salts of carboxymethyl cellulose or its derivatives obtained by reacting hydrogen atoms (hydrogen ions) of carboxylic acids contained in carboxymethyl cellulose or its derivatives with monovalent metal ions (e.g., Na + or K +The water-soluble salts are water-soluble salts made by ion exchange of carboxymethyl cellulose with divalent metal ions (such as alkali metal ions). Specifically, they include: sodium carboxymethyl cellulose, potassium carboxymethyl cellulose, sodium salts of carboxymethyl cellulose derivatives, or potassium salts of carboxymethyl cellulose derivatives. In a specific embodiment, the salt of carboxymethyl cellulose or its derivatives is sodium carboxymethyl cellulose or sodium salts of carboxymethyl cellulose derivatives. The monovalent metal salt solution of carboxymethyl cellulose or its derivatives forms a gel when mixed with a crosslinking agent. Alternatively, the metal salt of carboxymethyl cellulose or its derivatives can be prepared by reacting the hydrogen atoms (hydrogen ions) of the carboxylic acid contained in the carboxymethyl cellulose or its derivatives with divalent metal ions (for example, Mg 2+ , Ca 2+ A salt (cross-linked body) produced by ion exchange with alkaline earth metal ions such as ions.
[0441] In carboxymethyl cellulose, the position of the modified group (A) to be introduced is not particularly limited, but it is preferably introduced at the position of the carboxyl group contained in the carboxymethyl cellulose.
[0442] In a specific embodiment, the group represented by the above formula (A-1) is introduced into the polysaccharide by substituting the -OH group of the carboxyl group of carboxymethyl cellulose.
[0443] In one embodiment, the polysaccharide derivative includes a structural unit represented by the following formula (c14).
[0444] [Chemistry 29]
[0445]
[0446] In formula (c14), R 31 、R 32 and R 33 1 to 3 of them represent a group represented by the following formula (i).
[0447] [Chemistry 30]
[0448]
[0449] In the above formula (i), R 1 The definitions and preferred embodiments of the ring P are the same as those of R in the above formula (A). 1 The definitions and preferred embodiments are the same as those of ring P.
[0450] In the above formula (i), Y represents -L 1 -NH-, at this time L 1 Combined with ring P. L 1 The definition and preferred embodiment are the same as those of L in formula (A-1) 1 The definition and preferred embodiment are the same.
[0451] R 31 、R32 and R 33 The remainder (excluding the substituents represented by the group represented by formula (i)) are independently selected from hydrogen atoms, C 1-6 Alkyl, -C(=O)-C 1-6 The alkyl group and -CH2COOH are preferably selected from a hydrogen atom and -CH2COOH, and more preferably a hydrogen atom.
[0452] In one embodiment, R 31 is a group represented by the above formula (i), R 32 and R 33 A hydrogen atom.
[0453] (Carboxymethyl dextran)
[0454] In one embodiment, the polysaccharide is carboxymethyl dextran, a derivative thereof, or a salt thereof (hereinafter also referred to as "carboxymethyl dextran").
[0455] Carboxymethyl dextran is the carboxymethyl ether of dextran.
[0456] Derivatives of carboxymethyl dextran are not particularly limited and are products obtained by subjecting carboxymethyl dextran to any modifications, or salts thereof. Examples of modifications applied to carboxymethyl dextran include esterification, sulfation, maleimide modification, thiol modification, acrylate modification, aldehyde modification, and disulfide modification (e.g., pyridyl disulfide). These modifications of carboxymethyl dextran can be performed by known methods or methods based thereon.
[0457] Examples of salts of carboxymethyl dextran or its derivatives include metal salts of carboxymethyl dextran or its derivatives. Examples include salts of carboxymethyl dextran or its derivatives obtained by reacting hydrogen atoms (hydrogen ions) of carboxylic acids contained in carboxymethyl dextran or its derivatives with monovalent metal ions (e.g., Na + or K + ions (such as alkali metal ions). Specifically, there are carboxymethyl dextran sodium, carboxymethyl dextran potassium, sodium salt of carboxymethyl dextran derivatives, or potassium salt of carboxymethyl dextran derivatives. In a specific embodiment, the salt of carboxymethyl dextran or its derivatives is a sodium salt of carboxymethyl dextran or a carboxymethyl dextran derivative. The monovalent metal salt solution of carboxymethyl dextran or its derivatives forms a gel when mixed with a cross-linking agent. Alternatively, the metal salt of carboxymethyl dextran or its derivatives can be obtained by reacting the hydrogen atoms (hydrogen ions) of the carboxylic acid contained in the carboxymethyl dextran or its derivatives with divalent metal ions (for example, Mg 2+ , Ca 2+ A salt (cross-linked body) produced by ion exchange with alkaline earth metal ions such as ions.
[0458] In carboxymethyl dextran, the position of the modified group (A) to be introduced is not particularly limited, but it is preferably introduced into the position of the carboxyl group contained in the carboxymethyl dextran.
[0459] In a specific embodiment, the group represented by the above formula (A-1) is introduced into the polysaccharide by substituting the -OH group of the carboxyl group of carboxymethyl dextran.
[0460] In one embodiment, the polysaccharide derivative includes a structural unit represented by the following formula (c15).
[0461] [Chemistry 31]
[0462]
[0463] In formula (c15), R 41 、R 42 and R 43 1 to 3 of them represent a group represented by the following formula (i).
[0464] [Chemistry 32]
[0465]
[0466] In the above formula (i), R 1 The definitions and preferred embodiments of the ring P are the same as those of R in the above formula (A). 1 The definitions and preferred embodiments are the same as those of ring P.
[0467] In the above formula (i), Y represents -L 1 -NH-, at this time L 1 Combined with ring P. L 1 The definition and preferred embodiment are the same as those of L in formula (A-1) 1 The definition and preferred embodiment are the same.
[0468] R 41 、R 42 and R 43 The remainder (excluding the substituents represented by the group represented by formula (i)) are independently selected from hydrogen atoms, C 1-6 Alkyl, -C(=O)-C 1-6 The alkyl group and -CH2COOH are preferably selected from a hydrogen atom and -CH2COOH, and more preferably a hydrogen atom.
[0469] In one embodiment, R 41 is a group represented by the above formula (i), R 42 and R 43 A hydrogen atom.
[0470] The polysaccharide may be heparin, a derivative thereof, or a salt thereof, heparan sulfate, a derivative thereof, or a salt thereof, chondroitin sulfate, a derivative thereof, or a salt thereof, dermatan sulfate, a derivative thereof, or a salt thereof, regenerated oxidized cellulose, a derivative thereof, or a salt thereof, and pectic acid, a derivative thereof, or a salt thereof. In one embodiment of the polysaccharide derivative, the polysaccharide is heparin, a derivative thereof, or a salt thereof, heparan sulfate, a derivative thereof, or a salt thereof, chondroitin sulfate, a derivative thereof, or a salt thereof, dermatan sulfate, a derivative thereof, or a salt thereof, regenerated oxidized cellulose, a derivative thereof, or a salt thereof, and pectic acid, a derivative thereof, or a salt thereof, and the group represented by the above formula (A-1) is introduced by substituting -OH of a carboxyl group contained in the above polysaccharide.
[0471] In some embodiments, the polysaccharide is an amino group-containing polysaccharide. The amino group-containing polysaccharide can be introduced into the polysaccharide by reacting the amino group with the carboxyl group to form an amide bond.
[0472] In a specific embodiment, the polysaccharide is an amino group-containing polysaccharide, and the group represented by formula (A) is a group represented by formula (A-2). The group represented by formula (A-2) is introduced into the polysaccharide by replacing the hydrogen atoms of the amino group of the polysaccharide to form an amide bond. The formation of the amide bond provides a polysaccharide derivative with improved stability.
[0473] The polysaccharide having an amino group includes polysaccharides having an amino group in their structure, their derivatives, or their salts (for example, chitosan, its derivatives, or their salts), and polysaccharides having no amino group but having an amino group introduced into a part of the polysaccharide.
[0474] For example, examples of polysaccharide derivatives obtained by introducing a group represented by the above formula (A-2) into a polysaccharide having an amino group are shown below.
[0475] [Chemistry 33]
[0476]
[0477] In the above formula, R 1 The definitions and preferred embodiments of the ring P are the same as those of R in the above formula (A). 1 The definitions and preferred embodiments are the same as those of ring P.
[0478] In addition, in the above formula, L 2 The definition and preferred embodiment are the same as those of L in formula (A-2) 2 The definition and preferred embodiment are the same.
[0479] (Chitosan)
[0480] The polysaccharide may be chitosan, a derivative thereof, or a salt thereof (also referred to as "chitosans"). Chitosan is a polysaccharide composed of D-glucosamine units and N-acetyl-D-glucosamine units linked by β-(1-4) glycosidic bonds. Chitosan can be obtained by partial deacetylation of chitin as a polysaccharide. The degree of deacetylation is not particularly limited. In some embodiments, the chitosans are deacetylated to a degree exceeding about 50% (more typically, to a degree exceeding about 75%).
[0481] There is no particular limitation on the derivatives of chitosan, and they are products or salts thereof to which chitosan has been subjected to any modification. The arbitrary modifications applied to chitosan include, for example, esterification, sulfation, maleimide modification, thiol modification, acrylate modification, aldehyde modification, and disulfide modification (e.g., pyridyl disulfide). Examples of chitosan derivatives include: carboxymethyl chitosan, hydroxybutyl chitosan, N-acyl chitosan, O-acyl chitosan, N-alkyl chitosan, O-alkyl chitosan, N-alkylene chitosan, O-sulfonyl chitosan, sulfated chitosan, phosphorylated chitosan, nitrated chitosan, alkali chitosan, or metal chelates with chitosan. These modifications to chitosan can be carried out by known methods or methods based thereon. In addition, commercially available products can be used.
[0482] Chitosan has primary amino groups. In the polysaccharide derivative according to one embodiment, the polysaccharide is chitosan, a derivative thereof, or a salt thereof, and the group represented by the formula (A-2) is introduced by substituting a hydrogen atom of an amino group contained in the polysaccharide.
[0483] The position of the modifying group (A) introduced into the chitosan is not particularly limited, but is preferably introduced into the amino group of the D-glucosamine unit constituting the chitosan. In a specific embodiment, the group represented by the formula (A-2) is introduced into the polysaccharide by replacing the hydrogen atom of the amino group of the chitosan.
[0484] In one embodiment, the polysaccharide derivative includes a structural unit represented by the following formula (c16).
[0485] [Chemistry 34]
[0486]
[0487] In formula (c16), R 1 The definitions and preferred embodiments of the ring P are the same as those of R in the above formula (A). 1 The definitions and preferred embodiments are the same as those of ring P.
[0488] In formula (c16), Y represents -L 2 -C(=O)-, at this time L 2 Combined with ring P. L 2The definition and preferred embodiment are the same as those of L in formula (A-2) 2 The definition and preferred embodiment are the same.
[0489] In formula (c16), R 81 and R 82 are independently selected from hydrogen atoms, C 1-6 Alkyl and -C(=O)-C 1-6 In one embodiment, R 81 and R 82 All are hydrogen atoms.
[0490] In a specific embodiment, the polysaccharide is a polysaccharide having an olefinic double bond group. The polysaccharide having an olefinic double bond group forms a sulfide bond (-S-) by reacting the olefinic double bond group with a thiol group (-SH), and the above-mentioned modifying group (A) can be introduced into the polysaccharide. In a specific embodiment, the polysaccharide is a polysaccharide containing an olefinic double bond group, the group represented by the above-mentioned formula (A) is a group represented by the above-mentioned formula (A-3), and the group represented by the above-mentioned formula (A) is introduced into the polysaccharide by reacting with the olefinic double bond group of the above-mentioned polysaccharide.
[0491] The polysaccharide having ethylenic double bonds is not particularly limited, and examples thereof include polysaccharides (e.g., alginic acid, hyaluronic acid, carboxymethyl cellulose, carboxymethyl dextran, carboxymethyl starch, pectin, regenerated oxidized cellulose, chitosan) modified with maleimide or acrylate, or salts thereof.
[0492] For example, examples of polysaccharide derivatives in which a group represented by the above-mentioned formula (A-3) is introduced into a maleimide-modified polysaccharide are shown below.
[0493] [Chemistry 35]
[0494]
[0495] In the above formula, R 1 The definitions and preferred embodiments of the ring P are the same as those of R in the above formula (A). 1 The definitions and preferred embodiments are the same as those of ring P.
[0496] In addition, in the above formula, L 3 The definition and preferred embodiment are the same as those of L in formula (A-3) 3 The definition and preferred embodiment are the same.
[0497] The polysaccharide derivative may have a structure in which a modifying group (A) is introduced into a hydroxyl group contained in the polysaccharide.
[0498] In a specific embodiment, the group represented by the formula (A-4) is introduced by substituting the hydrogen atom of the hydroxyl group contained in the polysaccharide. In this embodiment, as described below, the polysaccharide derivative forms an ether bond via the oxygen atom derived from the hydroxyl group contained in the polysaccharide.
[0499] [Chemistry 36]
[0500]
[0501] (Molecular weight and viscosity of polysaccharide derivatives)
[0502] It is generally difficult to accurately measure the molecular weight of high-molecular-weight polysaccharides, but they generally have a weight-average molecular weight in the range of 1,000 to 10,000,000.
[0503] For example, the molecular weight of the polysaccharide derivative is preferably 1,000 to 5,000,000, more preferably 1,000 to 3,000,000, as measured by a weight average molecular weight (Mw) of gel filtration chromatography (GFC).
[0504] The preferred range of the molecular weight of the polysaccharide derivative also varies depending on the type of polysaccharide constituting the polysaccharide derivative (such as the presence or absence of degrading enzymes or inflammatory responses) or the intended use of the polysaccharide derivative.
[0505] For example, when used in DDS applications, it also depends on the charge of the polysaccharide derivative. It is generally believed that the excretion limit of the kidney is 40,000 to 50,000. Therefore, polysaccharide derivatives composed of (non-biodegradable) polysaccharides (glucan, cellulose derivatives, alginic acid, their salts, or their derivatives, etc.) that have no decomposition enzymes in the body are generally preferably in the range of 1,000 to 50,000 or 1,000 to 40,000 in terms of weight average molecular weight (Mw).
[0506] However, although alginic acid has no degrading enzyme in the body, it has almost no immunogenicity, and therefore alginic acid with a larger weight average molecular weight (eg, Mw of 1,000 to 5,000,000 or 1,000 to 2,000,000) can be used.
[0507] Hyaluronic acid is rich in degradative enzymes in the body, so hyaluronic acid with a large weight average molecular weight (e.g., Mw of ∼2,000,000 or less, or ∼5,000,000 or less) can be used. However, hyaluronic acid with a low molecular weight (around 100,000) is known to cause inflammation, so hyaluronic acid with a weight of 500,000 or more is preferred.
[0508] Typically, when calculating the molecular weight of high-molecular-weight polysaccharides by gel filtration chromatography, a measurement error of 10 to 20% or more occurs. For example, a weight average molecular weight of 400,000 may result in a value fluctuation within a range of approximately 320,000 to 480,000; a weight average molecular weight of 500,000 may result in a value fluctuation within a range of approximately 400,000 to 600,000; and a weight average molecular weight of 1,000,000 may result in a value fluctuation within a range of approximately 800,000 to 1,200,000. Therefore, the appropriate weight average molecular weight range for polysaccharides is at least 1,000. Polysaccharides with excessively high molecular weights are difficult to manufacture and, when formulated into aqueous solutions, have excessively high viscosity and reduced solubility, leading to problems such as difficulty maintaining physical properties during long-term storage. Therefore, the weight average molecular weight is preferably 5,000,000 or less, and more preferably 3,000,000 or less.
[0509] The weight average molecular weight of the polysaccharide derivative into which the modifying group (A) has been introduced is increased due to the introduction of the modifying group (A) compared to the polysaccharide before the introduction of the modifying group (A). By appropriately selecting the molecular weight of the polysaccharide used as the starting material, a polysaccharide derivative having a desired molecular weight can be obtained.
[0510] Generally, high molecular weight substances derived from natural products do not have a single molecular weight, but rather are aggregates of molecules with various molecular weights, and are therefore measured as having a molecular weight distribution within a certain range. A representative measurement method is gel filtration chromatography. Representative information on molecular weight distribution obtained by gel filtration chromatography includes weight average molecular weight (Mw), number average molecular weight (Mn), and dispersion ratio (Mw / Mn).
[0511] The weight average molecular weight is the one that contributes most to the average molecular weight of high molecular weight polymers and is represented by the following formula.
[0512] Mw=Σ(WiMi) / W=Σ(HiMi) / Σ(Hi)
[0513] The number average molecular weight is calculated by dividing the total weight of the polymer by the total number of polymers.
[0514] Mn=W / ΣNi=Σ(MiNi) / ΣNi=Σ(Hi) / Σ(Hi / Mi)
[0515] Here, W is the total weight of the polymers, Wi is the weight of the i-th polymer, Mi is the molecular weight at the i-th dissolution time, Ni is the number of molecules with molecular weight Mi, and Hi is the height at the i-th dissolution time.
[0516] When measuring the molecular weight of naturally derived high-molecular-weight substances, it is known that the values vary depending on the measurement method (for example, hyaluronic acid: Chikako YOMOTA et al., Bull. Natl. Health Sci., Vol. 117, pp. 135-139 (1999), Chikako YOMOTA et al., Bull. Natl. Inst. Health Sci., Vol. 121, pp. 30-33 (2003)). Regarding the molecular weight measurement of alginate, there are documents describing methods for calculating the molecular weight from intrinsic viscosity and SEC-MALLS (Size Exclusion Chromatography with Multiple Angle Laser Light Scattering Detection) (ASTM F2064-00 (2006), published by ASTM International). It should be noted that in this document, when measuring molecular weight by size exclusion chromatography (= gel filtration chromatography), in addition to using pullulan as a calibration curve of a standard substance, it is also recommended to use a multi-angle light scattering detector (MultiAngle Light Scattering: MALS) (= measurement based on SEC-MALS). SEC-MALS is described in ASTM F2065-16. In addition, there are examples of using molecular weights measured by SEC-MALS as standard values in catalogs of alginate (FMC Biopolymer, PRONOVA TM Sodium alginate catalog).
[0517] In the present invention, when specifying the molecular weight of a polysaccharide derivative, unless otherwise specified, it refers to a weight average molecular weight calculated by gel filtration chromatography.
[0518] Representative conditions for gel filtration chromatography include: using a calibration curve with pullulan as a standard substance. As the molecular weight of pullulan used as a standard substance, it is preferred to use pullulan of at least 1.6 million, 788,000, 404,000, 212,000 and 112,000 as a standard substance. In addition, specific eluents (200mM sodium nitrate solution), column conditions, etc. can be used. As column conditions, it is preferred to use a polymethacrylate resin-based filler, and at least 1 to 3 columns with an exclusion limit molecular weight of more than 10 million are used. A representative column is TSKgel GMPW x1 (7.8mm diameter × 300mm) and G2500PW XL (7.8 mm in diameter × 300 mm) (manufactured by Tosoh Corporation).
[0519] (Modification rate)
[0520] The modification ratio refers to the number of modification groups (A) per monosaccharide structural unit contained in the polysaccharide derivative.
[0521] [Mathematical formula 1]
[0522]
[0523] The modification rate of the modifying group (A) in the polysaccharide derivative is not particularly limited and can be adjusted according to the intended use. For example, the modification rate of the modifying group (A) in the polysaccharide derivative can be adjusted to a desired range by adjusting the type of modifying group (A), the number of functional groups reactive with the modifying group (A) contained in the polysaccharide, the reaction conditions for introducing the modifying group (A), and the like.
[0524] The modification rate of the modifying group (A) in the polysaccharide derivative can be set to, for example, 0.01 to 1, 0.02 to 0.6, 0.05 to 0.2, or 0.1 to 0.2. Modification rates within these ranges may be employed when the polysaccharide derivative is used as a drug delivery carrier.
[0525] In another embodiment, the modification rate of the modifying group (A) in the polysaccharide derivative can be set to, for example, 0.1 to 1, or 0.1 to 0.8, or 0.15 to 0.6. Modification rates within these ranges may be employed when the polysaccharide derivative is used in the form of a hydrogel.
[0526] In another embodiment, the modification rate of the modification group (A) in the polysaccharide derivative can be set to, for example, a range of 0.00001 to 0.01.
[0527] For example, when the polysaccharide is alginic acid, since each monosaccharide structural unit has one carboxyl group, when a modifying group (A) is introduced into the carboxyl group, the modification rate of the modifying group (A) in the polysaccharide derivative is at most 1, and can be set to, for example, the range of 0.01 to 1, 0.01 to 0.6, 0.05 to 0.2, or 0.00001 to 0.01.
[0528] For example, when the polysaccharide is hyaluronic acid, hyaluronic acid is composed of a monosaccharide structural unit having one carboxyl group (D-glucuronic acid) and a monosaccharide structural unit having no carboxyl group (N-acetyl-D-glucosamine). Therefore, when a modifying group (A) is introduced into the carboxyl group, the modification rate of the modifying group (A) in the polysaccharide derivative is a maximum of 0.5, and can be set to, for example, the range of 0.01 to 0.5, 0.05 to 0.2, or 0.00001 to 0.01.
[0529] For example, when the polysaccharide is a carboxymethyl cellulose type, it has 1 to 3 carboxyl groups in the monosaccharide structural unit. When a modifying group (A) is introduced into the carboxyl group, the modification rate of the modifying group (A) in the polysaccharide derivative is a maximum of 3 (when carboxymethyl substitution is performed at all three positions), and can be set, for example, in the range of 0.01 to 3, 0.05 to 1.5, 0.05 to 1, or 0.00001 to 0.01.
[0530] For example, when the polysaccharide is a carboxymethyl glucan, the monosaccharide structural unit has 1 to 3 carboxyl groups. When a modifying group (A) is introduced into the carboxyl group, the modification rate of the modifying group (A) in the polysaccharide derivative is a maximum of 3 (when carboxymethyl substitution is performed at all three positions), and can be set, for example, in the range of 0.01 to 3, 0.05 to 1.5, or 0.05 to 1, or 0.00001 to 0.01.
[0531] The modification rate can be 1 It was calculated by H NMR measurement (D2O).
[0532] In addition, the modification rate can be calculated by colorimetric measurement.
[0533] pass 1 The modification rates calculated by H NMR measurement or colorimetric aldehyde measurement are not completely consistent, and sometimes there is a difference between the two. However, in the present invention, 1 The modification rate calculated by either H NMR measurement or colorimetric aldehyde measurement may be within the above range.
[0534] When introducing the modifying group (A), a spacer may be further used. Usable spacers are any common spacers in the art (e.g., those described in Greg T. Hermanson, Bioconjugate Techniques, 3rd edition (2013)). More specifically, they include polyethylene glycol, peptides, and other polyamides and hydrocarbons.
[0535] 2. Method for producing polysaccharide derivatives
[0536] The method for producing the polysaccharide derivative is not particularly limited. For example, the polysaccharide derivative can be produced by a method comprising reacting a compound (a) represented by the following formula (a) with a polysaccharide having a functional group reactive with the -X group of the compound (a). This yields a polysaccharide derivative (C) into which a modifying group (A) corresponding to the compound (a) (a represented by the formula (A) described above) is introduced.
[0537] [Chemistry 37]
[0538]
[0539] In the above formula (a), X is selected based on Y in formula (C).
[0540] In Y is -L 1 -NH-(At this time L 1 In the case of binding to ring P), X is -L 1 -NH2.
[0541] In Y is -L 2 -C(=O)-(At this time L 2 In the case of binding to ring P), X is -L 2 -C(=O)OH.
[0542] In Y is -L 3 -S-(At this time L 3 In the case of binding to ring P), X is -L 3 -SH.
[0543] In Y is -L 4 -(At this time L 4 In the case of binding to ring P), X is -L 4 -R L , R L is selected from halogen atoms (F, Cl, Br, or I).
[0544] The rings P and R in the above formulas (a) and (C) are 1 , and the definitions and preferred embodiments of Y in formula (C) are the same as those in the above-mentioned formula (A) and formulas (A-1), (A-2), (A-3) and (A-4).
[0545] In the manufacturing method of this embodiment, the polysaccharide can be reacted with a compound (a) represented by formula (a) having a benzene ring or a pyridine ring with high hydrophobicity under mild and highly safe conditions in a single stage by having an acidic, basic or both (amphoteric) functional group (i.e., a charged functional group) to introduce a modification group (A) into the polysaccharide.
[0546] In a specific embodiment, the method for producing a polysaccharide derivative represented by formula (C) comprises: adding an acidic, basic or amphoteric polysaccharide and a compound (a) represented by the above formula (a) to a solution containing the above compound (a) and the polysaccharide in an aqueous solvent, a polar solvent or a higher alcohol, and reacting them.
[0547] By such a reaction, the modification group (A) can be introduced into the polysaccharide at a high modification rate.
[0548] In the following, Y is -L 1 -NH-(At this time L 1 Combined with ring P), X is -L 1-NH2 is taken as an example to illustrate the method for producing a polysaccharide derivative. 1 In cases other than -NH-, the polysaccharide derivative represented by the above formula (C) can also be produced by methods known in the literature.
[0549] One embodiment of the present invention relates to a method for producing a polysaccharide derivative represented by the following formula (C1).
[0550] The polysaccharide derivative represented by the following formula (C1) can be obtained by condensing the carboxyl groups of the polysaccharide with the amino groups of the compound (a1) represented by the following formula (a1). This reaction forms an amide bond between the amino groups of the compound (a1) and the carboxyl groups of the polysaccharide, thereby obtaining a polysaccharide derivative represented by the following formula (C1) in which a modifying group (A) corresponding to the compound (a1) (the group represented by the formula (A-1) described above) is introduced into the polysaccharide.
[0551] [Chemistry 38]
[0552]
[0553] The rings P and R in the above formulas (a1) and (C1) are 1 , and L in formula (C1) 1 The definitions and preferred embodiments are the same as those in the above-mentioned formula (A) and formula (A-1).
[0554] The condensation reaction method is not particularly limited and can be carried out according to known methods in the literature, for example, methods described in "Experimental Chemistry Lectures, 5th Edition, Vol. 16, Synthesis of Organic Compounds IV, Carboxylic Acids and Derivatives, Esters, pp. 35-70, Acid Amides and Acid Imides, pp. 118-154, Amino Acids / Peptides, pp. 258-283, 2007, Maruzen" etc. The reaction is usually carried out in a solvent.
[0555] In a specific embodiment, the method for producing a polysaccharide derivative represented by formula (C1) comprises condensing a carboxyl group-containing polysaccharide with a compound (a1) represented by the following formula (a1) in a solvent (eg, an aqueous solvent).
[0556] In one embodiment, the compound (a1) is dissolved or dispersed in an aqueous solvent, a polar solvent, or a higher alcohol solvent, and then added to a solution containing a polysaccharide to react with the polysaccharide. This allows the modification group (A) to be introduced into the polysaccharide at a high modification rate.
[0557] Generally, the compound (a1) represented by formula (a1) has low solubility in aqueous solvents. Therefore, the compound (a1) can be added to an aqueous solvent containing a polysaccharide and reacted with the polysaccharide under stirring to allow the compound (a1) to react in a suspended state.
[0558] In one embodiment, compound (a1) is dissolved in a polar solvent (preferably DMSO) or a higher alcohol solvent, and the solution of compound (a1) is added to an aqueous solvent containing a polysaccharide. This can increase the modification rate of compound (a1).
[0559] Surprisingly, by using a simple method of dissolving or dispersing compound (a1) in a specific solvent and then adding it to the polysaccharide, the modification rate is greatly improved. The details of the factors that increase the modification rate are still unclear, but the inventors speculate as follows: relative to compound (a1), there are excess carboxyl groups, and in this environment, the compound (a1) with low solubility (hydrophobicity) is consumed in the reaction, thereby promoting the dissolution of the following compound (a1), so that the modification rate is improved. In addition, it is speculated that the reaction of the carboxyl group of the polysaccharide with the amino group of the compound (a) is more effective than the reaction of the amino group of the compound (a) with the aldehyde group of the compound (a) (Schiff base formation reaction), which is also a factor that increases the modification rate. However, the manufacturing method of this embodiment is not limited by this mechanism.
[0560] Examples of the polar solvent include N,N-dimethylformamide, dimethyl sulfoxide (DMSO), dioxane, and N-methyl-2-pyrrolidone (NMP).
[0561] Examples of the aqueous solvent include water; mixed solvents of water and ether solvents such as tetrahydrofuran (THF) and 1,4-dioxane, alcohol solvents such as methanol, ethanol, and 2-propanol, polar solvents such as N,N-dimethylformamide, dimethyl sulfoxide (DMSO), dioxane, and N-methyl-2-pyrrolidone (NMP), to the extent that polysaccharides are not precipitated; and the like.
[0562] The condensation reaction of compound (a1) and polysaccharide is preferably carried out under conditions of pH 5 to 10 (more preferably pH 5.5 to 8.5, and even more preferably pH 7.5 to 8.0). By adjusting the pH to this range while carrying out the reaction, the modification rate of the modifying group (A) can be further increased. When adjusting the pH range, it is preferred to use an aqueous sodium hydroxide solution or an aqueous hydrochloric acid solution. Alternatively, the reaction can be carried out using a buffer solution.
[0563] The condensation reaction of compound (a1) and the polysaccharide is preferably carried out in the presence of a condensing agent selected from 1,3-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (WSC / HCl), benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP reagent), bis(2-oxo-3-oxazolidinyl)phosphinoyl chloride (BOP-Cl), 2-chloro-1,3-dimethylimidazolinium hexafluorophosphate (CIP) or 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholine chloride (DMT-MM), in the presence or absence of an inorganic base such as sodium bicarbonate or sodium carbonate, or an organic base such as triethylamine or pyridine.
[0564] Such a condensation reaction can be carried out, for example, in the range of 0°C to 50°C. The preferred temperature range is 15°C to 40°C. By carrying out the reaction at a temperature near room temperature, the reaction time can be shortened while suppressing the decrease in the molecular weight of the polysaccharide. In addition, by adopting such a temperature range, the side reaction (Schiff base formation reaction) between the amino group of compound (a) and the aldehyde group of compound (a) can be suppressed.
[0565] In order to suppress the formation of by-products during the condensation reaction, additives such as 1-hydroxy-1H-benzotriazole (HOBt) and 1-hydroxy-7-azabenzotriazole (HOAt) may be added.
[0566] After the reaction, purification treatment can be performed by filtration and / or dialysis.
[0567] One embodiment of the present invention relates to a method for producing a polysaccharide derivative represented by the following formula (C2). In some embodiments, the method for producing a polysaccharide derivative represented by formula (C2) comprises condensing an amino group-containing polysaccharide with a compound (a2) represented by the following formula (a2).
[0568] The polysaccharide derivative represented by the following formula (C2) can be obtained by condensing the amino groups of the polysaccharide with the carboxyl groups of the compound (a2) represented by the following formula (a2). This reaction forms an amide bond between the carboxyl groups of the compound (a2) and the amino groups of the polysaccharide, thereby obtaining a polysaccharide derivative represented by the following formula (C2) in which a modifying group (A) corresponding to the compound (a2) (the group represented by the formula (A-2) described above) is introduced into the polysaccharide.
[0569] [Chemistry 39]
[0570]
[0571] The rings P and R in the above formulas (a2) and (C2) are 1 , and L in formula (C2) 2The definitions and preferred embodiments are the same as those in the above-mentioned formula (A) and formula (A-2).
[0572] The condensation reaction method is not particularly limited, and the condensation reaction can be carried out by a conventionally known method such as a method using a carbodiimide-based condensing agent.
[0573] The condensation reaction of compound (a2) and polysaccharide is preferably carried out under conditions of pH 4 to 7 (more preferably pH 5 to 6). By carrying out the reaction while adjusting the pH to this range, precipitation of the reaction product can be suppressed, and the reaction can be carried out efficiently. It is preferred to use an aqueous sodium hydroxide solution or an aqueous hydrochloric acid solution to adjust the pH range. Alternatively, the reaction can be carried out using a buffer solution.
[0574] Furthermore, it is preferred to react compound (a2) and polysaccharide in a ratio (molar ratio) of carboxyl groups of compound (a2) to amino groups of polysaccharide of 0.8:1 to 1.2:1. In this case, precipitation of the reaction product can be suppressed, and the reaction can proceed efficiently.
[0575] 3. Polysaccharide derivative-drug conjugates
[0576] The polysaccharide derivative can form a polysaccharide derivative-drug conjugate of a drug containing a primary amino group and the polysaccharide derivative in the above manner. Therefore, in some embodiments, the tissue adhesive material comprises a polysaccharide derivative-drug conjugate. The polysaccharide derivative can form a conjugate by forming a Schiff base with the drug having a primary amino group. Specifically, the aldehyde group or ketone group (-CR 1 (=O)) reacts with the primary amino group of the drug to form a Schiff base.
[0577] Therefore, in the polysaccharide derivative-drug conjugate of this embodiment, the drug and the group represented by formula (A) (modifying group (A)) contained in the polysaccharide are covalently bonded via a Schiff base to form a structure represented by the following formula (D).
[0578] [Chemistry 40]
[0579]
[0580] In the above formula (D), Drug represents the drug moiety excluding the primary amino group.
[0581] In the above formula (D), R 1 The definitions and preferred embodiments of rings P and Y are the same as those of R in the above formula (A). 1 The definitions and preferred embodiments are the same as those of ring P.
[0582] (Drugs with primary amino groups)
[0583] The drug is not particularly limited as long as it has one or more primary amino groups within the molecule. The drug may be a synthetic or natural product. Examples thereof include at least one selected from low molecular weight compounds, medium molecular weight compounds, peptides, nucleic acids, nucleic acid derivatives, aptamers, vitamins, monoamines, amino acids, polyamines, antibodies, fluorescent dyes, and contrast agents.
[0584] The primary amino group may be a hydrazide group (-C(=O)-NH-NH2). The hydrazide group may react with the aldehyde group or ketone group (-CR 1 The hydrazone bond is more stable than a common Schiff base and can be expected to delay the release of the hydrazone.
[0585] Examples of low molecular weight compounds (e.g., molecular weight of 500 or less) and medium molecular weight compounds (e.g., molecular weight of 500 to 2000) having a primary amino group include: doxorubicin, gemcitabine, aminosalicylic acid, pemetrexed, methotrexate, alendronate, eribulin, memantine, remdesivir, ampicillin, amoxicillin, aztreonam, tigemonam, vancomycin, cephalosporin C, gentamicin, trimethoprim, sulfamethoxazole, and oseltamivir. , mexiletine, midodrine, levodopa, tenofovir, darunavir, procaine, ethyl aminobenzoate, procainamide, fluvoxamine, milnacipran, baclofen, benserazide, carbidopa, droxidopa, gumarilimus, ubenimex, fingolimod, amfenac, sulfonamide, triamterene, mexiletine (Mexiletine, メチシレチン), amlodipine, azelnidipine, methyldopa, hydralazine, mosapride, sitagliptin phosphate hydrate, valacyclovir, acyclovir, celecoxib, etc.
[0586] The peptide is not particularly limited as long as it has a primary amino group at the N-terminus, etc. Examples of the peptide include methionine-enkephalin, leucine-enkephalin, dynorphin A, β-endorphin, bacitracin, daptomycin, colistin, elcatonin, and oxytocin.
[0587] Nucleobases such as adenine, thymine, guanine, and cytosine have primary amino groups, and nucleic acids and nucleic acid derivatives containing these nucleobases have primary amino groups and can be used in the present invention. Examples of nucleic acid derivatives include cytarabine, cladribine, and fludarabine.
[0588] As the aptamer, a nucleic acid (DNA·RNA) aptamer or a peptide aptamer can be used.
[0589] Examples of vitamins having a primary amino group include folic acid, vitamin B1 (thiamine), vitamin B6 (pyridoxamine), vitamin B12 (cyanocobalamin), and niacinamide.
[0590] Examples of the monoamines having a primary amino group include dopamine, norepinephrine, serotonin, histamine, thiamine, and octopamine.
[0591] Examples of the amino acid include various amino acids having a primary amino group in the molecule. The amino acid may be a natural amino acid or an artificial amino acid such as tranexamic acid.
[0592] Examples of polyamines include molecules having multiple primary amines in the molecule, such as spermine, spermidine, and putrescine, which exist in living bodies.
[0593] Examples of the fluorescent dye include fluorescein-5-thiosemicarbazide (FTSC) and the like.
[0594] The drugs may be used alone or in combination of two or more.
[0595] Drugs can be water-soluble or water-insoluble.
[0596] The drug may be in the form of a salt, a hydrate, or a solvate as long as it has a primary amino group.
[0597] (Drug introduction rate)
[0598] The drug incorporation rate of the modifying group (A) in the polysaccharide derivative-drug conjugate is not particularly limited and refers to, for example, a ratio expressed as a percentage of the drug and the bond (Schiff base) introduced into the modifying group (A) introduced into the polysaccharide derivative. The drug incorporation rate is not particularly limited and can be, for example, 1 to 100%.
[0599] (Sustained release properties)
[0600] In the aldehyde or ketone group (-CR 1 The Schiff base formed between (=O)) and the primary amino group of the drug exists stably under neutral to alkaline pH conditions, but dissociates under low pH conditions to release the drug.
[0601] In this specification, "low pH conditions" refers to a pH lower than 7, typically a pH of 3.5 to 7.0.
[0602] It should be noted that in a neutral to alkaline (high pH) environment (e.g., pH 7.4 or above), a small amount of drug release occurs, but the release is sustained. On the other hand, in low pH conditions, the drug release rate is fast, and a large amount of drug is released.
[0603] The physiological pH of blood is known to be around pH 7.4. In contrast, inflamed tissues or tumor tissues (pH 6.5-7.2), or the interiors of lysosomes and endosomes (pH 4.5-5.5), are low pH environments. The polysaccharide derivative-drug conjugate of this embodiment responds to low pH to release the drug. For example, at pH 7.4, which is comparable to the pH of blood, drug release is suppressed to maintain drug stability, allowing for efficient drug release at target sites in low pH environments.
[0604] [Chemistry 41]
[0605]
[0606] In the above formula, Drug represents the drug moiety excluding the primary amino group.
[0607] In the above formula, R 1 The definitions and preferred embodiments of rings P and Y are the same as those of R in the above formula (A). 1 The definitions and preferred embodiments are the same as those of ring P.
[0608] (Manufacturing Method)
[0609] Another embodiment of the present invention relates to a method for producing a polysaccharide derivative-drug conjugate. The production method of this embodiment comprises: mixing the above-mentioned polysaccharide derivative and the drug containing a primary amino group in a solvent. By mixing, the aldehyde group or ketone group (-CR 1 (=O)) reacts with the amino group of the drug to form a Schiff base, thereby obtaining a polysaccharide derivative-drug conjugate.
[0610] This production method allows for the convenient, one-pot production of stable polysaccharide derivative-drug conjugates using mild and highly safe reaction conditions in a single step. This method eliminates the need for pre-conjugate drug modification and complex laboratory equipment or catalysts for conjugate formation, enabling in situ preparation of polysaccharide derivative-drug conjugates from the polysaccharide derivative and drug.
[0611] The solvent is not particularly limited, and any solvent that can dissolve the polysaccharide to be used can be appropriately selected. For example, aqueous solvents or polar solvents such as dimethyl sulfoxide (DMSO) are preferably used because of their excellent solubility in polysaccharides.
[0612] Examples of the aqueous solvent include water; mixed solvents of water and ether solvents such as tetrahydrofuran (THF) and 1,4-dioxane to the extent that polysaccharides are not precipitated; alcohol solvents such as methanol, ethanol, and 2-propanol; and polar solvents such as N,N-dimethylformamide and dimethyl sulfoxide (DMSO); and the like.
[0613] The mixing temperature is not particularly limited and can be, for example, in the range of 0°C to 50°C. A preferred temperature range is 15°C to 40°C. By carrying out the reaction at a temperature near room temperature, a suitable reaction rate and prevention of a decrease in the weight can be achieved.
[0614] The pH at which the polysaccharide derivative reacts with the drug can be any pH at which the drug dissolves and does not undergo modification. However, from the perspective of reaction rate, a pH of 4.0 to 11.0 (more preferably 6.0 to 9.0, and even more preferably 7.0 to 8.0) is preferred. By adjusting the pH within this range while performing the reaction, the rate of drug incorporation into the modifying group (A) can be further increased. Hydrochloric acid or sodium hydroxide is preferably used to adjust the pH range.
[0615] In addition, in the case of drugs with poor photostability, the reaction between the polysaccharide derivative and the drug is preferably carried out under light-shielding conditions.
[0616] The reaction time is not particularly limited, but is about 1 minute to 24 hours, preferably 10 minutes to 2 hours.
[0617] The mixing ratio of the polysaccharide derivative and the drug can be appropriately determined depending on the number of modifying groups (A) introduced into the polysaccharide derivative, the desired drug incorporation rate, and the solubility of the resulting polysaccharide derivative-drug conjugate. For example, the mixing ratio is 0.001 to 10 moles, preferably 0.05 to 3 moles, and more preferably 0.1 to 1 mole, per 1 mole of the modifying group (A) introduced into the polysaccharide derivative.
[0618] The method for mixing the polysaccharide derivative and the drug is not particularly limited as long as the two components can be uniformly mixed.
[0619] The polysaccharide derivative-drug conjugate (reaction solution) obtained by mixing can be used directly without purification. After the conjugate is formed, it can be purified by dialysis, salting out, gel filtration, ion exchange chromatography, electrophoresis, or freeze-dried.
[0620] 4. Composition
[0621] Another embodiment of the present invention relates to a composition comprising the polysaccharide derivative of the above embodiment or the polysaccharide derivative-drug conjugate of the above embodiment.
[0622] In some embodiments, a composition is provided comprising the polysaccharide derivative or the polysaccharide derivative-drug conjugate described above and an aqueous solvent. In the composition, the weight ratio of the polysaccharide derivative or conjugate to the aqueous solvent is, for example, 0.0001:1 to 0.3:1, preferably 0.001:1 to 0.1:1.
[0623] In some embodiments, a composition is provided comprising the polysaccharide derivative of the above-described embodiment and a drug having a primary amino group. In the composition, the molar ratio of the polysaccharide derivative to the drug is as follows: for example, the molar ratio of A to the drug is in the range of 1:0.001 to 1:10, preferably 1:0.05 to 1:3, and more preferably 1:0.1 to 1:1.
[0624] In some embodiments, a composition is provided comprising the polysaccharide derivative of the above-described embodiment, a drug having a primary amino group, and an aqueous solvent. In this composition, the ratio of the combined weight of the polysaccharide derivative and the drug to the weight of the aqueous solvent is, for example, 0.0001:1 to 0.3:1, preferably 0.001:1 to 0.1:1. In this composition, the molar ratio of the polysaccharide derivative to the drug is as follows: for example, the ratio of A to the drug is in the range of 1:0.001 to 1:10, preferably 1:0.05 to 1:3, and more preferably 1:0.1 to 1:1.
[0625] In some embodiments, a composition is provided comprising a cross-linked structure of a polysaccharide derivative described below and an aqueous solvent. In the composition, the weight ratio of the cross-linked structure to the aqueous solvent is, for example, 0.0001:1 to 0.3:1, preferably 0.001:1 to 0.1:1.
[0626] In some embodiments, a composition is provided comprising a cross-linked structure of a polysaccharide derivative-drug conjugate (cross-linked structure-drug conjugate) described below and an aqueous solvent. In this composition, the weight ratio of the cross-linked structure to the aqueous solvent is, for example, 0.0001:1 to 0.3:1, preferably 0.001:1 to 0.1:1.
[0627] As the aqueous solvent, the solvents listed in the section of the method for producing a polysaccharide derivative or the method for producing a conjugate can also be used.
[0628] The polysaccharide derivative or polysaccharide derivative-drug conjugate of the present invention can be combined with conventionally known pharmaceutical carriers or diluents and other additives to form a pharmaceutical composition, which can be administered parenterally or orally to mammals or non-mammals including humans.
[0629] Examples of mammals include, but are not limited to, humans, gorillas, apes, monkeys, cows, horses, sheep, goats, pigs, rabbits, dogs, cats, rats, mice, guinea pigs, etc. Examples of non-mammals include, but are not limited to, birds, fish, insects, etc.
[0630] One embodiment provides a pharmaceutical composition comprising the polysaccharide derivative described above, a drug, and a pharmaceutically acceptable additive.
[0631] One embodiment provides a pharmaceutical composition comprising the polysaccharide derivative-drug conjugate described above and a pharmaceutically acceptable additive.
[0632] Examples of pharmaceutically acceptable additives include excipients, fillers, extenders, binders, wetting agents, disintegrants, lubricants, surfactants, dispersants, buffers, preservatives, solubilizers, preservatives, flavoring agents, pain relievers, stabilizers, and isotonic agents commonly used in pharmaceutical production. Pharmaceutical compositions can be prepared using conventional methods using appropriately selected additives.
[0633] The polysaccharide derivative or polysaccharide derivative-drug conjugate of the present invention can be mixed with additives commonly used in the food field (for example, at least one of various nutritional supplements (amino acids, vitamins, minerals, etc.), sugars, dairy products, sweeteners, flavorings, spices, antioxidants, preservatives, colorants, emulsifying agents, pH regulators, organic acids, buffers, fruit juices, etc.) to prepare a food composition.
[0634] The composition of the above embodiment is used as a tissue adhesive material or for producing a tissue adhesive material.
[0635] 5. Cross-linked structure
[0636] The polysaccharide derivative can form a cross-linked structure. One embodiment of the present invention relates to a cross-linked structure comprising a polysaccharide derivative.
[0637] (1) Cross-linked structures of polysaccharide derivatives formed via cross-linking agents
[0638] In some embodiments, the cross-linked structure is a cross-linked structure of a polysaccharide derivative or a cross-linked structure of a polysaccharide derivative-drug conjugate (also referred to as a "cross-linked structure-drug conjugate"). The cross-linked structure of a polysaccharide derivative is a structure in which a polysaccharide derivative is cross-linked via a cross-linking group to form a three-dimensional network structure. The cross-linked structure of a polysaccharide derivative-drug conjugate (cross-linked structure-drug conjugate) is a structure in which a polysaccharide derivative-drug conjugate is cross-linked via a cross-linking group to form a three-dimensional network structure. The cross-linked structure of a polysaccharide derivative can be obtained by subjecting a polysaccharide derivative having a cross-linking group to a cross-linking reaction using a cross-linking agent. The cross-linked structure of a polysaccharide derivative-drug conjugate (cross-linked structure-drug conjugate) is typically obtained by the following method: a method in which a cross-linking reaction is applied to a polysaccharide derivative-drug conjugate having a cross-linking group using a cross-linking agent; or a method in which the cross-linked structure is combined with a drug via a Schiff base after the cross-linked structure of the polysaccharide derivative is manufactured.
[0639] For example, cross-linking agents include metal ions; amino group-containing polymers and amino group-containing low molecular weight compounds containing two or more primary amino groups, hydrazide groups, or aminooxy groups; and compounds containing two or more aldehyde groups such as glutaraldehyde.
[0640] For example, unmodified carboxyl groups function as crosslinking groups and can form a crosslinked structure via a crosslinking agent such as a divalent metal ion. A crosslinked structure can be formed by reacting a composition containing a polysaccharide derivative or a polysaccharide derivative-drug conjugate containing an unmodified carboxyl group in a solution containing a crosslinking agent.
[0641] The shape of these cross-linked structures is not particularly limited, and examples thereof include tubular structures, fibrous structures, fibers, beads, gels, substantially spherical gels, capsules, sponges, sheets, and films.
[0642] In a specific embodiment, a gel, capsule, sponge, bead, fiber, tube, sheet or film is provided, which comprises the polysaccharide derivative, polysaccharide derivative-drug conjugate, cross-linked structure or cross-linked structure-drug conjugate described above.
[0643] Specifically, a solution containing an unmodified carboxyl group-containing polysaccharide derivative is added dropwise to a solution containing a divalent metal ion as a crosslinking agent, thereby partially crosslinking the solution to obtain a crosslinked structure. Alternatively, a solution containing an unmodified carboxyl group-containing polysaccharide derivative-drug conjugate is added dropwise to a solution containing a divalent metal ion, thereby partially crosslinking the solution to obtain a crosslinked structure.
[0644] The cross-linked structure produced by this method can be in the form of, for example, capsules, beads, fibers, tubes, or films.
[0645] Alternatively, a solution containing an unmodified carboxyl-containing polysaccharide derivative and a solution containing a divalent metal ion as a crosslinking agent are applied to a substrate, and the polysaccharide derivative is partially crosslinked to obtain a crosslinked structure. The crosslinked structure produced by this method can be in the form of a gel (hydrogel).
[0646] The gel was freeze-dried to obtain a sponge-shaped cross-linked structure.
[0647] As a method for binding the drug to the cross-linked structure via a Schiff base after forming the cross-linked structure, the same method as the method for producing the polysaccharide derivative-drug conjugate can be used. For example, a method can be used in which the cross-linked structure and the drug containing a primary amino group are mixed in a solvent after forming the cross-linked structure. By mixing, the aldehyde group or ketone group (-CR 1 (=O)) reacts with the amino group of the drug to form a Schiff base, thereby obtaining a cross-linked structure-drug conjugate.
[0648] A drug-supported cross-linked structure of a polysaccharide derivative can also be obtained by chemically binding or physically attaching the drug to the cross-linked structure of the polysaccharide derivative.
[0649] For example, a drug-loaded cross-linked structure of a polysaccharide derivative can be obtained by applying a solution containing a drug to the cross-linked structure of a polysaccharide derivative, immersing the cross-linked structure of a polysaccharide derivative in the solution, or printing the drug on the cross-linked structure of a polysaccharide derivative.
[0650] Specific examples of the divalent metal ions used as crosslinking agents in the crosslinking reaction include calcium ions, magnesium ions, barium ions, strontium ions, and zinc ions, with calcium ions being preferred. More specifically, divalent metal ion compounds include CaCl2, MgCl2, CaSO4, ZnCl2, BaCl2, and SrCl2 (preferably CaCl2, CaSO4, ZnCl2, SrCl2, and BaCl2).
[0651] In addition to the above-mentioned divalent metal ions (divalent metal ion compounds), Fe 3+ trivalent metal ion compounds (FeCl3), crosslinking agents having 2 to 4 amino groups in the molecule, etc. Crosslinking agents having 2 to 4 amino groups in the molecule include diaminoalkanes that may also have a lysyl group (-COCH(NH2)-(CH2)4-NH2) on the nitrogen atom, that is, diaminoalkanes and their derivatives in which the amino group is substituted with a lysyl group to form a lysylamino group. Specific examples include diaminoethane, diaminopropane, and N-(lysyl)-diaminoethane.
[0652] In addition to the above, when a drug has multiple primary amino groups, the drug itself introduced into the polysaccharide may function as a cross-linking group. For example, a polysaccharide derivative can be cross-linked via a medium-molecular compound (peptide) having multiple primary amino groups (e.g., bacitracin) to form a three-dimensional network structure.
[0653] As described below, amino-containing polymers and amino-containing low molecular weight compounds containing two or more primary amino groups, hydrazide groups, or aminooxy groups function as crosslinking agents and can crosslink by covalently bonding the modifying groups (A) of the polysaccharide derivative via a Schiff base.
[0654] Furthermore, compounds containing two or more aldehyde groups, such as glutaraldehyde, function as a cross-linking agent and can form a cross-linked structure (cross-linked structure) via the hydroxyl groups of the polysaccharide derivative.
[0655] The amount of the cross-linking agent used is preferably adjusted appropriately depending on the amount or molecular weight of the polysaccharide derivative used, the type of polysaccharide constituting the polysaccharide derivative, etc. For example, when calcium ions are used as the cross-linking agent, the calcium ion concentration of the solution containing calcium ions is not particularly limited, and examples thereof include 1 mM to 1 M, preferably 5 mM to 500 mM, and more preferably 10 mM to 300 mM.
[0656] By adjusting the amount of cross-linking agent used, the degree of cross-linking can be adjusted.
[0657] (2) Cross-linked structures of polysaccharide derivatives and amino-containing polymers / amino-containing low molecular weight compounds
[0658] In some embodiments, the cross-linked structure comprises a polysaccharide derivative and comprises at least one of an amino-containing polymer and an amino-containing low molecular compound containing two or more primary amino groups, hydrazide groups or aminooxy groups, and the primary amino group, hydrazide group or aminooxy group contained in the aforementioned amino-containing polymer and the amino-containing low molecular compound are covalently bonded to the group represented by formula (A) contained in the aforementioned polysaccharide derivative (modifying group (A)) via a Schiff base to form a cross-linked structure. That is, the amino-containing polymer and the amino-containing low molecular compound function as a cross-linking agent, and form a cross-linked structure (cross-linked structure) via the cross-linking group of the polysaccharide derivative (for example, the aldehyde group or carbonyl group of the modifying group (A)). Specifically, the aldehyde group or ketone group (-CR 1 (=O)) reacts with the primary amino group, hydrazide group or aminooxy group of the amino-containing polymer and the amino-containing low molecular compound to form a Schiff base (-CR 1 =N-). The hydrazide group is represented by -C(=O)-NH-NH2 and reacts with the aldehyde or ketone group of the modifying group (A) to form a hydrazone bond. The aminooxy group is represented by -O-NH2 and the terminal -NH2 reacts with the aldehyde or ketone group of the modifying group (A) to form an oxime bond.
[0659] An amino group-containing polymer is a polymer having a molecular weight of 1,000 or more and containing two or more primary amino groups, hydrazide groups, or aminooxy groups. In this specification, the term "amino group-containing polymer" also includes molecules having a molecular weight of about 1,000 to 10,000, such as those generally called oligomers.
[0660] The amino group-containing low molecular weight compound refers to a substance having a molecular weight of less than 1,000 and containing two or more primary amino groups, hydrazide groups, or aminooxy groups.
[0661] The amino group-containing polymer and the amino group-containing low-molecular compound may be synthetically produced or naturally occurring.
[0662] The amino group-containing polymer containing a primary amino group, a hydrazide group, or an aminooxy group (also referred to simply as an "amino group-containing polymer") is not particularly limited as long as it contains a total of two or more primary amino groups, hydrazide groups, or at least one of these groups. The primary amino group, hydrazide group, or aminooxy group may be present at the end of the polymer, in a side chain of the polymer, or in a pendant group within the polymer.
[0663] Examples of amino group-containing polymers include at least one selected from polyamines; polyalkylene glycols substituted with an amino group, a hydrazide group, or an aminooxy group; polyallylamine; polyvinylamine; polyacrylamine; amino-containing polysaccharides; amino-containing proteins; and polyamino acids. These may be commercially available or synthesized using conventionally known methods.
[0664] The polyamine may be linear, branched, or dendritic. "Dendritic" means that the polyamine has a hyperbranched shape like a dendron, and is a polymer having multiple arms of equal or unequal lengths.
[0665] The polyamine is not particularly limited, and examples thereof include linear, branched, or dendritic polyalkylene imines, and branched or dendritic polyetheramines.
[0666] Polyalkyleneimine refers to a polymer containing an alkyleneimine structure as a repeating unit and having a primary amino group at the end. The alkylene portion and the imine portion in the alkyleneimine structure may be substituted. Straight-chain polyalkyleneimine includes an alkyleneimine structure having a secondary amino group. Branched polyalkyleneimine and dendritic polyalkyleneimine include an alkyleneimine structure containing a primary amino group, a secondary amino group, or a tertiary amino group. Polyalkyleneimine preferably has a low-order (e.g., C1-C6, C1-C3) alkyleneimine structure, and specifically, polyethyleneimine, polypropyleneimine, etc. can be mentioned, but are not limited to these.
[0667] Branched or dendritic polyetheramines refer to polymers containing an alkylene oxide structure as a repeating unit and having a primary amino group at the end. Examples include, but are not limited to, amino-terminated star-shaped polyethylene oxide, amino-terminated dendritic polyethylene oxide, amino-terminated comb-shaped polyethylene oxide, amino-terminated star-shaped polypropylene oxide, amino-terminated dendritic polypropylene oxide, amino-terminated comb-shaped polypropylene oxide, amino-terminated star-shaped polyethylene oxide-polypropylene oxide copolymers, amino-terminated dendritic polyethylene oxide-polypropylene oxide copolymers, and amino-terminated comb-shaped polyethylene oxide-polypropylene oxide copolymers. Examples of amino-terminated star-shaped polymers include polymers having 3, 4, 6, or 8 arms capped with primary amines. For example, amino-terminated star-shaped polyethylene glycols include star-shaped polyethylene glycols having 3, 4, 6, or 8 arms capped with primary amines (3-, 4-, 6-, or 8-arm star-shaped PEG amines). However, these are not limiting. As the branched or dendritic polyetheramine, commercially available products such as polyoxyalkylene triamine sold by Huntsman LLC. (Houston, TX) under the trade name Jeffamine (registered trademark) triamine can be used.
[0668] Examples of the polyalkylene glycol substituted with an amino group, a hydrazide group or an aminooxy group include polyethylene glycol (PEG), polypropylene glycol or a polyethylene oxide-polypropylene oxide copolymer substituted with a plurality (two or more) of amino groups, hydrazide groups or aminooxy groups.
[0669] Polyallylamine refers to a polymer containing an allylamine structure as a repeating unit. The allyl group in the allylamine structure may be substituted. In addition to the repeating unit containing the allylamine structure, polyallylamine may also contain other repeating units as copolymer components.
[0670] Polyvinylamine refers to a polymer containing a vinylamine structure as a repeating unit, wherein the vinyl portion of the vinylamine structure may be substituted. Polyvinylamine may contain other repeating units as copolymer components in addition to the repeating units having the vinylamine structure.
[0671] Polyacrylamide refers to a polymer comprising an acrylic acid structure having a side chain containing a primary amino group. The vinyl portion of the acrylic acid structure may be substituted. Examples include acrylic acid polymers comprising an amine structure grafted with a polyalkyleneimine on the side chain. In addition to repeating units comprising an acrylic acid structure having a side chain containing a primary amino group, polyacrylamide may also contain other repeating units as copolymer components. Commercially available products such as aminoethylated acrylic acid polymers sold under the trade name Poriment (registered trademark) (Nippon Shokubai Co., Ltd.) can be used.
[0672] Examples of amino-containing polysaccharides include chitosan and other amino-containing polysaccharides. Furthermore, amino-containing polysaccharides may be polysaccharides obtained by modifying polysaccharides that do not have amino groups and introducing amino groups (aminated polysaccharides). Examples of aminated polysaccharides include amino-containing polysaccharides such as aminodextran.
[0673] Examples of amino group-containing proteins include fibrinogen, albumin, gelatins, and collagens.
[0674] Examples of the polyamino acid (polypeptide) include polylysine, polyarginine, polyglutamic acid, and polyaspartic acid.
[0675] The lower limit of the weight average molecular weight of the amino group-containing polymer is not particularly limited, but is usually 1.00 or more. The upper limit of the weight average molecular weight of the amino group-containing polymer is not particularly limited, but is usually 1,000,000 or less.
[0676] The amino group-containing low molecular weight compound is not particularly limited as long as it contains a total of two or more primary amino groups, hydrazide groups, or at least one of aminooxy groups. Examples thereof include hydrazide-based crosslinking agents such as adipic acid dihydrazide, sebacic acid dihydrazide, dodecane dihydrazide, and isophthalic acid dihydrazide.
[0677] The amino group in the amino group-containing polymer or the amino group-containing low molecular weight compound may form a salt. Examples of the salt of the amino group-containing polymer or the amino group-containing low molecular weight compound include halides (e.g., hydrochlorides), phosphates, phosphites, carbonates, bicarbonates, sulfates, bisulfates, hydroxides, nitrates, persulfates, sulfites, acetates, ascorbates, citrates, oxalates, succinates, tartrates, taurocholates, and cholates.
[0678] Figure 34 Schematic diagram showing a cross-linked structure composed of a polysaccharide derivative (AL-ABA) and an amino group-containing polymer (DPI; polyethyleneimine) prepared in Example I-17 described later. Figure 34 As shown, the cross-linked structure has a structure in which primary amino groups contained in polyethyleneimine, which is an amino group-containing polymer, and benzaldehyde groups contained in a polysaccharide derivative are covalently bonded via a Schiff base (—C═N—) to form cross-links.
[0679] The crosslinked structure of the polysaccharide derivative and the amino group-containing polymer or amino group-containing low molecular weight compound is typically produced by mixing the polysaccharide derivative and the amino group-containing polymer or amino group-containing low molecular weight compound in a solvent. As the solvent, an aqueous solvent (eg, water, physiological saline) is preferred in terms of biocompatibility.
[0680] After obtaining a cross-linked structure of a polysaccharide derivative and an amino-containing polymer or an amino-containing low-molecular compound, a cross-linked structure can be further formed via a cross-linking group (e.g., an unmodified carboxyl group) contained in the cross-linked structure using a cross-linking agent (e.g., a divalent metal ion) different from the amino-containing low-molecular compound. Specifically, after mixing the polysaccharide derivative and the amino-containing polymer or the amino-containing low-molecular compound in a solvent, a solution containing a divalent metal ion as a cross-linking agent is added dropwise to the solution containing the cross-linked structure; or after mixing the polysaccharide derivative and the amino-containing polymer or the amino-containing low-molecular compound in a solvent, the solution containing the cross-linked structure is added dropwise to a solution containing a divalent metal ion as a cross-linking agent, etc., to perform partial cross-linking, thereby obtaining a cross-linked structure.
[0681] The type of cross-linking agent and the amount of the cross-linking agent used are not particularly limited, and the same type of cross-linking agent and the amount of the cross-linking agent used in the cross-linking reaction of the polysaccharide derivative using the cross-linking agent can be used.
[0682] The shape of the crosslinked structure of the polysaccharide derivative and the amino group-containing polymer or amino group-containing low molecular weight compound is not particularly limited, and examples thereof include tubular structures, fibrous structures, fibers, beads, gels, approximately spherical gels, capsules, sponges, sheets, and films.
[0683] In one embodiment, the cross-linked structure of the polysaccharide derivative and the amino-containing polymer or amino-containing low molecular compound may be a gel (hydrogel). By freeze-drying the gel, a sponge-shaped cross-linked structure may be obtained.
[0684] 6. Tissue Adhesive Materials
[0685] In some embodiments, the tissue adhesive material comprises the above-mentioned polysaccharide derivative, polysaccharide derivative-drug conjugate, cross-linked structure, cross-linked structure-drug conjugate. In a specific embodiment, the tissue adhesive material is a biological tissue adhesive or sealant (leakage-proofing agent) for adhering biological tissue.
[0686] In some embodiments, a tissue adhesive material is provided, which comprises the above-mentioned polysaccharide derivative or cross-linked structure. The above-mentioned polysaccharide derivative or cross-linked structure is modified by introducing an aldehyde group or a ketone group (-C(=O)R 1 ) interacts with the functional groups of biological tissues and can adhere to biological tissues.
[0687] In a specific embodiment, the polysaccharide derivative or cross-linked structure is modified by introducing an aldehyde group or a ketone group (-C(=O)R 1 ) reacts with primary amino groups in biological tissues to form Schiff bases, which can adhere to biological tissues.
[0688] In some embodiments, the tissue adhesive material comprises a polysaccharide derivative-drug conjugate or a cross-linked structure-drug conjugate. Preferably, the polysaccharide derivative-drug conjugate or cross-linked structure-drug conjugate has a drug having a primary amino group bound to a portion of the modifying group (A), and has unreacted modifying groups (A) to which no drug is bound. According to this embodiment, the drug can be delivered to the adhesive site while the aldehyde group or ketone group (-C(=O)R 1 ) reacts with primary amino groups in biological tissues to form Schiff bases, thereby enabling adhesion to biological tissues.
[0689] The shape of the tissue adhesive material is not particularly limited, and examples thereof include tubular, fibrous, fiber, bead, capsule, gel, approximately spherical gel, sponge, sheet, and membrane. Beads, capsules, gel, or approximately spherical gel or sponge are preferred, with capsules, hydrogels, and sponges being more preferred, and hydrogels being even more preferred. Hydrogels can be used as tissue adhesives or sealants (leakage preventers) for medical applications requiring faster decomposition, such as preventing unwanted tissue-tissue adhesions caused by trauma or surgery.
[0690] There is no particular limitation on the method of using the tissue adhesive material.
[0691] In some embodiments, the tissue adhesive material is a tissue adhesive for bonding two biological tissues.
[0692] In some embodiments, the tissue adhesive comprising the polysaccharide derivative or cross-linked structure is applied to at least one adhesion site of a living tissue to bring two or more sites into contact, thereby adhering two living tissues.
[0693] In some embodiments, the tissue adhesive comprising a polysaccharide derivative or a cross-linked structure is applied to at least one bonding site of a biological tissue, and then a cross-linking agent (e.g., a solution comprising a divalent metal ion) is applied to the bonding site, bringing two or more sites into contact, thereby bonding the two biological tissues (a multi-layer method). In some embodiments, a cross-linking agent (e.g., a solution comprising a divalent metal ion) is applied to at least one bonding site of a biological tissue, and then the tissue adhesive comprising a polysaccharide derivative or a cross-linked structure is applied to the bonding site, bringing two or more sites into contact, thereby bonding the two biological tissues (a multi-layer method). In some embodiments, the tissue adhesive comprising a polysaccharide derivative or a cross-linked structure and a cross-linking agent (e.g., a solution comprising a divalent metal ion) are mixed, and the mixture is applied to the biological tissue, bringing two or more sites into contact, thereby bonding the two biological tissues (a hybrid method). In this hybrid method, in order to obtain sufficient adhesive strength, it is preferably applied to the biological tissue immediately after mixing. By applying a cross-linking agent, a hydrogel can be formed or the degree of cross-linking of the hydrogel can be increased.
[0694] In some embodiments, the tissue adhesive material is a sealant (leakage-proofing agent) used to seal air / fluid leakage from biological tissue, or to seal or fill small voids or defects in biological tissue.
[0695] In some embodiments, the sealant comprising the polysaccharide derivative or cross-linked structure is applied to biological tissue and allowed to stand, thereby sealing air / fluid leakage in the biological tissue or sealing or filling small cavities or defects in the biological tissue.
[0696] In some embodiments, the sealant comprising the polysaccharide derivative or cross-linked structure is applied to a living tissue, and then a cross-linking agent (e.g., a solution comprising a divalent metal ion) is applied to the applied area and allowed to stand, thereby sealing air / fluid leakage from the living tissue, or sealing or filling small voids or defects in the living tissue (a multi-layer method). In some embodiments, the cross-linking agent (e.g., a solution comprising a divalent metal ion) is applied to a living tissue, and then a sealant comprising the polysaccharide derivative or cross-linked structure is applied to the applied area and allowed to stand, thereby sealing air / fluid leakage from the living tissue, or sealing or filling small voids or defects in the living tissue (a multi-layer method). In some embodiments, the sealant comprising the polysaccharide derivative or cross-linked structure and a cross-linking agent (e.g., a solution comprising a divalent metal ion) are mixed, and the mixture is applied to the living tissue and allowed to stand, thereby sealing air / fluid leakage from the living tissue, or sealing or filling small voids or defects in the living tissue (a hybrid method). In this mixing method, in order to obtain sufficient adhesive / sealing ability, it is preferred to apply the mixture to the biological tissue immediately after mixing. By applying a crosslinking agent, a hydrogel can be formed or the degree of crosslinking of the hydrogel can be increased.
[0697] In some embodiments, the sealant can be combined with a tissue piece from a living tissue, and examples of the tissue piece include a skin flap and periosteum. The tissue piece combined with the sealant can be attached to a tissue for use.
[0698] In some embodiments, the sealant can be combined with biodegradable and non-biodegradable non-woven fabrics, sheets, or films, and these can also be used for fixing or bonding. Examples of biodegradable non-woven fabrics, sheets, or films include those made from polyglycolic acid, L-lactide / ε-caprolactone polymer, polylactic acid, glycolic acid / lactic acid polyester, and sodium alginate. Examples of non-degradable non-woven fabrics, sheets, or films include those made from polytetrafluoroethylene (PTFE). Non-woven fabrics, sheets, or films combined with these sealants can be attached to tissues for use.
[0699] By using a polysaccharide derivative in combination with a nonwoven fabric, sheet, film, or the like, the mechanical strength of the structure of the polysaccharide derivative (hydrogel, etc.) is improved, and breakage can be prevented even at higher pressure levels.
[0700] In some embodiments, the tissue adhesive material further comprises a nonwoven fabric, sheet, or film. In a specific embodiment, the tissue adhesive material is a sealant comprising the aforementioned polysaccharide derivative and a nonwoven fabric, sheet, or film. In one embodiment, the tissue adhesive material is a sealant for repairing dural lesions, comprising the aforementioned polysaccharide derivative and a nonwoven fabric, sheet, or film.
[0701] As the nonwoven fabric, sheet, or film, a commercially available product can be used, and for example, Neovil (registered trademark) from Gunze Medical Japan Ltd. (GMJ) or Vicryl (registered trademark) Mesh from Ethicon can be used.
[0702] The method of use when used in combination with a nonwoven fabric, sheet, or film is not particularly limited, and, for example, the following method can be used: first, the nonwoven fabric, sheet, or film is arranged or attached to a tissue (e.g., a damaged area of the tissue), then the tissue adhesive or sealant containing the polysaccharide derivative or cross-linked structure is applied to the nonwoven fabric, sheet, or film, or between the nonwoven fabric, sheet, or film and the tissue, and then a cross-linking agent (e.g., a solution containing divalent metal ions) is applied to the applied area and allowed to stand. According to this method, the damaged area of the tissue can be easily and reliably repaired. As other methods, the following methods can be used: a method in which the above-mentioned tissue adhesive or sealant containing a polysaccharide derivative or a cross-linked structure is applied to a tissue (e.g., a damaged part of the tissue), and then the above-mentioned non-woven fabric, sheet or film is arranged or pasted on the applied part, and then a cross-linking agent (e.g., a solution containing divalent metal ions) is applied and the mixture is allowed to stand; a method in which the above-mentioned tissue adhesive or sealant containing a polysaccharide derivative or a cross-linked structure is applied to a tissue (e.g., a damaged part of the tissue), and then a cross-linking agent (e.g., a solution containing divalent metal ions) is applied and then, before gelation occurs, the above-mentioned non-woven fabric, sheet or film is arranged or pasted on the applied part, and the like.
[0703] In a specific embodiment, the tissue adhesive material (tissue adhesive, sealant) is applied to the biological tissue in the form of an aqueous solution or dispersion.
[0704] In certain embodiments, the tissue adhesive material (tissue adhesive, sealant) is applied to the biological tissue in the form of a gel, sponge, sheet or film.
[0705] The tissue adhesive material may further contain various additives depending on the intended use. Examples of the various additives include at least one selected from the group consisting of a pH adjuster, an antibacterial agent, a colorant, and a surfactant.
[0706] As described above, in the first embodiment, the tissue adhesive material is preferably used for hard and thick tissues and / or connective tissues, but can also be used for a wide range of biological tissues other than hard and thick tissues and connective tissues.
[0707] Biological tissues to which the tissue adhesive material is applied are not particularly limited, and include, for example, the dura mater, skin, oral cavity, periodontal ligament, gum, alveolar bone, esophagus, stomach, small intestine, large intestine (rectum, rectum), bone, nerve, exon, cartilage, perichondrium, elastic cartilage (e.g., auricular cartilage, nasal cartilage, epiglottic cartilage, etc.), blood vessels, cornea, muscle, fascia, brain, prostate, breast, endometrium, lung, spleen, liver, testis, ovary, neck, lymph node, bone marrow, and kidney. Preferred among these are the dura mater, perichondrium, periodontal ligament, elastic cartilage (e.g., auricular cartilage, nasal cartilage, epiglottic cartilage, etc.), skin, mucosa of the digestive tract (oral cavity, esophagus, stomach, small intestine, large intestine), and submucosa of the digestive tract (mucosal injury site).
[0708] In some embodiments, the living tissue to which the tissue adhesive material is applied is a living tissue having amino groups exposed on the surface. In this case, the aldehyde group or ketone group (-C(=O)R 1 ) and the amino group via a Schiff base, thereby increasing the adhesive strength. Examples of biological tissues with exposed amino groups include skin (particularly exposed collagen sites after surgery), healthy mucosa, the submucosa of the digestive tract (mucosal damage sites), dura mater, perichondrium, and periodontal ligament. Furthermore, it is also preferably used in biological tissues such as the lung, heart, pancreas, kidney, liver, and bladder.
[0709] The specific site of the biological tissue is not particularly limited, and sites where tissue adhesive materials have been used in the past can be appropriately used. Examples of such application sites include suture sites after surgery, bleeding sites, fixation sites for bone fractures, anastomosis sites for peripheral nerves or microvascular anastomosis, affected areas for tendon adhesion or tendon suture, and adhesion sites for organ wounds.
[0710] Tissue adhesive materials can be used for applications such as dura mater adhesion, nerve anastomosis, microvascular anastomosis, preservation of vascular sutures, closure of traumatic tympanic membrane defects, closure of substitute blood vessels and preservation of suture sites, liver destruction, adhesion of liver incisions and cholecystectomies, wound management during partial nephrectomy, kidney destruction and prostatectomy, preservation of intestinal anastomosis, adhesion of split flaps, closure of bone and cartilage wound cavities (especially in patients at risk of bleeding), adhesion of cartilage and bone, reinforcement of tendon sutures, adhesion of the pleura in pneumothorax, alveolar closure after tooth extraction when there is a risk of bleeding, use of collagen fiber bundles to seal tonsillar fossa (especially in patients at risk of bleeding), free skin grafting for patients with burns, etc.
[0711] As described above, the use of tissue adhesive materials is not particularly limited. For example, in neurosurgery, during brain injury / brain tumor / intracerebral hemorrhage surgery, it can be used as an adhesive (dura mater repair / protection) when repairing the outermost dura mater within the meninges, i.e., when performing a dura mater incision, or when filling a defect with an artificial dura mater. In plastic surgery, during spinal / spinal cord surgery, it can be used to repair / protect the dura mater, particularly within the meninges. Furthermore, in otolaryngology, it can be used to bond elastic cartilage such as auricular cartilage, nasal cartilage, and epiglottic cartilage during transplantation / repair.
[0712] In digestive surgery, it is used to bond digestive tract anastomoses, repair tissue during hemorrhoidal fistulas or anal fistula formation, and to protect / repair damaged areas of the digestive tract during endoscopic surgery, such as during pancreatic / liver resections, to prevent pancreatic fistulas or bile leakage. In respiratory surgery, it is used to prevent air leakage during lung resections (lung tissue protection) and to bond tissues such as tracheal cartilage. Furthermore, in urological surgery, it is used to protect tissue during surgery, prevent urine leakage caused by bonding at urethral anastomoses, repair anastomoses, and protect / repair tissue during obstetric surgery.
[0713] According to some embodiments, a kit is also provided, comprising: a tissue adhesive material suitable for use in biological tissue to adhere the biological tissue; and instructions for use of the tissue adhesive material.
[0714] According to some embodiments, a kit is also provided, comprising: a precursor of a tissue adhesive material suitable for use in bonding biological tissue to the biological tissue; and instructions for use of the tissue adhesive material. In one embodiment, the precursor of the tissue adhesive material comprises: an uncrosslinked polysaccharide derivative or a partially crosslinked structure, or a conjugate thereof with a drug; and a crosslinking agent (e.g., a solution containing a divalent metal ion).
[0715] II. Second Method
[0716] The second embodiment of the present invention is a cross-linked structure comprising: (a) a polysaccharide derivative obtained by introducing a group represented by the following formula (A) into an acidic, basic or amphoteric polysaccharide; and (b) at least one of an amino-containing polymer and an amino-containing low molecular weight compound containing two or more primary amino groups, hydrazide groups or aminooxy groups and containing a group represented by the following formula (x1) (hereinafter also referred to as "modifying group (x1)") (hereinafter also referred to as "amino-containing substance (b)"), wherein the primary amino group, hydrazide group or aminooxy group contained in the amino-containing polymer and the amino-containing low molecular weight compound and the group represented by formula (A) contained in the polysaccharide derivative are covalently bonded via a Schiff base to form a cross-linked structure.
[0717] [Chemistry 42]
[0718]
[0719] (In formula (A), R 1 Represents a hydrogen atom or C 1-4 alkyl;
[0720] Ring P is a benzene ring or a pyridine ring, and the aforementioned benzene ring or pyridine ring is optionally substituted by one or more substituents independently selected from halogen atoms, -CF3, -NO2, carboxyl groups and -SO3H;
[0721] Y represents a member selected from -NH-, -C(=O)-, -S-, -O-, C 1-6 Alkylene, -(CH2CH2O) n - and any combination thereof, wherein n is an integer from 1 to 9;
[0722] *Indicates the linker to the polysaccharide.)
[0723] [Chemistry 43]
[0724]
[0725] In formula (x1), k is an integer of 2 to 5, and preferably an integer of 2 to 3.
[0726] In formula (x1), L 5 L is a connecting group. 5 is a single bond, or represents a member selected from -C(=O)-, -S-, -O-, alkylene, -(CH2CH2O) n - and any combination thereof; n is an integer from 1 to 9. In some embodiments, L 5 is -C(=O)- or an alkylene group having 1 to 5 carbon atoms. 5 It is -C(=O)-.
[0727] In formula (x1), * represents a linking portion to an amino group-containing polymer or an amino group-containing low molecular weight compound.
[0728] In the cross-linked structure, the aldehyde group or ketone group (-CR 1 (=O)) reacts with the primary amino group, hydrazide group or aminooxy group of the amino-containing substance (b) to form a covalent bond (Schiff base (-CR 1 =N-), hydrazone bond or oxime bond).
[0729] In the cross-linked structure, the modification groups (x1) such as catechol (1,2-dihydroxyphenyl) group and pyrogallol (1,2,3-trihydroxyphenyl) group can form hydrogen bonds with hydrogen atoms on the tissue surface to promote adhesion.
[0730] The modifying group (x1) in the cross-linked structure and the modifying group (A) of the unreacted polysaccharide derivative can function as functional groups for tissue adhesion and the like.
[0731] In the second embodiment, as the (a) polysaccharide derivative, the polysaccharide derivatives described in the section "1. Polysaccharide derivatives" of the first embodiment can be used in the same manner.
[0732] In the second embodiment, as the amino group-containing substance (b), the substance obtained by introducing the modifying group (x1) into the "amino group-containing polymer" or "amino group-containing low molecular compound" in the first embodiment can be used.
[0733] The method for introducing the modifying group (x1) into the amino-containing substance (b) is not particularly limited. For example, a precursor compound having a modifying group (x1) and a carboxyl group, such as gallic acid, can be subjected to a carbodiimide reaction with the amino-containing substance (b) to bond the carboxyl group to the amino group of the amino-containing substance (b), thereby introducing the modifying group (x1).
[0734] In some embodiments, the amino group-containing substance (b) is a polyalkyleneimine modified with a modifying group (x1).
[0735] In the second embodiment, the ratio of the polysaccharide derivative to the amino-containing substance (b) is not particularly limited. In some embodiments, the ratio of the polysaccharide derivative to the amino-containing substance (b) is such that the modified group (A) of the polysaccharide derivative and the amino group of the amino-containing substance (b) are in the range of 1:1000 to 1000:1 (equivalent ratio).
[0736] When the reactivity of the amino group of the amino-containing substance (b) is high, there is a tendency to react quickly with the modifying group (A) (aldehyde group or ketone group) of the polysaccharide derivative to form a Schiff base. In this case, if the modifying group (A) of the polysaccharide derivative is less than the equivalent of the amino group of the amino-containing substance (b), sometimes almost all of the modifying group (A) of the polysaccharide derivative reacts with the amino group of the amino-containing substance (b) to form a Schiff base, and the unreacted modifying group (A) is small or absent. From this viewpoint, when the cross-linked structure of this embodiment is used for applications such as tissue adhesive materials described later, it is preferred to combine the polysaccharide derivative and the amino-containing substance (b) in such a way that a sufficient amount of unreacted modifying group (A) remains for reacting with the amino group of the tissue. For example, the ratio of the polysaccharide derivative to the amino-containing substance (b) is such that the modifying group (A) of the polysaccharide derivative and the amino group of the amino-containing substance (b) are in the range of 1:100 to 100:1 (equivalent ratio).
[0737] The method and manner for producing the cross-linked structure are the same as those of "(2) Cross-linked structure of polysaccharide derivative and amino-containing polymer / amino-containing low molecular compound" in "4. Cross-linked structure" of the first embodiment, except that the amino-containing substance (b) has a modifying group (x1).
[0738] The cross-linked structure of the second embodiment can be a cross-linked structure formed by a polysaccharide derivative-drug conjugate in which the drug is pre-conjugated to the polysaccharide derivative, and an amino group-containing substance (b), similarly to the first embodiment. As the "polysaccharide derivative-drug conjugate," the substances described in "3. Polysaccharide derivative-drug conjugate" of the first embodiment can be used in the same manner.
[0739] Some embodiments provide a composition comprising the cross-linked structure of the second embodiment. The embodiment of the "composition" is the same as the above-mentioned "4. Composition" of the first embodiment.
[0740] (use)
[0741] The use of the cross-linked structure described in the second embodiment is not particularly limited.
[0742] Cross-linked structures and cross-linked structure-drug conjugates and compositions can be preferably used as tissue adhesive materials for use in biological tissues. The embodiments of the "tissue adhesive material" (shape, method of use, or specific use mode, etc.) are the same as those in the first embodiment described above, under "6. Tissue Adhesive Material". The tissue adhesive material of the second embodiment can be applied to a wide range of biological tissues in the same manner as the first embodiment. That is, the tissue adhesive material of the second embodiment can be used for a wide range of biological tissues, such as soft tissues in a living body, as well as hard and thick tissues and / or connective tissues, as described in the first embodiment described above, under "6. Tissue Adhesive Material".
[0743] Furthermore, the cross-linked structures, cross-linked structure-drug conjugates, or compositions described above can be used in a wide range of fields, including food, medical treatment, cosmetics, daily necessities, fibers, and papermaking. Their shapes are not particularly limited and are selected based on the intended use. Examples include tubular structures, fibrous structures, fibers, beads, gels, approximately spherical gels, capsules, sponges, sheets, and films. In one embodiment, the cross-linked structure, cross-linked structure-drug conjugate, or composition can be in the form of a gel, sponge, film, or capsule.
[0744] Cross-linked structures can be used to replace existing polysaccharide materials in a wide range of fields such as food, medicine, cosmetics, daily necessities, fiber, and papermaking.
[0745] The cross-linked structure, cross-linked structure-drug conjugate, or composition described above has excellent biodegradability and biocompatibility and can therefore be suitably used as a medical material.
[0746] When used as medical materials, examples include drug release devices, sutures, materials for hemostasis, adhesion, and prevention of adhesion in vivo, tissue adhesive materials, wound dressing materials, materials for preventing leakage of tissue fluid, lung leak-proofing agents for preventing air leakage, cell culture substrates, cell transplantation substrates, materials for regenerative engineering, antithrombotic materials, diagnostic drugs, and dialysis carriers. Medical materials can be used on mammals or non-mammals.
[0747] In particular, polysaccharide derivatives can be combined with drugs with primary amino groups under neutral pH and high pH conditions and release (releasing pH responsive agents) under low pH conditions, and therefore can be suitable for use as drug delivery carriers (drug delivery carriers). One aspect of the present invention provides a drug delivery device comprising the cross-linked structure, cross-linked structure-drug conjugates or compositions comprising them. The drug delivery device can be used as a device for selectively and effectively importing the drug loaded on the polysaccharide derivative into the target tissue. In addition, another aspect provides a method for releasing the desired drug enclosed in the target tissue or a method for controlling release.
[0748] The shape of the cross-linked structure when used as a medical material includes tubular, fibrous, fiber, bead, capsule, gel, approximately spherical gel, sponge, sheet, membrane, etc., preferably, it is made into beads, capsule, gel or approximately spherical gel, sponge, and more preferably, it is made into capsule, hydrogel, or sponge.
[0749] According to some embodiments, an anti-adhesion material is provided, comprising the cross-linked structure or the cross-linked structure-drug conjugate.
[0750] Cross-linked structure-drug conjugates have excellent biocompatibility and can therefore be used as bioabsorbable raw materials and medical devices.
[0751] Since the cross-linked structure is bound to a drug having a primary amino group, it can be used as a separation material. Examples of separation materials include chromatography supports, nonwoven fabrics, and membrane materials.
[0752] The cross-linked structures and cross-linked structure-drug conjugates can be used as foods, supplements and food additives.
[0753] An example of the cross-linked structure of this embodiment is described in, for example, Example I-30 described later.
[0754] III. Third Method
[0755] A third embodiment of the present invention relates to a tissue adhesive material comprising an amino group-containing polysaccharide derivative. Some embodiments of the present invention provide a tissue adhesive material comprising a polysaccharide derivative obtained by introducing a group represented by the following formula (A-2) (hereinafter also referred to as "modifying group (A-2)") into an amino group-containing polysaccharide. The group represented by the aforementioned formula (A-2) is introduced into the polysaccharide by replacing a hydrogen atom of the amino group of the aforementioned polysaccharide, thereby forming an amide bond.
[0756] In some embodiments, the third aspect of the tissue adhesive material is in the form of a gel.
[0757] [Chemistry 44]
[0758]
[0759] (In formula (A-2),
[0760] R 1 Represents a hydrogen atom or C 1-4 alkyl;
[0761] Ring P is a benzene ring or a pyridine ring, and the aforementioned benzene ring or pyridine ring is optionally substituted by one or more substituents independently selected from halogen atoms, -CF3, -NO2, carboxyl groups and -SO3H;
[0762] L 2 is a single bond, or represents a member selected from -NH-, -S-, -O-, C 1-6 Alkylene, -(CH2CH2O) n - and divalent groups in any combination thereof;
[0763] n is an integer from 1 to 9;
[0764] *Indicates the linker to the polysaccharide.)
[0765] In the third embodiment, the amino group-containing polysaccharide derivative can be the same as the "amino group-containing polysaccharide derivative" in the first embodiment. The "amino group-containing polysaccharide" and the "group represented by formula (A-2)" are the same as those in the first embodiment.
[0766] The tissue adhesive material of the third embodiment has good adhesiveness due to the modified group (A-2) and / or amino group of the polysaccharide derivative. That is, the aldehyde group or ketone group (-C(=O)R 1) forms a Schiff base between the amino groups of the biological tissue and the aldehyde of the polysaccharide derivative, thereby exerting good adhesion to the tissue. In addition, electrostatic interactions or hydrogen bonds occur between the amino groups of the polysaccharide derivative and the carboxyl groups of the biological tissue, which can improve the adhesion to the tissue. In some embodiments, the amino groups of the polysaccharide derivative form ammonium ions (NH 3+ ), electrostatic interactions occur between carboxyl groups in biological tissues, thereby improving adhesion to the tissue. In some embodiments, the amino groups of the polysaccharide derivatives generate hydrogen bonds and other interactions between hydroxyl groups and carboxyl groups in biological tissues at high pH (e.g., a pH of 5 or above, or a pH of 5 to 10, or a pH of 5 to 8, or a pH of 6 to 10, or a pH of 6 to 8), thereby improving adhesion to the tissue. In this way, the third embodiment of the tissue adhesive material, by including a polysaccharide derivative containing an amino group, can exhibit excellent adhesion at various pH levels and can be applied to multiple locations in biological tissues.
[0767] The shape of the tissue adhesive material of the third embodiment is not particularly limited, and examples thereof include tubes, fibers, fibers, beads, capsules, gels, substantially spherical gels, sponges, sheets, and films.
[0768] In some embodiments, the tissue adhesive material is in the form of a gel.
[0769] (Gel form)
[0770] The shape of the tissue adhesive material in the form of a gel is not particularly limited, and examples thereof include tubes, fibers, disks, beads, sheets, and films. The gel form of the tissue adhesive material can be confirmed by, for example, the vial inversion method described in Example V-2 below.
[0771] In some embodiments, the tissue adhesive material is self-crosslinking. In some embodiments, the crosslinking is achieved by forming a crosslinked structure in the form of a gel through covalent bonds between the amino groups contained in the polysaccharide derivative and the group represented by the above formula (A-2) via a Schiff base.
[0772] In some embodiments, the tissue adhesive material has self-crosslinking properties that respond to pH (pH-responsive self-crosslinking properties). Figure 88 As shown in (A), the amino group-containing polysaccharide derivative reacts with the aldehyde group or ketone group (-C(=O)R) of the group represented by formula (A-2) at a high pH. 1) form covalent bonds via Schiff bases, resulting in a gel state. Meanwhile, at low pH, the amino groups contained in the polysaccharide derivative form ammonium ions (cations), resulting in a solution state.
[0773] In some embodiments, the tissue adhesive material is in a gel state when the polysaccharide derivative undergoes self-crosslinking at a pH of 5 or above (eg, a pH of 5 to 10 or a pH of 5 to 8).
[0774] The pH of the tissue adhesive material can be adjusted using an acid (e.g., hydrochloric acid) or an alkali (e.g., sodium hydroxide). By adjusting the pH of the solution containing the polysaccharide derivative to, for example, a pH of 5 or higher (e.g., a pH of 5 to 10 or a pH of 5 to 8), a hydrogel of the polysaccharide derivative can be obtained, and a tissue adhesive material containing the hydrogel of the polysaccharide derivative can be obtained.
[0775] In some embodiments, the tissue adhesive material of the third formula can be produced using the method based on the "Method for producing a polysaccharide derivative represented by formula (C2)" in the aforementioned "2. Method for producing a polysaccharide derivative." Specifically, the tissue adhesive material of the third formula can be produced by reacting an amino group-containing polysaccharide with a compound (a2) represented by the aforementioned formula (a2) to obtain a polysaccharide derivative represented by the following formula (C2) by introducing a group represented by formula (A-2) into the polysaccharide. Subsequently, the pH is adjusted to, for example, a pH of 5 or higher (e.g., a pH of 5 to 10 or a pH of 5 to 8) and gelation is performed.
[0776] In some embodiments, the tissue adhesive material has a structure (cross-linked structure) obtained by cross-linking via the cross-linking groups (e.g., carboxyl, aldehyde or carbonyl, amino, hydroxyl, etc.) of a polysaccharide derivative using a cross-linking agent (e.g., divalent metal ions such as calcium ions, magnesium ions, barium ions, strontium ions, zinc ions; amino-containing polymers and amino-containing low molecular weight compounds containing two or more primary amino groups, hydrazide groups, or aminooxy groups; compounds containing two or more aldehyde groups such as glutaraldehyde, etc.), and is in the form of a gel.
[0777] In some embodiments, the tissue adhesive material has a shear rate of 0.001 s measured at 25°C. -1 The viscosity of the composition (η 0.001 ) is preferably 10 9 ~1mPa·s, more preferably 10 9 ~10 3 mPa·s, more preferably 10 9 ~10 4 mPa·s range.
[0778] The tissue adhesive material of some embodiments has a shear rate of 1000s measured at 25°C. -1 The viscosity of the composition (η 1000 ) is preferably 0.1 to 10 4 mPa·s, more preferably 1 to 10 3 mPa·s, more preferably in the range of 1 to 100 mPa·s.
[0779] The tissue adhesive material of some embodiments has a shear rate of 0.001s measured at 25°C. -1 The viscosity (η 0.001 ) and shear rate of 1000s -1 The viscosity (η 1000 ) ratio (η 0.001 / η 1000 ) is preferably 10 or more, more preferably 100 or more, and further preferably 10 4 More than 10 5 Above. 0.001 / η 1000 The higher the value, the better. The upper limit is not particularly limited, for example, 10 9 Below. 0.001 / η 1000 For example, preferably 10 to 10 9 More preferably, 100 to 10 9 , more preferably 10 4 ~10 9 , particularly preferably 10 5 ~10 9 range.
[0780] Shear speed is 0.001s -1 The viscosity (η 0.001 ) and shear rate of 1000s -1 The viscosity (η 1000 ) ratio (η 0.001 / η 1000 ) Tissue adhesive materials within the above range have the advantage of high shear thinning properties, such as reduced resistance to injection using a catheter or injection needle.
[0781] In the tissue adhesive material of the third embodiment, the polysaccharide derivative may be a polysaccharide derivative-drug conjugate in which a drug is conjugated, as in the first embodiment. As the "polysaccharide derivative-drug conjugate," the substances described in "3. Polysaccharide Derivative-Drug Conjugate" of the first embodiment can be used in the same manner.
[0782] (Tissue Adhesive Material)
[0783] The third aspect of the tissue adhesive material is that the biological tissue to which it is applied is
[0784] The embodiments of the "tissue adhesive material" (such as shape, method of use, and specific usage) are the same as those described in "6. Tissue Adhesive Material" of the first embodiment. The tissue adhesive material of the third embodiment can be applied to a wide range of biological tissues. Specifically, the tissue adhesive material of the third embodiment can be applied to a wide range of biological tissues within the body, including soft tissues, as well as hard and thick tissues and / or connective tissues, as described in "6. Tissue Adhesive Material" of the first embodiment.
[0785] The hydrogel (gel-form composition) containing the amino group-containing polysaccharide derivative can also be used for applications other than as a tissue adhesive material (for example, the wide range of applications described in the second embodiment).
[0786] It should be noted that all publications cited in this specification, for example, prior art documents, open publications, patent publications and other patent documents are incorporated herein by reference.
[0787] In addition, the objects, features, advantages and concepts of the present invention will be apparent to those skilled in the art based on the description of this specification, and those skilled in the art can easily implement the present invention based on the description of this specification. The best mode for carrying out the invention and specific examples, etc., show preferred embodiments of the present invention and are shown for purposes of illustration or description, and the present invention is not limited thereto. Various modifications may be made based on the description of this specification within the intent and scope of the present invention disclosed in this specification, and this will be apparent to those skilled in the art.
[0788] Example
[0789] Hereinafter, the present invention will be described in further detail with reference to Examples and Comparative Examples, but the present invention is not limited to these Examples.
[0790] In this specification, "room temperature" generally means about 10° C. to about 35° C. Unless otherwise specified, "%" means percentage by weight.
[0791] In this specification, the term "about" means ±10%.
[0792] Unless otherwise specified, nuclear magnetic resonance spectroscopy ( 1 For HNMR measurements, an ALPHA FT-NMR spectrometer (500 MHz) JEOL JNM-A500 (JEOL) was used, and the deuterated solvent was D2O.
[0793] The abbreviations used in the examples are commonly used by those skilled in the art. Several abbreviations are given below.
[0794] AL: Alginic acid (sodium);
[0795] Alg: alginic acid (sodium);
[0796] ABA: 4-aminobenzaldehyde;
[0797] AL-ABA: benzaldehyde-modified alginate;
[0798] HOBt: 1-hydroxybenzotriazole;
[0799] WSCD / HCl, EDC / HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride;
[0800] THF: tetrahydrofuran;
[0801] DMSO: dimethyl sulfoxide;
[0802] NaCl: sodium chloride;
[0803] eq: equivalent;
[0804] Van: vancomycin;
[0805] PBS: phosphate-buffered saline;
[0806] FTSC: fluorescein-5-thiosemicarbazide;
[0807] FBS: fetal bovine serum;
[0808] DMEM: Dulbecco's modified Eagle's medium;
[0809] Bac: bacitracin;
[0810] HA: hyaluronic acid;
[0811] PMX: pemetrexed;
[0812] CMC: carboxymethyl cellulose;
[0813] DCC: N,N'-dicyclohexylcarbodiimide;
[0814] CMD, CMDX: carboxymethyl dextran;
[0815] Mw: weight average molecular weight.
[0816] In the synthesis diagrams or reaction formulas shown in the following examples, polysaccharides (AL, HA, CMC, CMDX) are shown in a free form (having carboxyl groups). The carboxyl groups (-COOH) in the polysaccharides (AL, HA, CMC, CMDX) shown in the synthesis diagrams or reaction formulas may be in an ionized state (-COO-) or in the form of a salt (-COOX). For example, in Example 1 below, sodium alginate, a sodium salt, is used as AL. The carboxyl groups (-COOH) in AL shown in Synthesis Diagram 1 may be in an ionized state (-COO-) or in the form of a sodium salt (-COONa).
[0817] I. Alginic acid derivatives
[0818] 1.AL-ABA
[0819] [Example I-1] Benzaldehyde-modified alginic acid (AL-ABA)
[0820] <Synthesis of AL-ABA (1)>
[0821] [Chemistry 45]
[0822] Composite Image 1
[0823]
[0824] In Figure 1 above, for convenience, a reaction is shown in which a modifying group derived from 4-aminobenzaldehyde (ABA) is introduced into the carboxyl group of the guluronic acid unit (the monosaccharide unit on the left). However, a modifying group derived from ABA can also be introduced into the carboxyl group of the mannuronic acid unit (the monosaccharide unit on the right). That is, in Figure 1, AL-ABA has a modifying group derived from ABA introduced into both the carboxyl group of the guluronic acid unit (the monosaccharide unit on the left) and the carboxyl group of the mannuronic acid unit (the monosaccharide unit on the right).
[0825] According to the above synthesis scheme, AL-ABA (1) was synthesized by the following steps (1) to (6) through an amidation reaction via carbodiimide.
[0826] (Synthesis Steps)
[0827] (1) 200 mg (1 mmol) of sodium alginate (AL) (IL-6G manufactured by KIMICA Co., Ltd., viscosity 50-80 mPa·s (1%), weight average molecular weight: Mw = 750,000-850,000) was dissolved in 50 mL of pure water and stirred overnight to prepare an alginic acid solution.
[0828] (2) 242.9 mg (2 mmol, 1 eq) of ABA was dissolved in 20 mL of THF and stirred overnight to prepare an ABA solution.
[0829] (3) 270.3 mg (2 mmol, 2 eq) of 1-hydroxybenzotriazole (HOBt) was dissolved in 10 mL of DMSO and added dropwise to the alginic acid solution prepared in (1). Then, 383.7 mg (2 mmol, 2 eq) of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (WSCD / HCl) was dissolved in 5 mL of pure water and added dropwise to the alginic acid solution.
[0830] (4) The ABA solution prepared in (2) above is added dropwise to the alginic acid solution obtained in (3) above.
[0831] (5) The solution obtained in (4) above was adjusted to pH 5.5, stirred for 3 to 4 hours, and then diluted with 100 mL of pure water.
[0832] (6) The solution obtained in (5) was filtered under reduced pressure, dialyzed against NaCl for 2 days and then against pure water for 2 days. It was then frozen in liquid nitrogen and freeze-dried for 3 days to obtain AL-ABA (1).
[0833] < 1 H NMR spectroscopy, UV-visible absorption spectroscopy (UV-vis) and FT-IR spectroscopy
[0834] AL-ABA(1) was tested 1 HNMR spectrum measurement, ultraviolet-visible absorption spectrum (UV-vis) measurement and Fourier transform infrared (FT-IR) spectrum measurement. Figures 1 to 3 .
[0835] exist 1 H NMR spectroscopy ( Figure 1 ), peaks derived from ABA (peaks b and c derived from the benzene ring and peak d derived from the aldehyde) were observed in the modified AL-ABA. Figure 2 ), characteristic peaks derived from ABA (peaks at about 235 nm and about 330 nm) were observed in the modified AL-ABA. In the FT-IR spectrum ( Figure 3 ), an absorption (about 1740 cm -1 These results confirmed the synthesis of benzaldehyde-modified alginate (AL-ABA) in which the amino group of 4-aminobenzaldehyde was bonded to the carboxyl group of alginic acid. 1 The ABA modification ratio relative to the carboxyl group (-COOH) of alginic acid was calculated from HNMR spectroscopy to be 0.069.
[0836] <Evaluation of cytotoxicity of benzaldehyde-modified alginic acid (AL-ABA) (WST assay)>
[0837] (Experimental Procedures)
[0838] MeT-5A (human mesothelial cell line), NIH / 3T3 (mouse embryonic fibroblasts), HUVEC (human umbilical vein endothelial cells), and RAW264.7 cells (mouse macrophage-like cell line) were seeded in a 24-well plate and cultured for 24 hours. The culture medium was then exchanged with culture medium containing AL-ABA and AL dissolved at different concentrations (0.01 mg / mL, 0.1 mg / mL, and 1 mg / mL). Cell viability (cell viability (%)) was measured 48 hours after sample addition using the WST-8 assay (Cell Counting Kit-8, Dojindo). AL-ABA (1) synthesized in Example I-1 was used as AL-ABA.
[0839] (result)
[0840] See the results Figure 4 AL-ABA showed a cell survival rate comparable to that of AL. AL-ABA was confirmed to have low cytotoxicity and high biocompatibility.
[0841] [Example I-2] Benzaldehyde-modified alginic acid (AL-ABA)
[0842] AL-ABA (2) to AL-ABA (3) were synthesized by another method described below.
[0843] <Synthesis of AL-ABA (2)>
[0844] Dissolve 1 g (0.0046 mol) of AL-500 (sodium alginate, viscosity: 400-600 mPa·s, manufactured by Mochida Pharmaceutical Co., Ltd.) in 300 ml of distilled water and stir for 6-8 hours. Dissolve 2.81 g (0.020 mol) of HOBt in 10 ml of DMSO and add dropwise to the AL-500 solution. Next, dissolve 3.97 g (0.020 mol) of WSCD / HCl in 10 ml of distilled water and add dropwise to the AL-500 solution. Stir the AL-500 solution for 10 minutes to obtain an alginate solution. Add 0.84 g (0.0039 mol) of 4-aminobenzaldehyde (ABA) in 10 ml of DMSO dropwise to the alginate solution. Maintain the pH of the reaction mixture at 7.5 with 1N NaOH and stir at room temperature for 16-20 hours. The reaction mixture was transferred to a 50 ml centrifuge tube and centrifuged at 3000 rpm for 10 minutes at room temperature to collect the supernatant. The solution was then dialyzed against deionized water using a dialysis tube (MWCO: 6-8 kDa) (Spectra / Pro (registered trademark)) for 72 hours and then freeze-dried to obtain AL-ABA (2).
[0845] <Synthesis of AL-ABA (3)>
[0846] AL-ABA (3) was obtained in the same manner as AL-ABA (2) except that the amount of HOBt used was changed to 1.04 g (0.007 mol), the amount of WSCD / HCl used was changed to 1.98 g (0.010 mol), and the pH of the reaction mixture was changed to 5.5.
[0847] < 1 H NMR spectroscopy and FT-IR spectroscopy
[0848] AL-ABA(2)~AL-ABA(3) were tested 1 H NMR spectroscopy and FT-IR spectroscopy (not shown) confirmed the synthesis of ABA-modified alginic acid (AL-ABA) in which the amino group of ABA was bonded to the carboxyl group of alginic acid.
[0849] In addition, by 1 The ABA modification ratio relative to the carboxyl group (-COOH) of alginic acid in AL-ABA (2) to AL-ABA (3) was calculated using HNMR spectroscopy. The results are shown in Table 1 below, along with the reaction conditions for AL-ABA (2) to AL-ABA (3).
[0850] <Quantification of aldehydes by colorimetric aldehyde measurement>
[0851] Aldehydes in AL-ABA (2) and AL-ABA (3) were quantified using a colorimetric aldehyde assay kit, blue (MAK140), and the ABA modification rate relative to the carboxyl group (-COOH) of alginic acid was calculated.
[0852] (Measurement Procedure)
[0853] (1) Dilute 10 μl of the 10 mM standard solution with 990 μl of assay buffer to prepare a 100 μM standard solution. Serially dilute the 100 μM standard solution 2-fold with assay buffer. Add 50 μl of the diluted standard solution to a 96-well plate to prepare standard solutions at 0 (blank), 1.56, 3.125, 6.25, 12.5, 25, 50, and 100 μM.
[0854] (2) Add 50 μL of Master Reaction Mix to each well. Mix thoroughly using a horizontal shaker or pipette and incubate the reaction at room temperature for 20 to 30 minutes. Protect the plate from light during the incubation period.
[0855] (3) Add 50 μL of blue enhancer to each well.
[0856] (4) Protect the plate from light and incubate the reaction at room temperature for another 20 minutes.
[0857] (5) After the incubation period, the absorbance at 620 to 660 nm was measured.
[0858] (result)
[0859] The ABA modification ratios of the carboxyl groups (-COOH) of alginic acid calculated from the aldehyde content were 0.56 or 0.64 for AL-ABA (2) and 0.33 for AL-ABA (3). The results are shown in Table 1 below.
[0860] [Table 1]
[0861] Table 1 Reaction conditions and ABA modification rates of AL-ABA (2) to AL-ABA (3)
[0862]
[0863] *1: Low DS, *2: High DS
[0864] In Table 1, DS is the degree of substitution, which is equivalent to the value obtained by converting the ABA modification rate into a percentage (ABA modification rate × 100). 1 The values are calculated from HNMR spectroscopy, and the DS colorimetric values are calculated from colorimetric aldehyde measurement.
[0865] *1 and *2 of AL-ABA(2) are AL-ABA prepared from different batches. In the following examples, *1 may be referred to as AL-ABA(2) (low DS) and *2 may be referred to as AL-ABA(2) (high DS).
[0866] 2.AL-AAP, AL-ADFBA, AL-APCA, AL-ANA
[0867] Alginic acid modified with 4-aminoacetophenone (AAP), 4-amino-2,6-difluorobenzaldehyde (ADFBA), 2-amino-3-pyridinecarboxaldehyde (APCA), or 6-aminonicotinaldehyde (ANA) was obtained by the same operation as in Example I-1. For convenience, the following diagram also shows the reaction of introducing a modifying group derived from AAP, ADFBA, APCA, or ANA into the carboxyl group of the guluronic acid unit (monosaccharide unit on the left). These modifying groups can also be introduced into the carboxyl group of the mannuronic acid unit (monosaccharide unit on the right). In other words, AL-AAP, AL-ADFBA, AL-APCA, and AL-ANA have a modifying group derived from AAP, ADFBA, APCA, or ANA introduced into both the carboxyl group of the guluronic acid unit (monosaccharide unit on the left) and the carboxyl group of the mannuronic acid unit (monosaccharide unit on the right).
[0868] [Example I-3] AAP-modified alginic acid (AL-AAP)
[0869] [Chemistry 46]
[0870]
[0871] Dissolve 0.5 g (0.0023 mol) of AL-500 (sodium alginate, viscosity: 400-600 mPa·s, manufactured by Mochida Pharmaceutical Co., Ltd.) in 100 ml of distilled water and stir for 6-8 hours. Dissolve 1.4 g (0.010 mol) of HOBt in 10 ml of DMSO and add dropwise to the AL-500 solution. Next, dissolve 1.97 g (0.010 mol) of WSCD / HCl in 10 ml of distilled water and add dropwise to the AL-500 solution. Stir the AL-500 solution for an additional 10 minutes to obtain an alginate solution. Add 0.310 g (0.0023 mol) of 4'-aminoacetophenone (AAP) in 10 ml of DMSO dropwise to the alginate solution. Maintain the pH of the reaction mixture at 5.5 with 1N NaOH and stir at room temperature for 16-20 hours. The reaction mixture was transferred to a 50 ml centrifuge tube and centrifuged at 3000 rpm for 10 minutes at room temperature. The supernatant was collected. The solution was then dialyzed against deionized water using a dialysis tube (MWCO: 6-8 kDa) (Spectra / Pro (registered trademark)) for 72 hours, followed by freeze-drying to obtain AL-AAP.
[0872] < 1 H NMR spectroscopy, FT-IR spectroscopy >
[0873] AL-AAP was 1 H NMR spectroscopy and FT-IR spectroscopy. The results are shown in Figure 5 and Figure 6 These results confirmed the synthesis of AAP-modified alginate (AL-AAP) in which the amino groups of AAP were bonded to the carboxyl groups of alginic acid.
[0874] In addition, by 1 The AAP modification ratio relative to the carboxyl group (-COOH) of alginic acid was calculated from HNMR spectroscopy to be 0.31.
[0875] <Quantification of aldehydes by colorimetric aldehyde measurement>
[0876] The AAP modification rate relative to the carboxyl group (—COOH) of alginic acid, calculated from the amount of aldehyde measured using a colorimetric aldehyde assay kit and blue (MAK140), was 0.34.
[0877] [Example I-4] ADFBA modified alginic acid (AL-ADFBA)
[0878] [Chemistry 47]
[0879]
[0880] The same operation as in Example I-3 was performed to obtain an alginic acid solution. A 10ml DMSO solution of 0.361g (0.0023mol) of 4'-4-amino-2,6-difluoro-benzaldehyde (ADFBA) was added dropwise to the alginic acid solution. The pH of the reaction mixture was maintained at pH 5.5 using 1N NaOH and stirred at room temperature for 16 to 20 hours. The reaction mixture was transferred to a 50ml centrifuge tube, centrifuged at 3000rpm for 10 minutes at room temperature, and the supernatant was collected. Then, using a dialysis tube (MWCO: 6-8kDa) (Spectra / Pro (registered trademark)), the solution was dialyzed in deionized water for 72 hours and then freeze-dried to obtain AL-ADFBA.
[0881] < 1 H NMR spectroscopy, FT-IR spectroscopy >
[0882] AL-ADFBA was tested 1 HNMR spectrum measurement and FT-IR spectrum measurement. The results are shown in Figure 7 and Figure 8 These results confirmed the synthesis of ADFBA-modified alginic acid (AL-ADFBA) in which the amino groups of ADFBA were bonded to the carboxyl groups of alginic acid.
[0883] In addition, by 1 The ADFBA modification ratio relative to the carboxyl group (-COOH) of alginic acid was calculated from H NMR spectroscopy to be 0.12.
[0884] <Quantification of aldehydes by colorimetric aldehyde measurement>
[0885] The ADFBA modification rate with respect to the carboxyl group (—COOH) of alginic acid, calculated from the amount of aldehyde measured using a colorimetric aldehyde assay kit and blue (MAK140), was 0.18.
[0886] [Example I-5] APCA modified alginic acid (AL-APCA)
[0887] [Chemistry 48]
[0888]
[0889] The same operation as in Example I-3 was performed to obtain an alginic acid solution. 0.28 g (0.0023 mol) of 2-amino-3-pyridinecarboxaldehyde (APCA) in 10 ml of DMSO was added dropwise to the alginic acid solution. The pH of the reaction mixture was maintained at pH 5.5 using 1N NaOH and stirred at room temperature for 16 to 20 hours. The reaction mixture was transferred to a 50 ml centrifuge tube, centrifuged at 3000 rpm for 10 minutes at room temperature, and the supernatant was collected. Next, using a dialysis tube (MWCO: 6-8 kDa) (Spectra / Pro (registered trademark)), the solution was dialyzed in deionized water for 72 hours and then freeze-dried to obtain AL-APCA.
[0890] < 1 H NMR spectroscopy, FT-IR spectroscopy >
[0891] AL-APCA was 1 HNMR spectrum measurement and FT-IR spectrum measurement. The results are shown in Figure 9 and Figure 10 These results confirmed the synthesis of APCA-modified alginate (AL-APCA) in which the amino groups of APCA were bonded to the carboxyl groups of alginic acid.
[0892] In addition, by 1 The APCA modification ratio relative to the carboxyl group (-COOH) of alginic acid was calculated from H NMR spectroscopy to be 0.41.
[0893] <Quantification of aldehydes by colorimetric aldehyde measurement>
[0894] The APCA modification rate with respect to the carboxyl group (—COOH) of alginic acid calculated from the amount of aldehyde measured using a colorimetric aldehyde assay kit and blue (MAK140) was 0.33.
[0895] [Example 1-6] ANA modified alginic acid (AL-ANA)
[0896] [Chemistry 49]
[0897]
[0898] The same operation as in Example I-3 was performed to obtain an alginic acid solution. 0.280 g (0.0023 moles) of 6-aminonicotinaldehyde (ANA) in 10 ml of DMSO was added dropwise to the alginic acid solution. The pH of the final reaction mixture was maintained at pH 5.5 using 1N NaOH and stirred at room temperature for 16 to 20 hours. The reaction mixture was transferred to a 50 ml centrifuge tube, centrifuged at 3000 rpm for 10 minutes at room temperature, and the supernatant was collected. Next, using a dialysis tube (MWCO: 6-8 kDa) (Spectra / Pro (registered trademark)), the solution was dialyzed in deionized water for 72 hours and then freeze-dried to obtain AL-ANA.
[0899] < 1 H NMR spectroscopy, FT-IR spectroscopy >
[0900] AL-ANA was 1 H NMR spectroscopy and FT-IR spectroscopy. The results are shown in Figure 11 and Figure 12 These results confirmed the synthesis of ANA-modified alginic acid (AL-ANA) in which the amino group of ANA was bonded to the carboxyl group of alginic acid.
[0901] In addition, by 1 The ANA modification rate relative to the carboxyl group (-COOH) of alginic acid was calculated from HNMR spectroscopy to be 0.17.
[0902] <Quantification of aldehydes by colorimetric aldehyde measurement>
[0903] The ANA modification rate to the carboxyl group (—COOH) of alginic acid, calculated from the amount of aldehyde measured using a colorimetric aldehyde assay kit and blue (MAK140), was 0.26.
[0904] Depend on 1 The modification rates of the modifying groups (A) determined by H NMR spectroscopy (NMR) and colorimetric aldehyde measurement (colorimetry) are summarized in the table below.
[0905] [Table 2]
[0906] Table 2 Modification rates of various alginate derivatives
[0907]
[0908] 3. AL-ABA drug conjugates
[0909] [Example I-7] Benzaldehyde-modified alginic acid-vancomycin conjugate (AL-ABA-Van)
[0910] Synthesis of AL-ABA-Van
[0911] [Chemistry 50]
[0912] Composite Image 2
[0913]
[0914]
[0915] Vancomycin (Van) is an antibiotic with a primary amino group. According to the above synthesis scheme, a conjugate of Van bound to AL-ABA (AL-ABA-Van) was synthesized by the following steps via a Schiff base reaction between the aldehyde group of AL-ABA and the primary amino group of Van.
[0916] Specifically, 50 mg of AL-ABA (1) obtained in Example I-1 was dissolved in 70 mL of pure water and stirred for more than 1 hour. 60 mg of vancomycin hydrochloride was dissolved in 60 mL of pure water and added to the AL-ABA solution. 0.1 M NaOH was added dropwise to adjust the pH to around 7.0, and the reaction was carried out while stirring at room temperature under light-proof conditions overnight. After dilution with 150 mL of pure water, the solution was dialyzed against pure water for 2 days (device: Spectra / Pro (registered trademark) 1 Dialysis Membrane Standard RC Tubing MWCO: 6-8 kD), and freeze-dried for 3 days to recover 86.8 mg of white AL-ABA-Van. (Yield: 78.9%)
[0917] < 1 H NMR spectroscopy, UV-visible absorption spectroscopy (UV-vis) and FT-IR spectroscopy
[0918] The obtained AL-ABA-Van was 1 HNMR spectrum measurement, ultraviolet-visible absorption spectrum (UV-vis) measurement and FT-IR spectrum measurement. The results are shown in Figures 13 to 15 .
[0919] exist 1 HNMR spectroscopy ( Figure 13 ), a peak derived from ABA and a peak derived from vancomycin (Van) were observed in AL-ABA-Van. Figure 14 ), a peak derived from ABA and a peak derived from vancomycin (Van) were observed in AL-ABA-Van (indicated by arrows in the figure; a shift toward the lower wavelength side was observed). In the FT-IR spectrum ( Figure 15 ), in AL-ABA-Van, absorption (about 1740 cm-1 peak).
[0920] From these results, it was confirmed that a conjugate of AL-ABA and Van was formed. 1 H NMR spectroscopy showed that the conjugation rate of Van, the drug, to the carboxyl group (-COOH) of alginic acid was 5.9%, indicating that 82.4% of the ABA in AL-ABA reacted with Van.
[0921] These results demonstrate that conjugation is instantaneous simply by mixing AL-ABA and Van in an aqueous solvent. Furthermore, the reaction product is solely water, eliminating the need for subsequent purification. Because this reaction is applicable to a wide range of primary amine-containing drugs, AL-ABA is expected to serve as a simple and versatile platform for the development of alginate-drug conjugates.
[0922] <Van Release Experiment from Benzaldehyde-Modified Alginate-Vancomycin Conjugate (AL-ABA-Van)>
[0923] (Experimental Procedures)
[0924] The release behavior of Van from AL-ABA-Van solution at different pH values was studied using a dialysis membrane (pore size: 50 kDa). Specifically, AL-ABA-Van obtained in Example 1-7 was dissolved in pure water at 3 mg / mL, and 1 mL of the resulting AL-ABA-Van solution was injected into a dialysis membrane cut into 9 cm pieces. The two ends of the dialysis membrane were tied with a kite string. This was placed in an 80 mL safety container, 79 mL of PBS solution was added, and the mixture was stirred at maximum rotation speed using a stirring plate with a diameter of 1 cm in a thermostatic bath at 37°C. 1.0 mL of the solution in the safety container was sampled at specified time points (1, 2, 3, 4, 6, 8, 12, 24, and 48 hours). The sampled solution was subjected to UV-vis spectroscopy, and the drug concentration in the solution was quantified by absorbance to calculate the release rate of Van as a drug (% vancomycin released). The above measurement was performed on PBS solutions of pH = 5.0, 6.0, and 7.4 (n = 4 for each pH sample).
[0925] For comparison, as control experiments, the above-mentioned release experiments were performed using a mixed solution of sodium alginate and vancomycin (AL+Van) obtained by dissolving 3 mg / mL sodium alginate (AL) (IL-6G manufactured by KIMICA Co., Ltd., viscosity 50-80 mPa·s (1%)) and 8.6 mg / mL vancomycin (Van) in pure water, and a solution obtained by dissolving 8.6 mg / mL vancomycin (Van) in pure water (Van only) instead of the AL-ABA-Van solution.
[0926] (result)
[0927] The results are shown in Figure 16. Figure 16A The release behavior of Van from AL-ABA-Van solution (cumulative release rate of Van, %) is shown. Figure 16B The release behavior of Van from AL+Van mixed solution (cumulative release rate of Van, %) is shown. Figure 16C The release behavior of Van from the Van solution (cumulative release rate of Van, %) is shown.
[0928] After 10 hours, over 80% of Van was released from the AL-ABA-Van solution at pH 5.0. In contrast, less than 50% remained unreleased at pH 7.4. This result suggests that Van release accelerates with decreasing pH. This is believed to be due to the fact that the imine bond between AL-ABA and Van dissociates more readily at low pH.
[0929] On the other hand, it was found that most of Van was released in the AL+Van solution or Van solution (control experiment) within the first 10 hours. No difference in release behavior was observed depending on pH.
[0930] The above results show that the AL-ABA-Van conjugate can sustainably release Van compared to the control group (AL+Van, Van only), and furthermore, selectively releases the drug at low pH, and can change the Van release rate in a pH-dependent manner.
[0931] [Chemistry 51]
[0932]
[0933] [Example I-8] AL-ABA microcapsules loaded with FTSC (AL-ABA-FTSC capsules)
[0934] (Capsule production)
[0935] [Chemistry 52]
[0936] Fluorescein-5-thiosemicarbazide (FTSC)
[0937]
[0938] Fluorescein 5-thiosemicarbazide (FTSC) is a fluorescent dye with a primary amino group. AL-ABA capsules loaded with FTSC were prepared.
[0939] Specifically, AL-ABA (1) prepared in Example I-1 was dissolved in pure water to prepare a 2 wt% AL-ABA solution. This solution was added dropwise to a 50 mM CaCl2 aqueous solution to obtain capsules (AL-ABA capsules). FTSCs were dissolved in DMEM (Dulbecco's Modified Eagle Medium) containing physiological saline and 10% FBS (fetal bovine serum), and the obtained AL-ABA capsules were immersed in this solution, thereby allowing the FTSCs to react and diffuse and be held in the capsules.
[0940] For comparison, as a control experiment, capsules (AL capsules) were prepared in the same manner as above, except that AL-ABA was replaced with sodium alginate (AL) (IL-6G manufactured by Kimica Co., Ltd., viscosity 50-80 mPa·s (1%)). The obtained AL capsules were similarly immersed in physiological saline containing FTSC to confirm whether FTSC was loaded.
[0941] (result)
[0942] AL and AL-ABA capsules immersed in FTSC solution were observed under a confocal microscope. The obtained transmission image (Transmitted), fluorescence image (amine-fluorescein), and the overlap (Merged) of the two are shown in Figure 17 .
[0943] Depend on Figure 17 It was observed that when AL-ABA was used, micro-scale capsules were also produced in the same manner as AL. Furthermore, almost no fluorescence from FTSC was detected in the AL capsules, whereas no fluorescence from FTSC was clearly detected in the AL-ABA capsules, indicating that FTSC was in situ loaded in the capsules. This confirmed that benzaldehyde-modified alginate (AL-ABA) can retain Ca in the same manner as alginate (AL). 2+ The capsules can be easily prepared due to the cross-linking ability, and can be loaded simply by impregnation with amine compounds.
[0944] [Example I-9] Van-loaded AL-ABA microcapsules (AL-ABA-Van capsules)
[0945] (Capsule production)
[0946] AL-ABA (1) prepared in Example I-1 was dissolved in pure water to prepare a 2 wt% AL-ABA solution. 15 mg of vancomycin (Van) was added to the solution to obtain a mixed solution of AL-ABA and Van. The mixed solution of AL-ABA and Van was added dropwise to a 50 mM aqueous solution of CaCl2 to obtain capsules (AL-ABA-Van capsules).
[0947] For comparison, as a control experiment, capsules (AL-Van capsules) were obtained in the same manner as above except that AL-ABA was replaced with sodium alginate (AL) (IL-6G manufactured by KIMICA Co., Ltd., viscosity 50-80 mPa·s (1%)).
[0948] (result)
[0949] It was confirmed that benzaldehyde-modified alginic acid (AL-ABA) also maintained Ca 2+ It has cross-linking ability and can be easily made into capsules like alginate (AL).
[0950] Release experiment of Van from AL-ABA-Van capsules
[0951] (Experimental Procedures)
[0952] The AL-ABA-Van capsules prepared above were collected and added to 1 mL of a 10 mM CaCl solution in normal saline. The external solution (sustained-release solution) was recovered at specified time points (3, 24, and 48 hours), and the total amount of external solution was exchanged with a fresh 1 mL of a 10 mM CaCl solution in normal saline.
[0953] The external solution (sustained-release solution) collected at a predetermined time point was subjected to UV-vis spectroscopy, and the drug concentration in the solution was quantified from the absorbance, and the release rate of Van (% vancomycin release) as the drug was calculated.
[0954] For comparison, as a control experiment, AL-Van capsules were used instead of AL-ABA-Van capsules to perform the above release experiment.
[0955] (result)
[0956] See the results Figure 18 . Figure 18 A shows the cumulative release rate (%) of Van from each capsule, Figure 18 B shows the change in the release rate (%) of Van from each capsule at each time point.
[0957] Depend on Figure 18 A and Figure 18 B confirmed that both AL-Van capsule and AL-ABA-Van capsule slowly released vancomycin, with about 60% of Van released at the 48-hour time point. Figure 18 A) No significant difference was observed between the two. This is probably because the rate of Van release from the microcapsule by diffusion is slower than the rate of Van release by dissociation of the Schiff base from ABA, making it difficult to see the effect of Schiff base loading.
[0958] <Bacterial proliferation inhibition test>
[0959] To verify the antibacterial efficacy of vancomycin-loaded AL-ABA microcapsules, we used the sustained-release solutions recovered at each time point in the Van release experiment from the AL-ABA-Van capsules described above. We then evaluated the proliferation inhibition of Staphylococcus aureus using a halo assay. The specific experimental procedures are as follows.
[0960] (Experimental Procedures)
[0961] (1) Implantation of Staphylococcus aureus in agar medium
[0962] 1.1 15 g of agar was added to 1 L of Mueller-Hinton medium (BD), dissolved and sterilized using an autoclave, and 15 mL was added to each 100 mm Petri dish and cooled at room temperature to prepare an agar medium.
[0963] 1.2 Add 700 μl of Mueller-Hinton medium to a 1.5 mL microtube (Asnol sterilized tube), inoculate the stock solution of Staphylococcus aureus with a toothpick, and culture in a 37°C incubator overnight.
[0964] 1.3 Dilute the bacterial solution to 1.0×10 7 cells / ml, 100 μl of which was added to the agar medium and spread evenly using a bacterial spreader.
[0965] (2) Allow the slow-release solution to penetrate into the filter paper and be applied to the agar medium
[0966] 2.1 1 mL of the sustained-release solution recovered in the release experiment was sterilized by filtration using a syringe filter (0.22 μm).
[0967] 2.2 Cut the filter paper (AS ONE: MFWG4780) into a circle with a diameter of 16 mm.
[0968] 2.3 Place the cut filter paper in the center of the agar medium seeded with Staphylococcus aureus.
[0969] 2.4 Add 40 μl of sustained-release solution evenly onto the filter paper to allow it to penetrate.
[0970] 2.5 Transfer the culture dish to an incubator and culture at 37°C for 24 hours.
[0971] 2.6 The culture dish was removed from the incubator, and the proliferating bacteria were photographed with a camera. The area of the portion where growth was inhibited was measured by image analysis using Image J (provided by NIH).
[0972] (result)
[0973] The growth of Staphylococcus aureus on agar medium under various conditions was observed. Figure 19 In both the Van-loaded AL capsule (AL-Van) and the Van-loaded AL-ABA capsule (AL-ABA-Van), circular areas where bacteria did not proliferate were observed around the filter paper, confirming a proliferation inhibitory effect.
[0974] The area of inhibited proliferation was calculated by image analysis, and the results of comparison under different conditions are shown in Figure 20 In the case of the AL capsule (AL-Van), the area of proliferation inhibition decreased over time, 3, 24, and 48 hours after the start of sustained release. In contrast, this decrease was suppressed in the AL-ABA capsule (AL-ABA-Van), with the difference in area after 3 and 48 hours showing a trend toward smaller differences. This result suggests that while the AL-Van capsule initially releases a large amount of vancomycin, the amount released decreases over time, leading to a decrease in antibacterial efficacy. In contrast, the AL-ABA-Van capsule suppresses the initial release of vancomycin, maintaining an effective concentration for a longer period of time.
[0975] [Example I-10] Benzaldehyde-modified alginate-bacitracin conjugate (AL-ABA-Bac)
[0976] Synthesis of AL-ABA-Bac
[0977] [Chemistry 53]
[0978]
[0979] Bacitracin (Bac) is a medium molecular weight polypeptide antibacterial drug with two primary amino groups. Benzaldehyde-modified alginate-bacitracin conjugate (AL-ABA-Bac) was synthesized using the same method as in Example I-7.
[0980] Specifically, 50 mg of AL-ABA (1) obtained in Example I-1 was dissolved in 70 mL of pure water and stirred for more than 1 hour. 15 mg of bacitracin (Bac) was dissolved in 15 mL of pure water and added to the AL-ABA solution. 0.1 M NaOH was added dropwise to adjust the pH to around 7.0, and the mixture was stirred overnight at room temperature under light-proof conditions while reacting. After dilution with 150 mL of pure water, the mixture was dialyzed against pure water for 2 days (device: Spectra / Pro (registered trademark) 1 Dialysis Membrane Standard RC Tubing MWCO: 6-8 kD), and freeze-dried for 3 days to recover 47.6 mg of gel-like AL-ABA-Bac. (Yield: 73.2%)
[0981] Ultraviolet-visible absorption spectroscopy (UV-vis) and FT-IR spectroscopy
[0982] The obtained AL-ABA-Bac was subjected to UV-visible absorption spectroscopy (UV-vis) and FT-IR spectroscopy. Figures 21 and 22 .
[0983] In UV-vis( Figure 21 ), peaks derived from bacitracin (Bac) and ABA were also observed in AL-ABA-Bac (indicated by arrows in the figure; a shift to the lower wavelength side was observed). In the FT-IR spectrum ( FIG16 ), absorption (about 1740 cm ) derived from the C═O of the amide that is the binding site between AL and ABA was observed in AL-ABA-Bac. -1 peak).
[0984] From these results, it was confirmed that a conjugate of AL-ABA and Bac was formed.
[0985] The recovered AL-ABA-Bac forms a hydrogel. It is believed that the two amino groups contained in Bac form bonds with the aldehyde groups of ABA, allowing Bac itself to act as a crosslinker (gelator), resulting in gelation. This gel structure is expected to enable long-term sustained release.
[0986] In addition to bacitracin (Bac), there are many polypeptide antibiotics with two or more amino groups (e.g., daptomycin, colistin, elcatonin, etc.). In these drugs, the drug itself also functions as a cross-linking agent and is expected to form a gel structure.
[0987] [Example I-11] Benzaldehyde-modified alginate-dopamine conjugate (AL-ABA-DOPA)
[0988] Synthesis of AL-ABA-DOPA
[0989] [Chemistry 54]
[0990]
[0991] Dopamine (DOPA) is a neurotransmitter that plays important roles in the brain and body. It is an organic chemical in the catecholamine and phenethylamine families. DOPA has a primary amino group. A benzaldehyde-modified alginate-dopamine conjugate (AL-ABA-DOPA) was synthesized by the following steps.
[0992] Dopamine (DOPA) is a neurotransmitter that plays an important role in the brain and body and has a primary amino group. A benzaldehyde-modified alginate-dopamine conjugate (AL-ABA-DOPA) was synthesized by the following steps.
[0993] 0.25 g (0.00115 mol) of AL-ABA (2) (low DS; modification rate (colorimetric method): 0.56) prepared in Example I-2 was dissolved in 100 ml of PBS (pH 7.4) and stirred for 6 to 8 hours. 0.43 g (0.0023 mol) of dopamine hydrochloride (Sigma Aldrich) was dissolved in 10 ml of PBS (pH 7.4) and added dropwise to the AL-ABA solution. The solution was dialyzed against deionized water using dialysis tubing (MWCO: 6-8 kDa) (Spectra / Pro (registered trademark)) for 72 hours to obtain an AL-ABA-DOPA solution, which was then freeze-dried.
[0994] < 1 H NMR spectroscopy and FT-IR spectroscopy
[0995] AL-ABA-DOPA was tested 1 H NMR spectroscopy and FT-IR spectroscopy confirmed the formation of a conjugate of AL-ABA and dopamine. Figures 23 and 24 .
[0996] according to 1 H NMR spectrum showed that the conjugation rate of DOPA as a drug to ABA in AL-ABA was 47% (DOPA modification rate to ABA: 0.47). 1The modification rate (colorimetric) calculated by colorimetric measurement is more accurate than the modification rate (NMR) calculated by HNMR spectroscopy. Therefore, the above-mentioned DOPA conjugation rate was calculated based on the modification rate (colorimetric) value based on the colorimetric measurement. In the following examples, when the modification rate (colorimetric) was measured, the drug conjugation rate relative to ABA was calculated based on the modification rate (colorimetric method) value.
[0997] [Example I-12] AL-ABA-DOPA-loaded sponge (AL-ABA-DOPA sponge)
[0998] (Production steps)
[0999] AL-ABA (modification ratio (NMR): 0.60) was synthesized under the same conditions as AL-ABA (2) in Example I-2. AL-ABA was dissolved in PBS (pH 7.4) to prepare a 0.5% AL-ABA solution. Dopamine (DOPA) was added at a molar equivalent of 2 times the amount of ABA, and the solution was stirred at room temperature for 16 to 20 minutes. The solution was then dialyzed against pure water for 72 hours and then freeze-dried to obtain AL-ABA-DOPA.
[1000] AL-ABA-DOPA was dissolved in PBS to obtain a 1.0 wt% AL-ABA-DOPA solution. The AL-ABA-DOPA solution was mixed with 1.0 ml of a 10 mM CaCl2 aqueous solution in a 35 mm Petri dish. After forming a hydrogel, the mixture was frozen at -20°C overnight and then freeze-dried. Freeze-drying yielded an AL-ABA-DOPA sponge.
[1001] Through calcium ion-based cross-linking, hydrogels and sponges of AL-ABA-DOPA as polysaccharide derivative-drug conjugates can be formed.
[1002] [Example I-13] Benzaldehyde-modified alginic acid-serotonin conjugate (AL-ABA-serotonin)
[1003] Synthesis of AL-ABA-serotonin
[1004] [Chemistry 55]
[1005]
[1006] Serotonin (5-HT) is a monoamine neurotransmitter with a primary amino group. A benzaldehyde-modified alginate-serotonin conjugate (AL-ABA-serotonin) was synthesized by the following steps.
[1007] 0.25 g (0.00115 mol) of AL-ABA (2) (low DS, modification rate (colorimetric method): 0.56) prepared in Example I-2 was dissolved in 100 ml of PBS (pH 7.4) and stirred for 6 to 8 hours. 0.489 g (0.0023 mol) of serotonin hydrochloride (Sigma Aldrich) was dissolved in 10 ml of PBS (pH 7.4) and added dropwise to the AL-ABA solution. The solution was dialyzed against deionized water for 72 hours using dialysis tubing (MWCO: 6-8 kDa) (Spectra / Pro (registered trademark)) and then freeze-dried.
[1008] < 1 H NMR spectroscopy and FT-IR spectroscopy
[1009] AL-ABA-serotonin was tested 1 H NMR spectroscopy and FT-IR spectroscopy confirmed the formation of a conjugate of AL-ABA and serotonin. Figures 25 and 26 .
[1010] according to 1 According to H NMR spectroscopy, the conjugation rate of ABA of AL-ABA to serotonin as a drug was 46% (modification rate of serotonin to ABA: 0.46).
[1011] [Example I-14] Benzaldehyde-modified alginic acid-celecoxib conjugate (AL-ABA-celecoxib)
[1012] <Synthesis of AL-ABA-celecoxib>
[1013] [Chemistry 56]
[1014]
[1015] Celecoxib is a nonsteroidal anti-inflammatory / analgesic drug with a primary amino group. Benzaldehyde-modified alginic acid-celecoxib conjugate (AL-ABA-celecoxib) was synthesized by the following steps.
[1016] 0.25 g (0.00115 mol) of AL-ABA (2) (low DS; modification rate (colorimetric method): 0.56) prepared in Example I-2 was dissolved in 100 ml of PBS (pH: 7.4) and stirred for 6 to 8 hours. 0.877 g (0.0023 mol) of celecoxib hydrochloride (TCI) was dissolved in 10 ml of DMSO and added dropwise to the AL-ABA solution. The solution was dialyzed against deionized water for 72 hours using dialysis tubing (MWCO: 6-8 kDa) (Spectra / Pro (registered trademark)) and then freeze-dried.
[1017] < 1 H NMR spectroscopy and FT-IR spectroscopy
[1018] AL-ABA-celecoxib was tested 1 H NMR spectroscopy and FT-IR spectroscopy (not shown) confirmed the formation of a conjugate of AL-ABA and celecoxib. 1 The results of HNMR spectroscopy are shown in Figure 27 .
[1019] according to 1 According to H NMR spectroscopy, the conjugation rate of celecoxib as a drug to ABA in AL-ABA was 11% (celecoxib modification rate to ABA: 0.11).
[1020] [Example I-15] Benzaldehyde-modified alginate-HGF aptamer conjugate (AL-ABA-Apt)
[1021] With the goal of developing a novel anti-adhesion hydrogel using AL-ABA that has the ability to sustain the release of an HGF aptamer (manufactured by Eurofins Genomics, Inc., Lot: 1649399-3), which has an effect on promoting mesothelial cell proliferation, we synthesized a benzaldehyde-modified alginate-HGF aptamer conjugate (AL-ABA-Apt) and conducted sustained-release experiments on the HGF aptamer from AL-ABA-Apt. Figure 28 Show experimental steps.
[1022] (experiment)
[1023] Synthesis of AL-ABA-Apt
[1024] AL-ABA (modification rate (NMR) 4.0%) was synthesized under the same conditions as AL-ABA (1) in Example I-1. AL-ABA was dissolved in phosphate-buffered saline (PBS, pH = 7.4) to obtain a 0.4 wt% AL-ABA solution. An HGF aptamer containing 1.0 equivalent of amino groups relative to the aldehyde group of AL-ABA was added to the AL-ABA solution and stirred for 1 hour. The solution was then dialyzed against pure water for 3 days to remove unreacted HGF aptamer, followed by freeze-drying.
[1025] Ultraviolet-visible absorption spectroscopy (UV-vis) was performed on the AL-ABA-HGF aptamer conjugate (AL-ABA-Apt) and the HGF aptamer. The peak at 256 nm in the UV-vis spectrum was used to evaluate whether the HGF aptamer (Apt) was loaded on AL-ABA.
[1026] Apt release experiment from AL-ABA-Apt
[1027] 1.0 wt% AL-ABA was dissolved in PBS (pH 7.4). An HGF aptamer containing 1.0 equivalents of amino groups relative to the aldehyde groups of AL-ABA was then added to the AL-ABA aqueous solution. The mixture was stirred for 1 hour to synthesize the AL-ABA-HGF aptamer conjugate (AL-ABA-Apt). The AL-ABA-HGF aptamer was then loaded into a dialysis membrane (MWCO = 50 kDa) and stirred in PBS (pH 7.4). 1 mL of the external fluid was collected at various time points from the start of stirring, and the cumulative release rate (%) of the HGF aptamer was calculated using UV-visible fluorescence (UV-Vis) analysis. As a control experiment, a mixture of ordinary alginic acid and the HGF aptamer (ALG-Apt) and the HGF aptamer monomer (Apt) were dissolved in PBS, loaded into dialysis membranes, and the same sustained-release experiment was performed to compare the sustained-release rates.
[1028] <AL-ABA-HGF aptamer / Ca 2+ Gel Preparation>
[1029] The synthesized AL-ABA-HGF aptamer (AL-ABA-APt) was dissolved in pure water at a concentration of 1.0 wt% to obtain an AL-ABA-HGF aptamer aqueous solution. The AL-ABA-HGF aptamer aqueous solution was mixed with 100 mM CaCl2 aqueous solution in a microtube to investigate whether gelation occurred.
[1030] (result)
[1031] <Synthesis of AL-ABA-HGF Aptamer>
[1032] In the UV-vis spectrum of the synthesized AL-ABA-HGF aptamer (not shown), a peak derived from the HGF aptamer was confirmed at around 256 nm, indicating that the AL-ABA-HGF aptamer (AL-ABA-Apt) was successfully synthesized.
[1033] <Sustained release of HGF aptamers from AL-ABA-HGF aptamers>
[1034] The results of the sustained release experiments of HGF aptamers (Apt) from AL-ABA-HGF aptamer (AL-ABA-Apt), a mixture of alginic acid and HGF aptamer (ALG-Apt), and HGF aptamer monomer (Apt) are shown in Figure 29Compared with the ALG-Apt or Apt groups, the release of the HGF aptamer (Apt) was delayed in the AL-ABA-Apt group. This suggests that the sustained release of the HGF aptamer can be achieved under physiological pH conditions by conjugating the HGF aptamer and AL-ABA.
[1035] <AL-ABA-HGF aptamer / Ca 2+ Gel Preparation>
[1036] Through Ca 2+ Cross-linking, AL-ABA-HGF aptamer instant gelation, successfully produced gel. As shown in Examples I-16 and I-17 below, it was confirmed that AL-ABA 2+ Therefore, it is suggested that the conjugate of HGF aptamer and AL-ABA has almost no effect on the gelation performance of AL-ABA.
[1037] We successfully synthesized the AL-ABA-HGF aptamer loaded with the HGF aptamer that promotes mesothelial cell proliferation, and showed that the HGF aptamer can be released slowly from the AL-ABA-HGF aptamer. We also successfully produced a Ca-based 2+ Cross-linked AL-ABA-HGF aptamer (AL-ABA-Apt) gel suggests its potential as an anti-adhesion material.
[1038] 4. AL-ABA sponge and hydrogel
[1039] [Example I-16] Calcium-crosslinked benzaldehyde-modified alginic acid sponge (AL-ABA sponge)
[1040] (Production steps)
[1041] A total of 20 mg of sodium alginate (AL) (IL-6G manufactured by KIMICA Co., Ltd., viscosity 50-80 mPa·s (1%)) and AL-ABA (1) obtained in Example I-1 were dissolved in 2 ml of pure water at weight ratios of 75:25, 50:50, and 25:75, respectively, to prepare AL-ABA aqueous solutions. This was mixed with 2 ml of a 10 mM CaCl2 aqueous solution on a petri dish to obtain an AL-ABA hydrogel. The hydrogel was then frozen overnight in a -20°C freezer and freeze-dried for 3 days using a freeze dryer to obtain an AL-ABA sponge.
[1042] For comparison, as a control experiment, a sponge (AL sponge) was obtained in the same manner as above except that AL-ABA was replaced with AL alone (AL was 100% by weight).
[1043] (result)
[1044] The optical photographs of the AL-ABA sponge obtained in the above example and the AL sponge as a control (Control) are shown in FIG. Figure 30 , SEM photos see Figure 31 .
[1045] Using the same simple method as AL, we confirmed that benzaldehyde-modified alginic acid sponge (AL-ABA sponge) can be produced. Figure 31 The AL-ABA sponge was confirmed to have the same porous structure as the AL sponge. It is believed that the unmodified carboxyl groups of AL and AL-ABA are cross-linked via calcium (Ca) ions, forming a cross-linked structure. The content of benzaldehyde (ABA), a modifying group, and the cross-linking density in the sponge obtained by mixing AL and AL-ABA can be controlled.
[1046] [Example I-17] Calcium-crosslinked benzaldehyde-modified alginic acid hydrogel (Ca-crosslinked AL-ABA hydrogel)
[1047] A hydrogel (calcium-crosslinked AL-ABA hydrogel) was prepared by crosslinking AL-ABA (2) (High DS, modification rate (colorimetry): 0.64) prepared in Example 1-2 with calcium. Specifically, 20 mg of AL-ABA (2) (High DS, modification rate (colorimetry): 0.64) prepared in Example 1-2 was dissolved in 1 ml of pure water to prepare an AL-ABA aqueous solution. This solution was mixed with 1 ml of a 100 mM CaCl2 aqueous solution in a culture dish to obtain a calcium-crosslinked AL-ABA hydrogel.
[1048] <In vitro swelling and decomposition test>
[1049] The Ca cross-linked AL-ABA hydrogel obtained above was swollen in phosphate buffered saline (PBS) at pH 7.4. Specifically, four freshly prepared hydrogel samples were prepared, the weight of each sample was measured, and each sample was added to 25 ml of PBS solution at 37°C and allowed to swell for 72 hours. The decomposition of each sample after 72 hours of swelling was monitored. The weight of the hydrogel sample was measured every 24 hours for 2 weeks. The PBS was replaced with fresh PBS that had been pre-equilibrated at 37°C every week. The completely swollen Ca cross-linked AL-ABA hydrogel was freeze-dried and the morphology was observed using a SEM device.
[1050] (result)
[1051] Figure 32 The swelling / decomposition curves (weight change of the hydrogel) of Ca-crosslinked AL-ABA hydrogels are shown. The weight change values are the average of four samples.
[1052] Figure 33A SEM photograph of a cross-section of a sponge obtained by freeze-drying a Ca-crosslinked AL-ABA hydrogel, cut with a scalpel (magnification x500; 24 hours after the start of swelling) shows the porous structure of the dried hydrogel.
[1053] 5. Hydrogels containing AL-ABA and amino-containing polymers
[1054] [Example I-18] Hydrogel of AL-ABA and DPI (AL-ABA-DPI)
[1055] [Chemistry 57]
[1056]
[1057] AL-ABA (2) (low DS, modification rate (colorimetric method): 0.56) prepared in Example I-2 was dissolved in physiological saline as a solvent to prepare a 2% w / v AL-ABA solution. Dendritic poly (ethyleneimine) (DPI; Dendritic Poly (ethyleneimine)) (BASF, product name: PS, weight average molecular weight M: 750,000) was dissolved in water to prepare a 10% w / v DPI solution. The two solutions were mixed so that the aldehyde group of the AL-ABA solution and the primary amino group (-NH2) of the DPI solution were equimolar (1:1). Specifically, 250 μL of the 10% w / v DPI solution (amino group: 2.59×10 -4 mol) were mixed in 5 mL of 2% w / v AL-ABA solution (aldehyde group: 2.59×10 -4 mol). A hydrogel was formed within 20 to 30 seconds ( Figure 35 ). The hydrogel was stable in water for 2 weeks.
[1058] [Example I-19] Hydrogel of AL-ABA and PEG (4k)-dihydrazide (AL-ABA-PEGDH)
[1059] Synthesis of PEGDH
[1060] [Chemistry 58]
[1061]
[1062] To prepare PEGDH, a two-stage reaction was performed.
[1063] First, 10 g of PEG (Mw 4000) (0.0025 mol) 162-09115, Wako) was dissolved in a 300 ml eggplant flask containing 100 ml of dichloromethane (DCM) solvent at room temperature. After adding 2.0 g (0.02 mol) of succinic anhydride to the PEG solution, 2.57 g (0.0125 mol) of N,N'-dicyclohexylcarbodiimide and 1.83 g (0.015 mol) of 4-dimethylaminopyridine were added. The flask was sealed with a rubber stopper and stirred at room temperature for 24 hours. After that, the reaction mixture was filtered with filter paper, and the filtrate was evaporated using a rotary evaporator at 50°C. After the DCM was completely evaporated, a viscous reaction mixture remained in the flask. Then, 100 ml of distilled water was added, stirred for another hour, and then the solution was dialyzed in pure water for 48 hours using (MWCO 1 kDa) (Spectra / Pro (registered trademark)) dialysis tubing. After dialysis, the solution was freeze-dried and 1 The product was characterized by HNMR (using D2O solvent). The yield was about 73%, and the conversion rate from PEG to PEG-COOH was about 100%.
[1064] The second stage is the carbodiimide reaction. Measure 4g (0.00097 mol) of freshly prepared PEG-COOH into a 200ml Erlenmeyer flask and dissolve it in 50ml of distilled water for 2-4 hours. Dissolve 1.05g (0.0070 mol) of HOBt in 10ml of DMSO (Wako), then dissolve 1.49g (0.0.0078 mol) of WSCD-HCl (Peptide Research Institute) in 10ml of distilled water and add dropwise to the PEG-COOH solution. Stir the solution for an additional 10 minutes. Dissolve 3.399g (0.019 mol) of adipic acid dihydrazide in 15ml of pure water and add it to the PEG-COOH solution. Maintain the pH of the final reaction mixture at 7.5 with 1N NaOH and stir at room temperature for 16-20 hours. The solution was then dialyzed extensively against deionized water using a dialysis tube (MWCO 1 kDa) (Spectra / Pro (registered trademark)) for 48 hours and then freeze-dried. 1 H NMR confirmed the incorporation of PEGDH. The degree of substitution was approximately 91%.
[1065] Synthesis of AL-ABA-PEGDH
[1066] AL-ABA (2) (high DS, modification rate (colorimetric method): 0.64) prepared in Example I-2 was dissolved in physiological saline as a solvent to prepare a 1.5% w / v AL-ABA solution (2).
[1067] The prepared PEGDH was dissolved in water to prepare a 10% w / v PEGDH solution. The two solutions were mixed so that the aldehyde groups of the AL-ABA (2) solution and the hydrazide groups of the PEGDH solution were equimolar (1:1). Specifically, 0.5 mL of a 10% w / v PEGDH solution (hydrazide groups: 2.27×10 -5 mol) were mechanically mixed in 1 mL of 1.5% w / v AL-ABA solution (aldehyde groups: 6.9 × 10 -5 A hydrogel was formed within 30 seconds ( FIG36 ).
[1068] Dynamic viscoelasticity measurement
[1069] The storage modulus G' and loss modulus G" were measured using a rheometer.
[1070] The results are shown in ( Figure 37 Within the measured frequency range, AL-ABA-PEGDH was confirmed to be G'>G", reliably confirming the formation of hydrogel.
[1071] [Example 1-20] Benzaldehyde-modified alginic acid membranes (uncrosslinked and crosslinked AL-ABA membranes)
[1072] <Film Preparation>
[1073] (1) Uncrosslinked AL-ABA film
[1074] An uncrosslinked AL-ABA film was prepared by solution casting and vacuum heating drying. Specifically, AL-ABA (2) prepared in Example I-2 (high DS, modification rate (colorimetric method): 0.64) was dissolved in distilled water to prepare a 1.5% w / v AL-ABA solution. After complete dissolution, bubbles were removed by ultrasonic treatment for 15 minutes. Thereafter, the solution was injected into a 60 mm Petri dish, and the Petri dish was kept in a vacuum dryer at 50°C for 40 to 48 hours, after which the membrane was peeled off and stored at 4°C. The membrane was non-porous and transparent, and the thickness of the membrane was about 63 μm.
[1075] (2) Cross-linked AL-ABA film
[1076] The uncrosslinked AL-ABA membrane obtained in (1) was crosslinked with PEGDH to obtain a crosslinked AL-ABA membrane. Specifically, the PEGDH synthesized in Example I-19 was dissolved in a butanol aqueous solution (butanol:water = 9:1), and the membrane obtained in (1) was immersed in the solution and maintained at room temperature for 6-8 hours. The membrane was removed from the PEGDH solution, dried in air, and stored at 4°C. The resulting crosslinked AL-ABA membrane was nonporous and transparent.
[1077] <Membrane swelling and dissolution test>
[1078] (Experimental Procedures)
[1079] The uncrosslinked AL-ABA membrane obtained in (1), the crosslinked AL-ABA membrane obtained in (2), and the AL membrane were immersed in PBS (pH = 7.4) for 2 to 4 weeks, and the swelling properties and dissolution of the membranes were observed. The AL membranes were prepared using the method (1) above, except that AL-500 (manufactured by Mochida Pharmaceutical Co., Ltd., sodium alginate, viscosity: 400 to 600 mPa·s) was used instead of the AL-ABA (2) prepared in Example I-2.
[1080] (result)
[1081] See the table below for the results.
[1082] [Table 3]
[1083] Table 3 Swelling and dissolution test results of the membrane
[1084] Swelling after 6 days Dissolve AL film - Dissolve Uncrosslinked AL-ABA film Large swelling Dissolved in 1 week Cross-linked AL-ABA film The swelling amount is less than that of the uncrosslinked AL-ABA film No dissolution at the 20-day time point
[1085] [Example I-21] Hydrogels of AL-ABA and polyallylamine (AL-ABA-PAA1, AL-ABA-PAA2, AL-ABA-PAA3, AL-ABA-PAA4)
[1086] [Chemistry 59]
[1087]
[1088] (i) PAA1: Product name: allylamine-maleic acid copolymer (Product No.: PAA-1151, NITTOBO MEDICAL Co., Ltd., viscosity: 20 cp at 20 wt% and 20°C);
[1089] (ii) PAA2: diallyldimethylammonium chloride-acrylamide copolymer (Product No.: PAS-J-81, NITTOBO MEDICAL Co., Ltd., viscosity 900 cp at 25 wt% and 20°C), weight-average molecular weight Mw: 180,000;
[1090] (iii) PAA3: allylamine hydrochloride-dimethylallylamine salt copolymer (Product No.: PAA-1112CL, NITTOBO MEDICAL Co., Ltd., viscosity 5 cp at 15 wt% and 20°C);
[1091] (iv) PAA4: allylamine hydrochloride polymer (Product No.: PAA-HCl-10L, NITTOBO MEDICAL Co., Ltd., viscosity at 40 wt %: 1500 cp (20° C.), weight average molecular weight Mw: 150,000.
[1092] The polyallylamines (PAA1 to PAA4) described above (i) to (iv) were respectively dissolved in water to prepare 10% w / v PAA solutions (PAA1 solution, PAA2 solution, PAA3 solution, PAA4 solution).
[1093] AL-ABA (2) prepared in Example I-2 (low DS, modification rate (colorimetric method): 0.56) was dissolved in physiological saline as a solvent to prepare a 2% w / v AL-ABA solution. The two solutions were mixed so that the aldehyde groups of the AL-ABA solution and the primary amino groups (-NH2) of the PAA solution were equimolar (1:1). Specifically, 10% w / v of each PAA solution (PAA1 solution, PAA2 solution, PAA3 solution, PAA4 solution) (amino groups in each solution: 2.59×10 -4 mol) were mixed in 5 mL of 2% w / v AL-ABA solution (aldehyde group: 2.59×10 -4 mol). Hydrogels were formed within 20 to 30 seconds ( Figure 38 ).
[1094] 6. Tissue adhesive material using AL-ABA
[1095] [Example I-22] Benzaldehyde-modified alginic acid (AL-ABA) as a tissue adhesive material (adhesion to the submucosa)
[1096] <Evaluation of adhesive behavior to mucous membranes>
[1097] The adhesiveness of AL-ABA to the submucosa was verified. The submucosa is rich in collagen and therefore contains numerous amino groups. The following experiments confirmed that the amino groups within the submucosa and the aldehyde groups of AL-ABA form Schiff base crosslinks, enhancing adhesion. The specific experimental procedures are as follows.
[1098] (Experimental Procedures)
[1099] 1. Cut the pig esophagus longitudinally into 2 cm x 2 cm sections. Remove the mucosal layer inside the esophagus to expose the submucosa. Fill each 80 mL safety container with 25 mL of saline solution supplemented with 0.1% sodium benzoate. Immerse each esophageal section, with the submucosa exposed, in this solution and place in a shaker in a 37°C incubator for overnight shaking. Measure the weight of each section after shaking. (Esophageal sections: n = 4)
[1100] 2. AL-ABA and unmodified AL (IL-6G) for comparative studies were dissolved in pure water at 2 w / v%. AL-ABA (1) prepared in Example I-1 was used.
[1101] 3. The alginic acid solution (AL-ABA aqueous solution or AL aqueous solution) prepared in step 2 was loaded into one side of the double syringe, and 50 mM CaCl2 aqueous solution was loaded into the other side.
[1102] 4. Take out the slices prepared in step 1 above from the safety container and place them on a culture dish. Use a double syringe and nitrogen to spray 0.5 mL of the prepared alginic acid solution in step 3 and 0.5 mL of a 50 mM CaCl2 aqueous solution from above the slices at the same time. The nitrogen flow rate at this time is 2 L / min. For gelation, let it stand at room temperature (25°C) for 10 minutes. Through this treatment, benzaldehyde-modified alginic acid (AL-ABA) or alginic acid (AL) is gelled by calcium (Ca 2+ ) cross-linked to form a hydrogel (AL-ABA gel, AL gel).
[1103] 5. Rinse the gel on the petri dish with pure water, wipe off the moisture from the esophageal slice, and then measure the weight of the esophageal slice. Deduct the weight of the esophageal slice measured in 1 above from this weight to calculate the weight of the gel on the esophageal slice. This is considered the weight of the gel after 0 hours.
[1104] 6. Replace the saline solution containing 0.1% sodium benzoate in the safety container with fresh saline. Immerse the esophageal slice, gel-side down, in the solution. Place the slice on a shaker and shake in a 37°C incubator.
[1105] 7. After a specified time (1, 2, 3, 4, 6, 8, 12, 24, and 48 hours), the weight of the esophageal slices was measured and the weight of the esophageal slices measured in step 1 above was subtracted to calculate the residual gel weight. The residual gel ratio at each time point was calculated from the gel weight after 0 hours and the residual gel weight [(residual gel weight) / (gel weight after 0 hours) × 100]. The appearance of the gel at each time point was also observed.
[1106] The above steps were repeated for four samples each of AL and AL-ABA, and the average value of the remaining ratio of gel at each time point was taken as the adhesion rate (%) of the gel.
[1107] (result)
[1108] See the results Figure 39 、 Figure 40 . Figure 39The appearance of AL gel and AL-ABA gel at each time point is shown. Figure 40 The adhesion rates (%) of AL gel and AL-ABA gel at each time point are shown.
[1109] like Figure 39 As shown, in the group sprayed with AL (ALG (IL-6G), AL gel), the gel of 3 out of 4 samples peeled off after 1 hour. The gel of the remaining sample also peeled off after 2 hours. In the group sprayed with AL-ABA (ALG-ABA, AL-ABA gel), the gel peeled off gradually after 2 hours, and a small amount of gel remained after 12 hours by visual inspection. Figure 40 The groups sprayed with AL (ALG (IL-6G), AL gel) showed a gel adhesion rate (%) of zero after 3 hours. In contrast, the groups sprayed with AL-ABA (ALG-ABA, AL-ABA gel) maintained a gel adhesion rate of approximately 40%. This result suggests that modifying AL with ABA improves adhesion.
[1110] [Example I-23] AL-ABA as a tissue adhesive material (Evaluation of adhesiveness to esophageal mucosa and submucosa and Ca 2+ Concentration effect evaluation) (37℃)
[1111] Adhesion test between mucosa and submucosa
[1112] The adhesion of AL-ABA and AL to the esophageal mucosa and submucosa was verified at 37°C. The sample with the mucosa was used as the control, and the sample with the mucosa peeled off to expose the submucosa was used as the ESD sample. 2+ The results were studied at two concentrations of 50M and 100mM. 2+ The change of concentration causes the change of adhesion. The experimental steps are shown in Figure 42 The specific steps are as follows.
[1113] (Material)
[1114] AL-ABA: AL-ABA (modification ratio (NMR): 0.052) prepared under the same conditions as AL-ABA (1) in Example I-1 was dissolved in pure water at 2 w / v%.
[1115] AL: IL-6G (IL-6G manufactured by KIMICA Co., Ltd., viscosity 50 to 80 mPa·s (1%)) was dissolved in pure water at 2 w / v%.
[1116] CaCl2 aqueous solution (for cross-linking): 50mM or 100mM;
[1117] Esophageal sections (control: with mucosal layer; ESD: stripping of mucosal layer to expose submucosa);
[1118] (Experimental Procedures)
[1119] 1. The pig esophagus was cut longitudinally and cut into 2 cm × 2 cm sections. In the submucosal layer group (ESD), the mucosal layer was removed with scissors.
[1120] 2. The mass of the cut pig esophagus slices (Control) and the slices with exposed submucosa (ESD) were measured.
[1121] 3. Dissolve AL or AL-ABA in pure water at 2 w / v%.
[1122] 4. Add the solution prepared in step 3 and the CaCl2 solution to a 2.5 mL syringe and place it on a double syringe. (Each sample should contain 0.5 mL of alginate solution and 0.5 mL of CaCl2 solution.)
[1123] 5. Install the spray tip on the double syringe and spray the solution along with nitrogen gas at 4 L / min towards the esophageal slices. (n = 4 per sample)
[1124] 6. Leave it for 10 minutes until gelation occurs. Through this treatment, benzaldehyde modified alginic acid (AL-ABA) or alginic acid (AL) is reacted with calcium (Ca 2+ ) were cross-linked to form a hydrogel (AL-ABA gel, AL gel). The quality of the esophagus slices at this time was measured.
[1125] 7. Place 25 mL of normal saline solution supplemented with 0.1% methyl benzoate and 1.25 mM CaCl2 in a 6 cm diameter glass dish, immerse the esophageal slices in it, and shake them with a shaker. 2+ Mimics the Ca content in saliva 2+ .
[1126] 8. The mass of the esophageal slices was measured after the specified time periods (1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours) to determine the mass of the residual gel. The residual gel ratio at each time point was calculated from the gel weight after 0 hours and the residual gel weight [(residual gel weight) / (gel weight after 0 hours) × 100]. The appearance of the gel at each time point was also observed.
[1127] Ca in esophageal sections (control) and sections with exposed submucosa (ESD) 2+The above steps were repeated for four samples each of AL and AL-ABA at a concentration of 50 mM or 100 mM, and the average value of the remaining ratio of gel at each time point was taken as the adhesion rate (%) of the gel.
[1128] (result)
[1129] The appearance of the gel at each time point (2, 4, 12, 24, 48, 72 hours later) is shown in Figure 43 In addition, the remaining ratio of gel at each time point (gel adhesion rate, %) is shown in Figure 44 .
[1130] The samples sprayed with AL-ABA on the submucosal layer (AL-ABA ESD) and the mucosal layer (AL-ABA control; AL-ABA Con) showed that the gel adhesion rate was maintained for a longer period of time compared to the groups sprayed with AL (AL ESD and AL control (Con)). This confirmed that the modification of AL with ABA improves adhesion.
[1131] In particular, the sample sprayed with AL-ABA on the submucosa (AL-ABA ESD) showed further improved adhesion compared to the sample sprayed with AL-ABA on the mucosal layer (AL-ABA Control; AL-ABA Con). This is presumably due to the binding of ABA to amino groups in the submucosa, resulting in strong adhesion.
[1132] Furthermore, at a high CaCl2 concentration (100 mM), the gel's adhesion rate was maintained for a longer period of time. This is believed to be due to the increased amount of Ca ions, which increases the crosslinking point density and prolongs the gel's mechanical strength and decomposition time. Since cohesive failure occurs at the maximum breaking strength in the tensile test, it is believed that the gel's mechanical strength is enhanced, or its adhesive strength is increased.
[1133] <Adhesion evaluation based on tensile testing>
[1134] In the above adhesion test, both the peeling and dissolution of the gel occurred simultaneously. In order to verify only the adhesion of AL-ABA, a tensile test was performed. The steps of the tensile test are shown in Figure 45 .
[1135] (Material)
[1136] AL-ABA: AL-ABA (modification ratio (NMR): 0.052) prepared by the same method as in Example I-1 was dissolved in pure water at 2 w / v%.
[1137] AL: IL-6G (IL-6G manufactured by KIMICA Co., Ltd., viscosity 50 to 80 mPa·s (1%)) was dissolved in pure water at 2 w / v%.
[1138] CaCl2 aqueous solution (for cross-linking): 50mM or 100mM;
[1139] Esophageal sections (control: with mucosal layer; ESD: stripping of mucosal layer to expose submucosa).
[1140] (Device)
[1141] Rheometer for physical property measurement (SHIRO Sangyo Co., Ltd., M993R-3000S)
[1142] (Experimental Procedures)
[1143] 1. The pig esophagus was longitudinally cut and cut into 1 cm x 3 cm sections. As the mucosal group (control), the cut sections were used directly. In the submucosal group (ESD), the mucosal layer of the sections was peeled off (n = 3).
[1144] 2. Alginic acid solution (AL-ABA or AL) was added to a 1 cm x 1 cm area at one end of each slice.
[1145] 3. Add CaCl2 solution from above the alginate solution to cause gelation.
[1146] 4. Place a heavy object on top (fill 80mL of storage box with 30mL of water) to expel the air.
[1147] 5. Place in a thermostat at 37°C for 1 hour.
[1148] 6. The breaking strength (N) was measured using a rheometer.
[1149] 7. Based on the breaking strength (N) of 6. above and the area (m 2 )The fracture pressure (Pressure, Pa) was calculated.
[1150] (result)
[1151] See the results Figure 46 It was confirmed that the adhesive strength of AL-ABA hydrogel to the mucosa and submucosa was significantly greater than that of AL hydrogel. In addition, it was confirmed that the adhesive strength was determined by the crosslinking agent (Ca 2+ ions) concentration varies.
[1152] [Example I-24] AL-ABA as a tissue adhesive material (Evaluation of adhesiveness to submucosal layer and skin tissue based on overlapping shear method)
[1153] The adhesion strength of AL-ABA, AL, and existing tissue adhesives to biological tissues was evaluated using the lap shear test. Specifically, the following pregel solution was used, and porcine submucosa and porcine skin tissue were used as biological tissues. The adhesion strength of each material to biological tissues was evaluated using the following procedures. The experimental procedures for the lap shear test are shown in the following table. Figure 47 .
[1154] (Pre-gel solution)
[1155] AL-ABA: 4 w / v% aqueous solution of AL-ABA (2) (high DS; modification rate (colorimetry): 0.64) prepared in Example I-2;
[1156] AL500: 4 w / v% AL-500 (manufactured by Mochida Pharmaceutical Co., Ltd., sodium alginate, viscosity: 400-600 mPa·s);
[1157] Fibrin glue: fibrin paste adhesive (Beriplast P manufactured by CSL Behring Co., Ltd.);
[1158] Hydrofit (registered trademark) (polyurethane hemostatic agent; Terumo Co., Ltd.);
[1159] Dermabond (registered trademark) (cyanoacrylate-based skin surface adhesive; Johnson & Johnson)
[1160] The pregel solution was gelled as follows.
[1161] For AL-ABA and AL500, a pregel solution (AL-ABA or AL500) was applied to overlap the biological tissues, and then 200 μL of a 50 mM or 100 mM CaCl 2 aqueous solution (200 μL×2) was applied from both sides of the biological tissues.
[1162] Fibrin glue was gelled using a double syringe.
[1163] Hydrofit (registered trademark) is a one-component product and can be applied directly.
[1164] Dermabond (registered trademark) is a one-component product and can be applied directly.
[1165] (Biological tissue)
[1166] Submucosal tissue (submucosa): The porcine esophagus was cut into a size of 40 mm in length and 10 mm in width, and the mucosal layer on the inner side of the esophagus of the cut mucosal layer tissue was removed to expose the submucosa, thereby preparing the tissue.
[1167] Skin tissue (skin): Pig skin tissue cut into a size of 40 mm in length and 10 mm in width was prepared.
[1168] (Device)
[1169] Dynamic Mechanical Analyzer (DMA) CR3000-EX manufactured by Sun Scientific Co., Ltd.;
[1170] (Experimental steps of overlapping shearing method)
[1171] 0.5 mL of the pregel solution was applied to the overlapping area (10 mm in length and 10 mm in width) at the ends of two pieces of biological tissue (40 mm in length and 10 mm in width), overlapped, and then gelled. After 20 minutes of gelation, an overlapping shear test was performed at a speed of 5 mm / min using a dynamic mechanical analyzer (DMA). The bond energy was measured by a 180° peel test. The bond strength was calculated using the following formula.
[1172] Adhesion strength = force (N / m 2 ) / overlapping area (m 2 )
[1173] (result)
[1174] See the results Figure 48 .
[1175] It was shown that AL-ABA hydrogel can be used as a tissue adhesive for biological tissues such as submucosa and skin tissue.
[1176] [Example I-25] AL-ABA as a tissue adhesive material (tissue leakage preventer) (Evaluation of effectiveness as a sealant for submucosal tissue and skin tissue by a fracture test)
[1177] In order to study the effectiveness of the invention as a tissue leakage preventer, a fracture test was conducted using a device designed by slightly modifying the device reported by Lei Zhou et al., ADVANCEDFUNCTIONAL MATERIALS, Vol. 31, Issue 14, 2021, 2007457, “Injectable Self-Healing Natural Biopolymer-Based Hydrogel Adhesive with Thermoresponsive Reversible Adhesion for Minimally Invasive Surgery”. Specifically, the fracture test was conducted using the following pre-gel solution, porcine submucosa and porcine skin tissue as biological tissues, and according to the following fracture test procedure. The device and fracture test procedure for the fracture test are shown in FIG. Figure 49 .
[1178] (Pre-gel solution)
[1179] AL-ABA: 4 w / v% aqueous solution of AL-ABA (2) (high DS; modification rate (Colorimetric): 0.64) prepared in Example I-2
[1180] AL500: 4 w / v% AL-500 (manufactured by Mochida Pharmaceutical Co., Ltd., sodium alginate, viscosity: 400-600 mPa·s)
[1181] Fibrin glue: Fibrin paste adhesive (Beriplast P manufactured by CSL Behring Co., Ltd.)
[1182] Hydrofit (registered trademark) (polyurethane hemostatic agent; Terumo Co., Ltd.);
[1183] Dermabond (registered trademark) (cyanoacrylate-based skin surface adhesive; Johnson & Johnson).
[1184] The pregel solution was gelled as follows.
[1185] For AL-ABA and AL500, the pregel solution (AL-ABA or AL500) was injected into the puncture site, and 500 μL of a 100 mM CaCl 2 aqueous solution was added dropwise from the top to allow cross-linking for 5 to 10 minutes to achieve gelation.
[1186] For fibrin glue, use a double syringe to gel it.
[1187] Hydrofit (registered trademark) is a one-component product and can be applied directly.
[1188] Dermabond (registered trademark) is a one-component product and can be applied directly.
[1189] (Biological tissue)
[1190] Submucosal tissue (submucosa): The porcine esophagus was cut into a size of 50 mm in length and 50 mm in width, and the mucosal layer on the inner side of the esophagus of the cut mucosal layer tissue was removed to expose the submucosa, thereby preparing the tissue.
[1191] Skin tissue (skin): Pig skin tissue cut into a size of 50 mm in length and 50 mm in width was prepared.
[1192] (Fracture test steps)
[1193] The biological tissue was fixed on the top of the fracture pressure device and punctured to create a 2 mm diameter hole in the center of the tissue. 2.5 to 3 mL of the pregel solution was injected into the 2 mm diameter hole (puncture site) to cause gelation.
[1194] The measuring device was connected to a syringe pump filled with PBS solution. Finally, PBS solution was injected into the device and the maximum burst pressure (burst pressure, mmHg) was recorded using a digital manometer. The experiment was repeated five times.
[1195] (result)
[1196] The results are shown in the table below and Figure 50 .
[1197] [Table 4]
[1198] Table 4 Fracture test results
[1199]
[1200] like Figure 50 As shown, the AL-ABA hydrogel had no significant difference from fibrin glue, indicating the possibility of using it as a tissue sealant (leakage preventer).
[1201] 7. Tissue adhesive materials obtained using AL-ABA, AL-AFA, AL-AAP, AL-APA, and AL-ANA
[1202] [Example I-26] Modified Alginic Acid as a Tissue Adhesive Material for Dura Mater Tissue (Evaluation of Adhesion to Dura Mater Tissue by Overlap Shear Method)
[1203] To evaluate the adhesive properties and adhesive capacity of alginic acid derivatives (AL-ABA, AL-AFA, AL-AAP, AL-APA, AL-ANA), a lap shear test according to the ASTM D1002 test procedure was performed. The adhesive capacity of the alginic acid derivatives was compared with that of various commercially available adhesive materials (fibrin glue (Beriplast (registered trademark) P), Duraseal (registered trademark), Dermabond (registered trademark), Hydrofit (registered trademark)) and unmodified sodium alginate (AL-500).
[1204] <Sample>
[1205] Alginic acid derivatives (AL-ABA, AL-AFA, AL-AAP, AL-APA, AL-ANA) were prepared by the same method as AL-ABA (2) in Example I-2 and Examples I-3 to I-6. The modification ratios described below represent the modification ratios of carboxyl groups (-COOH) of alginic acid, calculated from the amount of aldehyde measured using a colorimetric aldehyde assay kit and blue (MAK140).
[1206] AL-ABA: Alginic acid modified with benzaldehyde (ABA) (modification rate: 0.56 (56%))
[1207] AL-AFA (AL-ADFBA): Alginic acid modified with 4'-4-amino-2,6-difluorobenzaldehyde (ADFBA) (modification rate: 0.12 (12%))
[1208] AL-AAP: Alginic acid modified with 4'-aminoacetophenone (AAP) (modification ratio: 0.25 (25%))
[1209] AL-APA (AL-APCA): Alginic acid modified with 2-amino-3-pyridinecarboxaldehyde (APA, APCA) (modification rate: 0.31 (31%))
[1210] AL-ANA: Alginic acid modified with 6-aminonicotinaldehyde (ANA) (modification rate: 0.17 (17%))
[1211] AL-500: Sodium alginate (produced by Mochida Pharmaceutical Co., Ltd., viscosity: 400-600 mPa·s)
[1212] Fibrin glue: Fibrin paste adhesive (Beriplast (registered trademark) P manufactured by CSL Behring Co., Ltd.)
[1213] Duraseal (registered trademark) (dura-seal anti-seepage material: manufactured by Integra Japan)
[1214] Dermabond (registered trademark) (cyanoacrylate-based skin surface adhesive; Johnson & Johnson)
[1215] Hydrofit (registered trademark) (polyurethane hemostatic agent; Terumo Co., Ltd.)
[1216] <Biological tissue>
[1217] Porcine dura mater was purchased from Tokyo ShibauraZouki Co., Ltd.
[1218] Experiment according to Figure 74 The steps shown in (A) are performed as follows.
[1219] (experiment)
[1220] First, each alginic acid derivative and unmodified sodium alginate (AL-500) were dissolved in PBS (pH 7.4) for 48 hours to prepare a 3% w / v solution (pre-gel solution) of each. Thereafter, the porcine dura mater was thawed and washed in distilled water, and cut into multiple rectangular pieces of similar size with a length of 3cm and a width of 1cm to prepare the dura mater tissue. Approximately 0.1mL of the pre-gel solution (alginic acid derivative or alginate 3%, w / w) was applied to a 1×1cm 2 At the end of the dura mater tissue in the coated area, two sheets of dura mater tissue were overlapped so as to cover the coated area. The tissue sample was immediately immersed in a 100 mM CaCl2 solution for 2 minutes and then incubated at 37°C for 1 hour to gel the pregel solution (RCom MARU Delux Max Digital Incubator). ...
Claims
1. A tissue adhesive material for use on hard and thick tissues and / or connective tissues, the tissue adhesive material comprising a polysaccharide derivative obtained by introducing a group represented by the following formula (A) into an acidic, basic or amphoteric polysaccharide, [Chemistry 72] In the formula, R 1 Represents a hydrogen atom or C 1-4 alkyl; Ring P is a benzene ring or a pyridine ring, and the benzene ring or the pyridine ring is optionally substituted by one or more substituents independently selected from halogen atoms, -CF3, -NO2, carboxyl groups and -SO3H; Y represents a member selected from -NH-, -C(=O)-, -S-, -O-, C 1-6 Alkylene, -(CH2CH2O) n - and any combination thereof, wherein n is an integer from 1 to 9; * indicates the linking portion to the polysaccharide.
2. The tissue adhesive material according to claim 1, wherein The polysaccharide is selected from alginic acid, its derivatives or their salts, hyaluronic acid, its derivatives or their salts, carboxymethyl cellulose, its derivatives or their salts, carboxymethyl dextran, its derivatives or their salts, carboxymethyl starch, its derivatives or their salts, heparin, its derivatives or their salts, heparan sulfate, its derivatives or their salts, chondroitin sulfate, its derivatives or their salts, dermatan sulfate, its derivatives or their salts, chitosan, its derivatives or their salts, regenerated oxidized cellulose, its derivatives or their salts, and pectin acid, its derivatives or their salts.
3. The tissue adhesive material according to claim 1 or 2, wherein: The polysaccharide is a polysaccharide containing a carboxyl group, the group represented by the formula (A) is a group represented by the following formula (A-1), and the group represented by the formula (A-1) is introduced into the polysaccharide by replacing the -OH of the carboxyl group of the polysaccharide to form an amide bond; or The polysaccharide is an amino group-containing polysaccharide, the group represented by the formula (A) is a group represented by the following formula (A-2), and the group represented by the formula (A-2) is introduced into the polysaccharide by replacing the hydrogen atom of the amino group of the polysaccharide to form an amide bond, [Chemistry 73] In formulas (A-1) and (A-2), R 1 Represents a hydrogen atom or C 1-4 alkyl; Ring P is a benzene ring or a pyridine ring, and the benzene ring or the pyridine ring is optionally substituted by one or more substituents independently selected from a halogen atom, -CF3, -NO2, a carboxyl group and -SO3H; L 1 is a single bond, or represents a member selected from -C(=O)-, -S-, -O-, C 1-6 Alkylene, -(CH2CH2O) n - and divalent groups in any combination thereof; L 2 is a single bond, or represents a member selected from -NH-, -S-, -O-, C 1-6 Alkylene, -(CH2CH2O) n - and divalent groups in any combination thereof; n is an integer from 1 to 9; * indicates the linking portion to the polysaccharide.
4. The tissue adhesive material according to any one of claims 1 to 3, wherein The polysaccharide is alginic acid, its derivatives or their salts, The polysaccharide derivative comprises a structural unit represented by the following formula (c11) and / or (c12), [Chemistry 74] In the formula, R 11 , R 12 , R 13 and R 14 are independently selected from hydrogen atoms, C 1-6 Alkyl and -C(=O)-C 1-6 alkyl; R 1 Represents a hydrogen atom or C 1-4 alkyl; Ring P is a benzene ring or a pyridine ring, and the benzene ring or the pyridine ring is optionally substituted by one or more substituents independently selected from a halogen atom, -CF3, -NO2, a carboxyl group and -SO3H; Y stands for -L 1 -NH-, at this time, L 1 Bonded to ring P; L 1 Selected from single bond, C 1-6 Alkylene and -(CH2CH2O) n -; n is an integer from 1 to 9.
5. The tissue adhesive material according to any one of claims 1 to 4, wherein The group represented by the formula (A) is selected from the following groups: [Chemistry 75] In the formula, * represents the linking portion to the polysaccharide.
6. Tissue adhesive materials, which are used for hard and thick tissues and / or connective tissues, The tissue adhesive material comprises a cross-linked structure in which at least a portion of a polysaccharide derivative obtained by introducing a group represented by the following formula (A) into an acidic, basic or amphoteric polysaccharide is cross-linked, [Chemistry 76] In the formula, R 1 Represents a hydrogen atom or C 1-4 alkyl; Ring P is a benzene ring or a pyridine ring, and the benzene ring or the pyridine ring is optionally substituted by one or more substituents independently selected from a halogen atom, -CF3, -NO2, a carboxyl group and -SO3H; Y represents a member selected from -NH-, -C(=O)-, -S-, -O-, C 1-6 Alkylene, -(CH2CH2O) n - and any combination thereof, wherein n is an integer from 1 to 9; * indicates the linking portion to the polysaccharide.
7. The tissue adhesive material according to any one of claims 1 to 6, which is in the form of a gel, a sponge, a sheet or a film.
8. The tissue adhesive material according to any one of claims 1 to 7, further comprising a nonwoven fabric, sheet or film.
9. A cross-linked structure comprising: (a) a polysaccharide derivative obtained by introducing a group represented by the following formula (A) into an acidic, basic or amphoteric polysaccharide; and (b) at least one of an amino group-containing polymer and an amino group-containing low molecular compound containing two or more primary amino groups, hydrazide groups or aminooxy groups and containing a group represented by the following formula (x1), The primary amino group, hydrazide group or aminooxy group contained in the amino-containing polymer and the amino-containing low molecular compound and the group represented by formula (A) contained in the polysaccharide derivative are cross-linked by covalent bonding via a Schiff base. [Chemistry 77] In formula (A), R 1 Represents a hydrogen atom or C 1-4 alkyl; Ring P is a benzene ring or a pyridine ring, and the benzene ring or the pyridine ring is optionally substituted by one or more substituents independently selected from a halogen atom, -CF3, -NO2, a carboxyl group and -SO3H; Y represents a member selected from -NH-, -C(=O)-, -S-, -O-, C 1-6 Alkylene, -(CH2CH2O) n - and any combination thereof, wherein n is an integer from 1 to 9; * indicates the linking part with polysaccharide, [Chemistry 78] In formula (x1), k is an integer from 2 to 5; L 5 is a single bond, or represents a member selected from -C(=O)-, -S-, -O-, an alkylene group, -(CH2CH2O) n - and divalent groups in any combination thereof; n is an integer from 1 to 9; * represents a linking portion to an amino group-containing polymer or an amino group-containing low molecular compound.
10. The cross-linked structure according to claim 9, wherein The amino-containing polymer is at least one selected from the following: linear, branched or dendritic polyamines; polyalkylene glycols substituted with amino groups, hydrazide groups or aminooxy groups; polyallylamine; polyethyleneamine; polypropyleneamine; amino-containing polysaccharides; amino-containing proteins; and polyamino acids.
11. The cross-linked structure according to claim 9 or 10, wherein The polysaccharide is alginic acid, its derivatives or their salts, The polysaccharide derivative comprises a structural unit represented by the following formula (c11) and / or (c12), [Chemistry 79] In the formula, R 11 , R 12 , R 13 and R 14 are independently selected from hydrogen atoms, C 1-6 Alkyl and -C(=O)-C 1-6 alkyl; R 1 Represents a hydrogen atom or C 1-4 alkyl; Ring P is a benzene ring or a pyridine ring, and the benzene ring or the pyridine ring is optionally substituted by one or more substituents independently selected from a halogen atom, -CF3, -NO2, a carboxyl group and -SO3H; Y stands for -L 1 -NH-, at this time, L 1 Bonded to ring P; L 1 Selected from single bond, C 1-6 Alkylene and -(CH2CH2O) n -; n is an integer from 1 to 9.
12. A tissue adhesive material comprising the cross-linked structure according to any one of claims 9 to 11.
13. A tissue adhesive material comprising a polysaccharide derivative obtained by introducing a group represented by the following formula (A-2) into an amino group-containing polysaccharide, The group represented by the formula (A-2) is introduced into the polysaccharide by replacing the hydrogen atom of the amino group of the polysaccharide to form an amide bond. The tissue adhesive material is in the form of a gel, [Chemistry 80] In formula (A-2), R 1 Represents a hydrogen atom or C 1-4 alkyl; Ring P is a benzene ring or a pyridine ring, and the benzene ring or the pyridine ring is optionally substituted by one or more substituents independently selected from a halogen atom, -CF3, -NO2, a carboxyl group and -SO3H; L 2 is a single bond, or represents a member selected from -NH-, -S-, -O-, C 1-6 Alkylene, -(CH2CH2O) n - and divalent groups in any combination thereof; n is an integer from 1 to 9; * indicates the linking portion to the polysaccharide.
14. The composition according to claim 13, wherein the shear rate measured at 25°C is 0.001s -1 The viscosity (η 0.001 ) and the shear rate is 1000s -1 The viscosity (η 1000 ) ratio (η 0.001 / η 1000 ) is 10~10 9 .
15. The tissue adhesive material according to claim 13 or 14, wherein: The polysaccharide derivative is cross-linked by forming a covalent bond between the amino group contained in the polysaccharide derivative and the group represented by the formula (A-2) via a Schiff base, thereby forming a cross-linked structure.
16. The tissue adhesive material according to any one of claims 13 to 15, wherein The polysaccharide is chitosan, its derivatives or their salts, The polysaccharide derivative comprises a structural unit represented by the following formula (c16): [Chemistry 81] In the formula, R 81 and R 82 are independently selected from hydrogen atoms, C 1-6 Alkyl and -C(=O)-C 1-6 alkyl; R 1 Represents a hydrogen atom or C 1-4 alkyl; Ring P is a benzene ring or a pyridine ring, and the benzene ring or the pyridine ring is optionally substituted by one or more substituents independently selected from a halogen atom, -CF3, -NO2, a carboxyl group and -SO3H; Y stands for -L 2 -C(=O)-, at this time, L 2 Bonded to ring P; L 2 Selected from single bond, C 1-6 Alkylene, -(CH2CH2O) n -、-(CH2) m1 -(CH2CH2O) n -(CH2) m2 - and -(CH2) m1 -O-(CH2CH2O) n -(CH2) m2 -; n is an integer from 1 to 9; m1 and m2 are each independently an integer of 1-9.
Citation Information
Patent Citations
Sustained release base material for heparin-binding growth factor and heparin-binding growth factor releasing agent
JP2001233786A
Temperature control furniture
JP2021029573A
Novel reactive alginic acid derivatives
WO2019189330A1
